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Ascending CNS Progression of EAE: Linkage of Events at the Choroid Plexus and Spinal Cord 
 
 
Bandana Shrestha 
University of Connecticut (2015) 
 
Dysfunction of the blood brain barrier (BBB), the specialized complex of cells situated at the 
central nervous system (CNS) microvasculature has been associated with numerous 
neuroinflammatory disorders like multiple sclerosis (MS) and its animal model, experimental 
autoimmune encephalomyelitis (EAE). BBB known to restrict passage of soluble and cellular 
elements between the blood and CNS is breached. The mechanism by which auto-reactive T 
cells cross the normally “impermeable” BBB, invade the initially naive CNS, and cause 
neuroinflammation, remains unclear. Recent studies suggest an initial route by which these cells 
first gain entry from circulating blood through the choroid plexus (CP). The permeable 
fenestrated capillaries of CP allow these sentinal T cells into the cerebrospinal fluid (CSF) across 
the surrounding tight junction expressing choroidal epithelium also known as the blood-CSF-
barrier (BCSFB). Once into the CSF, these cells travel to the subarachnoid space (SAS) that 
surrounds the CNS parenchyma. Here, T cells are known to encounter their cognate antigen and 
set off a cytokine storm that propagates inflammation. The effects are first observed within the 
SAS in the meningeal vessels followed by activation of parenchymal inflammation. However, 
several critical questions in this scenario remain.  First, how do these T cells cross the epithelium 
of the CP to enter the CSF? Does this involve changes in the tight junctional integrity between 
adjacent epithelial cells to allow leukocyte diapedesis? Second, once they enter the CSF, do these 
cells select a segment within the SAS to ignite the inflammatory sequence? Given the ascending 
inflammation within spinal cord segments in developing EAE (caudal to rostral), regional blood 
vessels in meninges and parenchyma might display unique vulnerabilities depending upon the 
segment of the spinal column in which they reside. Third, what links the inflammatory signals in 
the SAS to neuroinflammation in the parenchyma? Results obtained from this work show 
evidence towards the hypothesis that the ascending course of EAE is due to initial penetration of 
sentinal T cells through a structurally compromised CP choroidal epithelium, followed by a 
spinal segment-dependent relay of inflammatory signals between meningeal and parenchymal 
vessels. 
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Publications and contributions to Thesis project: 
1. Chapter II: Choroid Plexus in evolving EAE:  This work focuses on the regulation of the 
Blood-Cerebrospinal Fluid barrier at the level of the Choroid Plexus (CP), in terms of tight 
junctions within the epithelial layer of the CP and the functional assessment of permeability 
associated with it during evolving EAE induced by immunization with myelin 
oligodendrocyte glycoprotein (MOG) peptide35-55 along with adjuvants. This study sheds 
light on how the leukocytes navigate across the tight junctions of the choroidal epithelial 
layer into circulating Cerebrospinal Fluid (CSF) leading to anatomical changes within this 
intricate system. Understanding the changes in the tight junctions between the epithelial cells 
of the CP has provided valuable information about the regulation of BCSFB via possible 
trans epithelial migration of infiltrating immune cells. BCSFB breach has also been assessed 
functionally by permeability studies, thus co-relating the breakdown of tight junctions with 
possible increase in the “leakiness” of the barrier. 
 
2. Chapter III: Spinal cord in evolving EAE:  Once the immune cells enter the CSF from the 
choroid plexus during evolving EAE, do they select a segment within the SAS to ignite the 
inflammatory sequence? This work provides the possibility that regional blood vessels in the 
meninges and parenchyma might display unique vulnerabilities depending upon the segment 
of the spinal column in which they reside. These differences could aid in preferential 
accumulation and infiltration of inflammatory cells within the lumbar segment followed by 
ascending progression in disease pathology. This work has attempted to address these issues 
using 3D confocal microscopy of spinal cord segments, whole spinal cord images and a 
systematic and detailed segmental transcriptomic analysis of inflammatory gene expression 
patterns of spinal cord meningeal and parenchymal venules. 
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3. Chapter IV: CCL2 sources in evolving EAE:  This report uses two qRT-PCR-based 
approaches to clarify the relative contributions of the parenchymal and vascular 
compartments to CNS CCL2 gene expression during evolution of EAE induced by 
immunization with myelin oligodendrocyte glycoprotein (MOG) peptide35-55 along with 
adjuvants. One approach used a crude separation of CNS parenchymal and microvessel 
fractions, based on a common preparative method from homogenized CNS tissue. The other 
employed the laser capture microdissection (LCM), to more precisely retrieve separate 
BMEC, astrocyte and other parenchymal cell types. Additionally, we assessed CCL2 
expression levels following MOG immunization as well as after injection of these adjuvants 
alone, to highlight the effects due to MOG immunoreactivity. 
 
• Appendix-Attached paper 1:  This work focuses on the CCL2 synthesis inhibitor bindarit 
and it effects on the cells of the neurovascular unit effectively suppressing experimental 
autoimmune encephalomyelitis. Bindarit repressed CCL2 expression in cultured murine 
astrocytes, microglia and BMEC, and antagonized upregulated expression of CCL2 in both 
brain and spinal cord in vivo following LPS administration. Bindarit also significantly 
modified the course and severity of clinical EAE, diminished the incidence and onset of 
disease, and evidenced signs of disease reversal. 
 
• Appendix-Attached paper 2: This work allowed us to perfect an experimental technique 
coupling Laser Capture Microdissection (LCM) with Taqman Low Density Arrays (TLDA) 
plates using expression profiling of brain microvascular endothelial cells. We were able to 
report, for the first time, the feasibility of direct cDNA synthesis without RNA isolation in 
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mircoarrays. This set the ground work for our following publications using the technique to 
show the differential CP epithelial and endothelial expression profile and CP regulation 
during EAE. 
 
• Appendix-Attached paper 3:  This work was instrumental to establish the feasibility of 
LCM on separate compartments of the intricate system of choroid plexus structure and 
coupling it with TLDA analysis. This work put down the ground works, building upon 
which, CP epithelial cells were isolated using LCM and probed for tight junctions 
expression. This led to experiments towards understanding how these tight junctions were 
regulated and BSCFB was maintained during evolving inflammation in EAE. 
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MS and its comprehensive animal model, EAE are widely considered as chronic immune 
mediated demyelinating diseases of the CNS (1-5). Breakdown of the BBB and leukocyte 
extravasation have been associated with the pathology of these diseases (6, 7). Little is known 
however about the initial trigger that activates the healthy, naïve immune system and the resting 
vasculature of the CNS within which BBB resides. The spark that initiates the sequence of events 
leading to targeted demyelination and subsequent neurodegeneration has been speculative (8, 9). 
Reports have highlighted important initial inflammatory events that occur before the breakdown 
of the BBB and provide possible leads to the earlier steps necessary for disease (10-13).  These 
studies suggest that the molecular changes at the level of the BBB are downstream effects of 
earlier reported events such as entry of inflammatory T cells via routes other than the BBB. 
Evidences point to the CP, cells primarily known to produce CSF (14, 15), as a possible site 
where pioneer T cells infiltrate the CNS in MS/EAE.  
CP has garnered attention as a critical player in immune reactions of the CNS (13, 16-
18). It is located within the cerebral ventricles and is composed of a highly vascularized stroma 
encapsulated by a “tight” layer of epithelial cells decorated with tight junctions (TJ) (19, 20). CP 
stromal capillaries are fenestrated and permit hydrophilic molecules typically excluded by the 
BBB (21). This leaky nature of the CP endothelium is known to allow extravasation of T cells 
engaged in immunosurveillance. Reboldi et al.(22) reported that CCL20, produced by choroidal 
epithelial cells, attracts TH17 cells bearing the cognate receptor CCR6, in circulation within the 
capillaries, across the endothelium. However these cells need to cross the blood-CSF barrier 
(BCSFB)(6, 23) formed by a tighter epithelium juxtaposed with the  “leaky” capillaries in order 
to get into the CSF. The CCL20 chemokine gradient doesn’t explain how these cells get past the 
CHAPTER I: Introduction 
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epithelial layer. Reports of adhesion molecules being present in the apical surface of the 
epithelial cells rather than the basolateral side further fuels the question of how do T cells get 
past the BCSFB (18). Works included within the scope of this thesis contributes to bridge this 
gap in knowledge and answer unresolved critical questions lingering in the field.  
Is there breach of the BCSFB? Significance of this work lies in understanding how the 
leukocytes navigate across the tight junctions of the choroidal epithelial layer. There has been 
very limited work in terms of understanding the tight junction regulation of the CP epithelial 
layer during naïve as well as pathological scenarios(18, 24, 25). Having established the 
importance of the CP, it is as important to understand the anatomical changes within this intricate 
system. Understanding the changes in the tight junctions between the epithelial cells of the CP 
has provided valuable information about the regulation of BCSFB via possible trans epithelial 
migration of infiltrating immune cells. BCSFB breach has also been assessed functionally by 
permeability studies, thus co-relating the breakdown of tight junctions with possible increase in 
the “leakiness” of the barrier.  
 In association, the SAS, which is connected to the CP via CSF, is reported to be 
another important compartment that supports earlier inflammatory events (10-12). It is within the 
SAS, the initial inflammatory T cells are known to encounter their cognate antigen. T cells are 
reactivated within the SAS by MHC class II expressing macrophages and DCs presenting myelin 
epitopes (26). Reactivated T cells are then known to produce inflammatory cytokines that set off 
an inflammatory cascade. The effects are first observed within the SAS in the meningeal vessels 
followed by activation of parenchymal inflammation(27). Parenchymal vascular changes in 
terms of expression of adhesion molecules and production of cytokines activate the BBB and 
allow leukocytes to permeate this normally restrictive BBB (28, 29). 
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Once across this barrier and into the CNS parenchyma, these cells then release soluble factors 
that initiates destruction of myelinated axons and damage to neurons (4). However, there are 
several critical questions within this scheme of events. This work aimed at providing some 
answers that will stipulate a holistic picture of immune pathology in EAE. 
What links the inflammatory signals in the spinal cord SAS to neuroinflammation in the 
parenchyma?  Studies have shown that the inflammatory cascade begins in the SAS long before 
it is observed in the parenchyma during developing EAE (10, 11, 13). Meningeal vessels within 
the SAS are shown to accumulate immune cells and to allow extravasation earlier than the 
underlying parenchymal vessels. Why do infiltrating T cells prefer meningeal to parenchymal 
vessels to begin infiltration? Is there differential regulation of inflammation within the two 
vascular regions and what links them? A detailed immune profile of regional vascular 
endothelium within the meninges and underlying parenchyma provided a key in answering these 
questions. Major immune players such as adhesion molecules, cytokines, chemokines, statins, 
interleukins, T cells activation markers, co-stimulatory molecules, transcription factors and 
apoptotic markers were probed to provide a complete immune profile during developing EAE.  
Does heterogeneity within the spinal cord segments lead to ascending EAE? Ascending 
progression of spinal cord pathology and clinical disease observed in many EAE models has 
remained enigmatic (5). The reasons behind the progression of inflammation from the 
caudal/lumbar segment to the rostral/cervical segment are yet to be explained. Once the immune 
cells enter the CSF from the choroid plexus, do they select a segment within the SAS to ignite 
the inflammatory sequence? Our work has shed light on the possibility that regional blood 
vessels in the meninges and parenchyma might display unique vulnerabilities depending upon 
the segment of the spinal column in which they reside. These differences could aid in preferential 
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accumulation and infiltration of inflammatory cells within the lumbar segment followed by 
ascending progression in disease pathology. This work has attempted to address these issues 
using a systematic and detailed segmental analysis of inflammatory gene expression patterns of 
spinal cord meningeal and parenchymal venules. 
The significance of this work lies in tackling unresolved questions important to 
understand the nascent alternate routes proposed. i.e. the CP and SAS meningeal venules. First, 
how do leukocytes navigate across the tight junctions of the tight choroidal epithelial layer and 
possibly breach the BCSFB during disease onset? Second, what are the immune gene changes 
within the meningeal and underlying parenchymal vessels in the spinal cord segments that could 
highlight differences within regional vascular environments and the segmental co-relation 
between them? Understanding the earliest events in disease pathology will provide uniquely 
sensitive avenues for therapeutic interventions that could halt or delay the progression of the 
disease. 
This study is novel not just in terms of the unique questions asked but in using new and 
challenging technical approaches as well. Quantitative 3D analysis of TJ breakdown and 
permeability assessment was used to highlight aspects of CP morphological and functional 
changes not resolved before.  Previous works in similar accounts (24) have been defined by 2D 
qualitative analysis in thin sections, which is restricted to visualization of only a small portion of 
the given specimen. Given the tortuosity of the complex of cells within CP, visualizing TJs 
embedded within the epithelial cells and the leakage is limited. Focal changes in TJ expression 
and functional changes in BCSFB breach was quantified effectively using an encompassing 3D 
approach in thicker sections, providing an enhanced perspective of in vivo changes in tight 
junctions and permeability within the CP. 
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  Characterization of immune genes between regional and segmental vasculature was done 
with a novel isolation procedure- Laser Capture Microdissection (LCM). With this work we 
were able to resolve the differences in meningeal and underlying parenchymal vessels in 
terms of their immune gene profile. This work encompassed specialized isolation of vascular 
endothelium from meningeal and parenchymal regions within spinal cord segments. This 
laboratory has successfully demonstrated that immunohistochemistry-guided laser capture 
microdissection (immuno-LCM) can precisely acquire designated cell populations in highly 
purified form from their in situ setting (30-34). These lab reports have shown that immuno-
LCM coupled to qRT-PCR enables highly reproducible, quantitative gene expression profiling 
of captured cells. This level of intricate isolation and profiling has not been done before in 
comparing meningeal and parenchymal vascular endothelial cells. Tenacious profiling of 
immune genes within these vascular types has provided cues for the ascending course of EAE, 
which we hypothesized, is due to spinal segment-dependent relay of inflammatory signals 
between meningeal and parenchymal vessels. 
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Alterations in tight junction protein and IgG permeability accompany 
leukocyte extravasation across the choroid plexus during neuroinflammation. 
 
1. Abstract 
 The choroid plexus (CP) is considered a point of leukocyte entry into the central nervous 
system (CNS) during normal immune surveillance and developing neuroinflammatory disease. 
However, structural or functional alterations within the CP that support this migration are much 
less understood. Quantitative, high-resolution 3D fluorescence imaging was thus used to detail 
inflammatory responses within the CP following induction of experimental autoimmune 
encephalomyelitis (EAE) by immunization with myelin oligodendrocyte glycoprotein (MOG) 
and Complete Freund’s Adjuvant/pertussis toxin (MOG-CFA/PTX), or adjuvants alone (CFA-
PTX). MOG-CFA/PTX and CFA/PTX produced near comparable effects, the former being 
consistently more severe. Both treatments resulted in accumulation of serum IgG and leukocytes 
in the CP stroma, consistent with elevated stromal capillary permeability. They also provoked 
remarkable distortions in staining pattern of tight junction (TJ) adaptor protein ZO-1 in the 
choroidal epithelium, with diminished staining but no obvious change in pattern of the associated 
TJ protein, claudin-2. Only MOG-CFA/PTX triggered visible extravasation of IgG and 
leukocytes across the choroidal epithelium. Results suggest CFA/PTX primes the CP for 
neuroinflammation by inducing several structural changes that are exacerbated when co-
administered with MOG, and reinforce the CP is a gateway for leukocytes to enter the CNS by 
accessing the cerebrospinal fluid and meninges. 
 
CHAPTER II: Choroid plexus in evolving EAE 
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2. Introduction 
 
 The choroid plexus (CP) is a specialized out-pocketing of the roofs of the third, fourth and 
lateral ventricles, and has long been recognized as the site of production of cerebrospinal fluid 
(CSF), within which it hangs suspended (14, 19). A highly compartmentalized structure, the CP 
contains at its core, a tortuous capillary plexus displaying a fenestrated endothelium more 
permeable than that of capillaries forming the blood-brain barrier (BBB) in the CNS parenchyma 
(21). This vascular core is surrounded by a layer of choroidal epithelium having a relatively high 
density of tight junctions (TJs) and limited permeability, providing the CP its classification as 
part of the blood-CSF-barrier (BCSFB) (6, 23). Located between the capillaries and choroidal 
epithelium is a confined stromal space.  
 Since the pioneering work of Helen Cser (35), the CP has been commonly recognized for its 
role in generating CSF, as most recently reviewed (36).  However, a growing number of reports 
has turned attention to the CP as a site through which T cells might enter an initially uninflamed 
central nervous system (CNS) to spark neuroinflammatory disease, such as multiple sclerosis 
(MS) and its animal model experimental autoimmune encephalomyelitis (EAE) (13, 16-18, 22). 
It has been proposed that once encephalitogenic T cells cross the CP and enter the CSF, they can 
migrate to the subarachnoid space (SAS) surrounding the brain and spinal cord, and there forge 
immune synapses with resident dendritic cells. Cytokine bursts stemming from such synapses, in 
turn, are reasoned to activate the endothelial surfaces of nearby microvessels within the SAS, 
thereby enabling adhesion and extravasation of leukocytes circulating in the bloodstream (10-
12). Interactions between these leukocytes and other dendritic cells in the SAS are thought to 
follow, ultimately propagating an inflammatory wave along the surface-penetrating microvessels 
that enter the CNS parenchyma.  
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 This scenario begs the question: Are there changes within CP anatomy and integrity during 
evolving neuroinflammation that would allow leukocytes to navigate across the TJs of the 
choroidal epithelium and enter into the CSF? Currently, direct evidence of leukocyte 
extravasation across the CP into the CNS ventricles, or structural arrangements of the choroidal 
epithelium that might support this process, is lacking. High-resolution 3D fluorescence imaging, 
was thus used to highlight aspects of CP morphological and functional changes not previously 
resolved during progression of EAE.  
 Specifically, immunization with myelin oligodendrocyte glycoprotein (MOG) peptide35-55, 
along with Complete Freunds Adjuvant (CFA) and pertussis toxin (PTX), was used to induce 
EAE, and at different time-points qualitative and quantitative assessments were made for two TJ 
proteins expressed by the CP: claudin-2 (CLN-2) and zonula occludens-1 (ZO-1) (24, 25, 37). 
CLN-2 belongs to a large family of claudins (> 20 members), integral membrane proteins that 
perform cell-cell bridging, while ZO-1 is a peripheral membrane scaffolding/adaptor protein that 
directly or indirectly links claudins (and other integral membrane TJ proteins) to the actin 
cytoskeleton (38-40). TJ protein changes were further correlated with leakage of serum 
immunoglobulin G (IgG) – a marker of barrier permeability status (41)– and leukocyte 
extravasation across the successive CP compartments. As administration of just the adjuvants 
CFA and PTX can significantly alter gene expression patterns in the CP (42), MOG35-55-
immunized mice were contrasted with those receiving these adjuvants alone or no treatment.  
 Results indicate that ZO-1 and CLN-2 immunostaining patterns within the CP choroidal 
epithelium displayed significant, yet different, changes during evolution of EAE, with the former 
showing a severely altered morphology, and the latter a gradual decrease in staining intensity. 
IgG was detectable at a low level in the CP stroma even in naïve animals, appreciably increased 
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during disease, and later in acute disease was observed to extravasate across the CP choroidal 
epithelium. A few leukocytes were also detected in the CP stroma of naïve mice. These cells, 
showed an acute transient accumulation early in EAE, and then seemed to reduce to near pre-
disease level. Correlating with this decline, leukocytes could apparently be seen in the process of 
extravasating across the CP choroidal epithelium and into the ventricles, presenting direct 
evidence supporting the theory that the CP is the entry site into the CNS for leukocytes in the 
ontogenesis of neuroinflammation (13).  
 
3. Materials and Methods 
 
3.1 Animals: Female C57BL/6 mice, age 8–10 weeks, were obtained from Charles River 
Laboratories, Inc. (Wilmington, MA) and used throughout. A total of n = 3 animals/group were 
used for each treatment and time-point assessed. All animal experimental procedures were 
performed following Animal Care and Use Guidelines of the University of Connecticut Health 
Center (Animal Welfare Assurance # A3471-01), and approved under protocol #100346-1214. 
 
3.2 EAE induction: EAE was induced in mice by active immunization with MOG35-55 peptide 
(MEVGWYRSPFSRVVHLYRNGK), of murine origin (W. M. Keck Biotechnology Resource 
Center, Yale University), as described (43) Briefly, on day 0 (D0), one group of mice was 
injected subcutaneously with 300 µg of MOG peptide in complete Freund’s adjuvant (CFA, 
DIFCO) into the right and left flank, 100 µl per site. These mice were also injected i.p. with 500 
ng pertussis toxin (PTX, List Laboratories, Campbell CA) in PBS on D0 and D2 following the 
first immunization (referred to as the MOG-CFA/PTX group). Another group of age-matched 
mice received only CFA and PTX (500 ng) injections on D0 and a second injection of 500 ng 
PTX on D2 (referred to as the CFA/PTX “control” group). A third group of age-matched mice 
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was left untreated (referred to as “naïve” mice), and represented “normal” tissue.  Only the 
MOG-CFA/PTX group developed EAE. Mice typically showed development of acute clinical 
symptoms at ~ D12, followed by ascending paralysis and chronic disease (44). Animals were 
killed at D0 (naïve), D6, D9 and D15 post-injection (with MOG and/or CFA/PTX). Animals 
were monitored for clinical disease severity and mean clinical scores were calculated where 0 
=normal; 1 = tail limpness; 2 = limp tail and weakness of hind legs; 3=limp tail and complete 
paralysis of hind legs; 4 = limp tail, complete hind leg and partial front leg paralysis; and 5 = 
death. The time-points selected for analysis, D6, D9 and D15, represent pre-clinical (score 0), 
early (score 0-0.5) and acute stages of EAE (score 2-2.5), respectively. 
 
3.3 Tissue preparation and sectioning for 3D analysis: Mice were anesthetized by 
intraperitoneal injection of Ketamine (80 mg/kg) and Xylazine (10mg/kg) in phosphate-buffered 
saline, pH 7 . 4 ( PBS). Animals were then transcardially perfused (via the left ventricle) first 
with Heparin-PBS (10 usp/ml) to eliminate vascular blood content, and then with fixation 
Buffer (2% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4), as described previously (43) 
Brains were embedded in OCT cryomatrix compound (Thermo Fisher Scientific, Waltham, 
MA) prior to sectioning. Cryosections of 20µm thickness were obtained using a Microm HM 
505M cryostat (Mikron Instruments; Oakland, NJ) maintained at -25°C, and deposited onto poly-
L-lysine coated slides.  
 
3.4 Immunostaining for 3D analysis: Sections were permeabilized with 0.6 % Triton X-100 
in PBS for 30 min, and non-specific binding blocked by incubation with Power block® for 10 
min in Ultrapure (GIBCO) distilled water (41). The CP capillary endothelium was stained by rat 
anti-mouse CD31 antibody (BD Pharmingen) at 1:160 dilution, followed by incubation with goat 
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anti-rat Alexa Fluor® 555 antibody (Life Technologies) at 1:250 dilution. Choroidal epithelial 
cells were stained using monoclonal pan-cytokeratin-FITC antibody (Sigma) at 1:160 dilution. 
Rabbit polyclonal antibodies to CLN-2 (Invitrogen) at 1:160 dilution, CLN-3 (Abcam) at 1:100 
dilution, ZO-2 (Invitrogen) at 1:100 and ZO-1 (Invitrogen) at 1:160 dilution, followed by Alexa 
Fluor® 488 goat anti-rabbit IgG (Life Technologies) at 1:250 dilution, were used to stain 
epithelial TJs.  Alexa Fluor® 488 goat anti-mouse IgG Fab fragment (Life Technologies) at 1:160 
dilution was used to detect endogenous IgG within the CP. DRAQ5 (Biostatus Ltd., 
Leicestershire, UK) was used at 1:1000 dilution to stain nuclei. Alexa Fluor® 647 anti-mouse 
CD45 (Biolegend) at 1:160 dilution was used to stain for leukocytes. Sections were mounted in 
Mowiol (Sigma-Aldrich). 
 
3.5 Image acquisition and quantitative analysis of TJ proteins, IgG and leukocytes in the 
CP: Confocal z-stacks (multi-track scan) were acquired using a Zeiss LSM 510 Meta equipped 
with Zeiss Fluar 40X/1.30, 63X Plan-neofluar/1.25, and 100X Plan-apochromatic/1.4 oil 
immersion objective lenses. Thereafter, z-stacks were imported into Bitplane Imaris® suite 
version 7.1 x64 software (Bitplane Inc., South Windsor, CT), as described previously (41).  
 The CP tissues specifically located in the lateral ventricles were evaluated in all 
experiments, as complexity and developmental changes of TJ proteins have been reported to 
show differences among the CP locales in rat (Kratzer et al., 2012). Images of these TJ proteins 
were first isosurface rendered to obtain a measure of total surface area, and the epithelial nuclei 
were represented as spots to estimate the number of epithelial cells per image. The total area of 
TJ protein staining per epithelial cell was calculated as follows:  
      Total TJ area/epithelial cell = Total surface area of green isosurface      
                      No. of epithelial nuclei 
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 A slightly different method was used for relative 3D quantification of endogenous IgG that had 
extravasated from the circulation into the CP.  Specifically, a volumetric approach was taken as 
IgG became diffusively distributed throughout the CP by D15 of EAE.  Images of extravasated 
IgG were isosurface rendered, and mean voxel intensities determined.  IgG staining along the 
endothelial lining of the capillaries was specifically masked in order to quantify only the IgG 
that leaked out of the vasculature. This was done by creating an isosurface of the capillary 
staining (CD31) and assigning all the included green (IgG) voxel intensities to zero. A mean red 
voxel intensity value of the capillary isosurface was then obtained. The volume of extravasated 
IgG per volume of capillaries was calculated as follows: 
Volume of IgG/ Volume of capillaries = Total green intensity 
           Total red intensity 
 
Total green intensity = Mean green intensity X no. of green voxels 
Total red intensity = Mean red intensity X no. of red voxels 
 
Leukocyte quantification was performed using the measurement points module of the 
Imaris® software suite, first representing the CD45+ cells as ‘spots’ and then counting the total 
number of spots present in the field of view. The surface area of the capillaries was determined 
by creating an isosurface of the capillary staining (CD31), and the number of leukocytes per 
capillary surface area of the CP was calculated as follows: 
Total number of leukocytes/capillary area =                 Total no. of spots  x 104 
                  Total surface area of the red isosurface 
 
3.6 LCM and qRT-PCR 
  
 Immunohistochemistry-guided LCM was performed as recently detailed (42).  In brief, naïve 
animals were euthanized by gradual CO2 inhalation. Brains were immediately removed, snap-
frozen in dry ice-cooled 2-methylbutane (Acros; Geel, Belgium), and embedded in cryomatrix 
	   13	  
compound (Thermo Fisher Scientific, Waltham, MA) for cryosectioning. Coronal sections (7µm) 
were cut on a Microm HM 505 M cryostat (Mikron Instruments; Oakland, NJ) and affixed to 
uncoated, pre-cleaned glass slides (Fisher Scientific, Pittsburgh, PA). The CP stromal capillaries 
were stained using a substrate combination of nitro-blue tetrazolium chloride/5-bromo-4-chloro-
3'-indolyphosphate p-toluidine salt (Vector Labs, Burlingame, CA) to detect the endogenous 
alkaline phosphatase activity in endothelial cells. The choroidal epithelial cells were 
immunostained with monoclonal pan-cytokeratin-FITC antibody (Sigma). A PixCell IIe laser 
capture microscope (Life Technologies, Foster City, CA) was used to retrieve CP choroidal 
epithelial tissue from the lateral ventricles. LCM samples were solubilized in Cell Lysate Buffer 
(Signosis; Sunnyvale, CA) for direct reverse transcription and relative cDNA levels were 
quantified by qRT-PCR using an ABI 7900HT Fast Real-Time PCR System (Life Technologies 
Corp, and normalized to housekeeping gene RPL-19 as described previously (34). Samples were 
probed for TJ proteins – CLN-1, -2 , -3, -11, occludin  and ZO-1 – and the purity of captured 
LCM material was assessed by epithelial marker (cytokeratin-8) and endothelial marker (CD31) 
levels. 
 
4. Statistical Analysis 
 Two CP sections from each animal and a total of three animals were used for each group: 
naïve, control (CFA/PTX) and EAE (MOG-CFA/PTX). Data from all experiments was initially 
assessed for normality using a Shapiro-Wilk test. Accordingly, data from ZO-1, IgG and 
leukocytes determinations was subsequently analyzed by a one-way non-parametric Kruskal-
Wallis test followed by Dunn’s post-test analysis, while data from CLN-2 determinations were 
analyzed by a one-way ANOVA followed by Bonferroni post-test. All statistical analyses were 
performed using GraphPad Prism 5 (GraphPad, La Jolla, CA). Results were considered 
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significant at p≤0.05.  
 
5. Results 
 
5.1 Relative expression of genes encoding TJ proteins in the CP  
  
 The normal CP choroidal epithelium was first analyzed by laser capture microdissection 
(LCM) to establish the relative expression of TJ components in this tissue layer of naïve mice 
(Fig. 1).  Prior descriptions by this laboratory (42) have highlighted the ability of LCM to resolve 
with high purity the choroidal epithelium from the vascularized core. Analysis of LCM-derived 
choroidal epithelial tissue by qRT-PCR revealed expression of cytokeratin 8 (K8), as well as 
mRNAs encoding the TJ proteins ZO-1, CLN-1, CLN-2, CLN-3 and CLN-11, which have also 
been previously identified in the CP in situ by immunocytochemistry as well as in cultured 
choroidal epithelial cells (24, 25, 37, 45).  Notably, expression of CD31 – found in all 
endothelial cells but not choroidal epithelial cells – was barely detectable, reinforcing the high 
precision of the LCM process. Because of their relatively prominent expression, 
immunofluorescence studies of ZO-1 and CLN-2 were further pursued to determine whether 
cytological changes of these CP TJ components were correlated with functional aspects of 
neuroinflammation during evolving EAE.  
 
5.2 Distribution of TJs proteins, IgG and leukocytes within the CP of naïve mice 
 
 Initial studies sought to demonstrate the status of the normal CP in naïve mice (Fig. 2). With 
respect to ZO-1 and CLN-2 distribution (Fig. 2a and 2b, respectively), strong immunostaining 
for both these TJ proteins revealed a smooth contour and continuous pattern, delimiting the 
junctions of all choroidal epithelial cells. A scarce amount of IgG could be detected within the 
CP stroma of naïve mice (Fig. 2c), along with a few leukocytes (Fig. 2d). The approaches used to 
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perform relative quantification of ZO-1, CLN-2, IgG and leukocytes in the CP are illustrated in 
Fig. 3. 
 
5.3 Distribution of ZO-1 in the CP following immunization  
 Subsequent studies evaluated immunostaining of TJ proteins and IgG at different time-points 
in both control mice (receiving CFA/PTX) and mice following EAE induction (receiving MOG-
CFA/PTX) (Fig. 4a). The staining pattern of ZO-1 was altered in both groups, but the changes 
varied in scope. In CFA/PTX-treated control mice, immunostaining of ZO-1 was a bit distorted 
at D6, showing ridge-like irregularities in the contour at some locales that persisted through D15. 
Treatment with MOG-CFA/PTX to induce EAE resulted in more drastic alterations in ZO-1 
staining pattern. Similar ridge-like irregularities were initially obvious along some choroidal 
epithelial cells at D6, but these became more pronounced through the disease course. By D15, 
the ZO-1 staining pattern was severely crenulated throughout the choroidal epithelium, giving a 
palisade appearance. To quantify these changes in TJ staining patterns, total area of ZO-1 
staining within the CP epithelium of each image was related to the number of CP epithelial 
nuclei (Fig. 4b) as shown in Fig. 3. Control mice evidenced no changes in this parameter over the 
time-points evaluated, while mice with EAE showed a step-wise elevation, with significant 
changes at D9 and D15 (compared to naïve).  As this suggested an increase in individual CP 
epithelial cell surface area during evolving EAE, inter-nuclei distances were also determined as a 
surrogate for corresponding volume/cell-size changes.  At D15 EAE, mean inter-nuclei distance 
in CP epithelial cells was nearly three-fold higher than that found in naïve mice, suggesting a 
significant increase in CP epithelial cell volume during neuroinflammatory disease (see Figure, 
Supplemental Digital content 1, which shows an increase in CP epithelial inter-nuclei distance). 
These observations were further supported by a significant increase in perimeter of ZO-1 
	   16	  
staining in CP epithelial cells in D15 EAE mice compared to naïve mice (see Figure, 
Supplemental Digital content 2, which shows an increase in perimeter of ZO-1 staining within 
the CP epithelium). 
 
5.4 Distribution of CLN-2 in the CP following immunization 
 
 The response of CLN-2 was different both qualitatively and quantitatively from that of ZO-1 
(Fig. 5a). The immunostaining pattern of CLN-2 did not appear to change in control mice 
receiving CFA-PTX alone, remaining relatively linear at intercellular borders. There was, 
however, a slight change in the staining intensity by D15. Likewise, the overall CLN-2 staining 
pattern remained unaltered following EAE induction with MOG-CFA/PTX, though a steeper 
reduction in staining intensity was more noticeable in this group, which by D15 revealed sites of 
sharp discontinuities (arrows). The ratio of total area of CLN-2 immunostaining to number of CP 
epithelial cell nuclei was calculated as for ZO-1 (Fig. 5b).  This parameter did not significantly 
change in control mice until D15, but was significantly reduced earlier in mice with EAE – 
showing a decrease at D9 and an even greater decline at D15 of MOG-CFA/PTX treatment as 
discontinuities became more evident. 
 Given the strongly disparate responses between ZO-1 and CLN-2, additional studies were 
carried out to determine whether the different patterns of TJ protein redistribution might be 
related to these proteins being of peripheral and integral membrane classes, respectively (see 
Figure, Supplemental Digital Content 3, which shows ZO-2 and CLN-3 staining in the CP from 
naïve and MOG-CFA/PTX-treated mice). ZO-2, another peripheral membrane TJ protein, 
demonstrated a response much like that of ZO-1, showing a similarly crenulated pattern while 
apparently maintaining constant intensity following MOG-CFA/PTX immunization. In contrast, 
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the response of CLN-3, another integral membrane TJ protein, paralleled that of CLN-2, 
exhibiting a less intense and discontinuous pattern. 
 
5.5 Distribution of IgG in the CP following immunization 
 
 Increased IgG staining was seen in both control mice and in mice following EAE induction, 
though to different extents (Fig. 6a). It increased in CFA/PTX-treated control mice by D6, and 
displayed greater elevation through D15. The IgG appeared to be restricted to the CP stroma, as 
none could be readily seen to infiltrate the choroidal epithelium. These changes in IgG were even 
more dramatic in mice subjected to EAE by MOG-CFA/PTX treatment.  A visible increase in 
IgG immunostaining was first noted by D6, becoming more extreme by D15. At this later time 
IgG was clearly seen permeating across the choroidal epithelium.  Because IgG staining became 
extremely diffuse by later stages of EAE, relative IgG leakage within the CP was quantified by 
relating its total volumetric staining to total volumetric staining of capillaries within each image 
(Fig. 3). An increase in IgG leakage was established in both control mice and those with EAE, 
with a greater level (~ three-fold) seen in the latter by D15 (Fig. 6b). 
 
5.6 Distribution of leukocytes in the CP following immunization 
 
 CFA/PTX injection alone resulted in increased apprearance of leukocytes in the CP, 
compared to that seen in naïve mice (Fig. 7a).  However, these leukocytes appeared to be in close 
association with the CP capillaries and/or confined to the stroma. This moderate leukocyte 
increase was reversed to normal level by D9, where it remained through D15.  MOG-CFA/PTX 
also resulted in an apparent influx of leukocytes in the CP at D6 and D9, which reverted by D15. 
Notably, at D15 leukocytes could be seen closely associated with the choroidal epithelium, a few 
apparently caught in the act of extravasating past the epithelial barrier.  That these leukocytes 
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were, in fact, outside of the CP stroma, was revealed by rotation of 3D images, wherein some 
extravasated leukocytes in the CSF could be seen still tethered to the luminal surface of 
choroidal epithelium (see Video, Supplemental Digital content 4, which shows leukocytes 
attached to the CP epithelium). It is important to emphasize here that any leukocytes fully 
extravasated into the CSF are unlikely to be represented in these images, as the cells would not 
be retained in the ventricles following tissue sectioning and immunostaining. Quantification 
showed that the number of leukocytes significantly increased in the CP at D6 following 
CFA/PTX treatment, and also did so at D6 and D9 after MOG-CFA/PTX, before returning to 
normal levels (Fig 7b). 
 
6. Discussion 
 
 While the appearance and developmental regulation of TJs in the CP have been rigorously 
investigated over nearly five decades (24, 25, 46-57), much less is understood of the alterations 
of these junctions and their protein constituents during neuroinflammatory disease and their 
relation to BCSFB permeability and leukocyte extravasation (58).  Hence, high resolution, 3D 
imaging of the CP was performed in this study to track and quantify such alterations and their 
functional correlates; i.e., extravasation of IgG and leukocytes, during evolving EAE, and to 
distinguish MOG-associated changes from those due to adjuvants alone.  
 Our use of LCM/qRT-PCR to selectively analyze the CP choroidal epithelium confirmed the 
relative gene expression of major TJ proteins in the particularly MOG-sensitive C57BL/6 mouse, 
a similar pattern having previously been described in the Sprague-Dawley rat by standard qRT-
PCR of total RNA from whole CP tissues (25). These results reinforced emerging LCM 
technology as a critical tool to probe gene changes in discrete compartments of the CP (42), and 
focused our attention on TJ proteins ZO-1 and CLN-2 for detailed, 3D image analysis.  
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 Strong and smooth immunostaining of both ZO-1 and CLN-2 was associated with all 
intercellular junctions of CP epithelial cells in naïve mice, as has been previously reported in 
these cells from various species (24, 37, 45, 59). However, ZO-1 and CLN-2 showed markedly 
different responses to MOG immunization or injection of adjuvants.  The pattern of ZO-1 
immunostaining became moderately distorted after CFA/PTX alone, and more drastically 
crenulated following MOG immunization. To the best of our knowledge, this is the first 
description of such alterations in TJ staining in vivo. Recent in vitro reports have given similar 
accounts of “ruffled” or “wavy” ZO-1 patterns associated with loosening of epithelial TJs of 
cultured Caco-2 and MDCK cells following application of nanoparticles or mechanical stretch 
(60, 61). Together, these observations seemingly highlight a common manifestation of ZO-1 
redistribution that accompanies epithelial barrier disruption.. While the basis and physiological 
significance of the peculiar alteration of ZO-1 appearance noted here remain unknown, Samak et 
al. (43) noted the comparable disruption in Caco-2 cells to be associated with JNK-2-, c-Src- and 
MLCK-dependent mechanisms. Interestingly, radical ultrastructural changes in CP epithelial 
cells, e.g., widening of intercellular clefts, have been reported following experimental traumatic 
brain injury (62), and the two findings may be related to observations in the current study. The ~ 
three-fold increase in both the mean inter-nuclei distance and ZO-1 perimeter of CP epithelial 
cells during EAE is further consistent with a significant increase in cell volume, and points 
toward an even more gross histopathology associated with EAE than has been previously 
imagined. Interestingly, while describing distributions of TJ proteins at the CP more than a 
decade ago, Wolburg et al. (24) did not note any changes in ZO-1 distribution in EAE afflicted 
mice, and specifically commented on the difficulties of obtaining quantitative results by 
immunohistochemistry when using conventional confocal microscopy. The advantages afforded 
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by state-of-the-art high-resolution 3D imaging may thus have uniquely enabled us to uncover 
and quantify the remarkable ZO-1 responses in the CP choroidal epithelium. 
 By contrast to the observed effects on ZO-1, changes in CP epithelial CLN-2 following 
immunization appeared much more subtle. CLN-2 showed no obvious alterations in pattern after 
CFA/PTX treatment and a minimal decrease in the amount of immunoreactivity. A similar trend 
was observed following MOG immunization, but with a sharper decrease in immunoreactivity of 
CLN-2 that ultimately presented a fragmented appearance. Wolburg et al.(24) similarly observed 
the immunostaining of CLN-2 to be “interrupted” in the CP choroidal epithelium following EAE 
immunization, but did not resolve whether this was due to MOG or adjuvant effects.  Kooij et 
al.(45) also recently described a comparatively tempered loss of CLN-3 immunostaining in this 
tissue in mice immunized for EAE, possibly suggesting this type response is common among the 
different CLN proteins of the CP during neuroinflammation, as opposed to the more peculiar 
change in pattern evidenced by ZO-1.  
 That the responses of the two classes of TJ proteins, ZO-1/ZO-2 and CLN-2/CLN-3, were 
vastly different from each other could reflect their respective positions and roles within the TJ 
complex. Peripheral membrane ZO proteins, lying internal to CLNs and directly connected to the 
actin cytoskeleton (38-40), might transduce the disruptive inflammatory signal to their integral 
membrane CLN protein partners.  Inasmuch as the epithelial actin cytoskeleton can become 
severely disorganized during both PTX treatment and inflammation (63, 64), this could 
potentially lead to retraction of ZO proteins from its membrane locale and disengagement from 
CLNs. No longer bound to ZO proteins, CLNs might be susceptible to rearrangement and/or 
degradation (41, 43).  Whatever their cause, the different effects on these two proteins 
underscores the complexity of actions taking place at the level of the TJ in the CP choroidal 
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epithelium, and that the response of individual TJ proteins cannot be assumed to be similar. 
Disparities in responsiveness among various TJ proteins have also been reported in cultured CP 
choroidal epithelial cells (65). In this case, CLN-2 showed reduced protein level by Western 
blotting following treatment with protein kinase C activator, phorbol 12-myristate 13-acetate, 
while levels of CLN-1, ZO-1 and occludin were spared.  
 In line with the characterization of the fenestrated CP capillaries as normally “leaky” (15, 66, 
67), there was some evidence – albeit scarce – of IgG immunostaining and a few leukocytes in 
the CP stroma of naïve mice. In contrast, while using the same technology as employed here, 
virtually no IgG or leukocytes were detected around parenchymal CNS microvessels in the naive 
situation (41, 43).  It would thus appear that while CP capillaries in the healthy state are 
somewhat more permeable than the BBB, their perception as being “highly permeable” (68) and 
“allowing the free passage of molecules and cells (69)” may merit some reconsideration.  This 
would concur with the description of fenestrated endothelia in airway exchange vessels having 
permeabilities to plasma proteins that are about the same as found in continuous endothelia (70).  
 CP capillaries nevertheless seemed to become significantly more leaky in response to 
CFA/PTX or MOG-CFA/PTX, allowing for extravasation of IgG and leukocytes into the stromal 
compartment. It is possible that some of the IgG appearing in the stroma might have derived 
from intrathecal synthesis by B cells. However, the fact that IgG levels continually increased 
while leukocytes decreased in the CP stroma at later time points argues against B cells being the 
exclusive or major source of IgG observed, suggesting a significant amount of this protein was 
serum-derived. The basis for this effect is unclear at this time, as the presence of TJs or other 
less-restrictive junctional specializations in CP capillaries has not been confirmed (68). 
Nevertheless, CLN-5, occludin and ZO-1 have been reported in this vascular bed (45, 53) and 
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could possibly be targets of CFA/PTX or MOG-CFA/PTX action. A previous finding by this 
laboratory that the chemokine CCL2 is elevated within the CP capillary plexus following 
CFA/PTX or MOG-CFA/PTX treatment (42) may thus relate to the enhanced IgG leakiness 
noted here, as this chemokine has been linked to downregulation and/or redistribution of 
endothelial CLN-5, occludin and ZO-1 in association with increased permeability (43, 71-75). 
Appearance of IgG leakage across the CP choroidal epithelium was only observed following 
MOG-CFA/PTX, and may be due to the more severe alterations in TJ proteins that accompany 
neuroinflammation.  
 The observation that few leukocytes were present in the CP stromal space in naïve mice is 
consistent with other recent descriptions (45, 76), and may reflect a limited permeability of 
normal CP capillaries to blood cellular elements. Specifically, scant CD3+ and CD4+ T cells, and 
CD68+ cells of myeloid lineage (dendritic cells and macrophages) have been shown to normally 
reside in this CP compartment (13, 77, 78). Both CFA/PTX and MOG-CFA/PTX produced a 
transient increase in the CP leukocyte population. The pathway(s) by which leukocytes 
accumulate in the CP stroma remains uncertain, as previous reports using immunohistochemistry 
at the light and ultrastructural levels noted expression of adhesion molecules, ICAM-1, VCAM-1 
or MAdCAM-1, on the CP choroidal epithelium but not along the CP capillaries in SJL mice 
with EAE induced by immunization with CFA/PTX and proteolipid protein (79, 80). However, 
this laboratory recently utilized laser capture microdissection to detect upregulated gene 
expression of VCAM-1, E-selectin, P-selectin and Smad-3 in the CP capillary bed of C57BL/6 
mice following CFA/PTX or MOG-CFA/PTX, with Smad-3 exclusively among these showing 
super induction during MOG-CFA/PTX-induced EAE (42). Reinforcing the relevance of these 
gene findings, E- and P-selectin immunoreactivity has also been described in the CP vasculature 
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of patients with non-neurological disorders (13). Previously noted examples of up-regulated 
chemokine expression in these microvessels, e.g., CCL2, CCL5 and CCL19 (42) may thus act 
cooperatively with elevated adhesion molecule expression to drive leukocyte extravasation 
across the CP capillaries into the stroma. At present, we are unaware of any descriptions of the 
CP bearing specialized post-capillary venules – the preferred sites of exit of leukocytes from the 
circulation (81) – but are mindful of the possibility that leukocyte extravasation from the 
circulation could occur at the transitional regions between the CP capillary plexus and draining 
venules (13). 
 Only MOG-CFA/PTX treatment showed clear evidence of leukocyte extravasation across the 
CP choroidal epithelium – which, for CCR6-bearing Th17 cells, is thought to be mediated, in 
significant part, by epithelial expression of the chemokine CCL20 (22). That the CD45+ cells 
observed clinging to the apical side of the CP choroidal epithelium actually represent 
extravasating leukocytes, is strongly supported by the sequence of images following MOG-
CFA/PTX immunization, which showed these cells first appearing in the CP stroma, then in 
association with the basolateral epithelial surface, and finally attached to the apical epithelial 
surface facing the CSF. To the best of these authors’ knowledge, the scenario shown is the first 
histological evidence of such directed transit through the entire CP. This finding is also in accord 
with inability of CFA/PTX treatment, alone, to cause clinical EAE in these mice (42), and 
directly supports that the rudimentary processes underlying neuroinflammatory diseases such as 
MS and EAE originate via the trafficking of leukocytes through CP into the CSF (13, 16-18, 22). 
The prior observation by Schmitt et al.(77), that CFA/PTX, alone, resulted in a subtle but 
definite increase in the number of myeloid cells in the extraventricular CSF spaces, could 
suggest that this adjuvant combination promotes modest leukocyte extravasation across the CP 
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choroidal epithelium but at a level too low to be readily detected even by high-resolution, 3D 
confocal microscopy. In this regard, histologically capturing leukocytes in the act of 
extravasating across the CP choroidal epithelium is particularly challenging, as they are, in 
effect, washed away after entering the CSF. 
 As with the observed IgG leakage at this site, the more profound perturbations in TJ proteins 
caused specifically by MOG-CFA/PTX treatment may enable leukocytes accumulating within 
the CP stroma to more effectively migrate between the choroidal epithelial cells and into the 
CSF, as depicted schematically in Fig. 8.  Alternatively, other factors induced by MOG-
CFA/PTX, e.g., chemokines and/or adhesion molecules, may facilitate leukocyte extravasation at 
this level, which, in turn, alters the integrity of the CP choroidal epithelium leading to the TJ 
protein manifestations and IgG leakage observed. The fact that the CP stroma showed apparent 
reduction in the leukocyte population from D9 to D15 may further represent time needed for 
leukocyte extravasation across the CP choroidal epithelium.  
 While no absolute cause and effect relationship between the observed TJ alterations and 
IgG/leukocyte extravasation can be established at this time, it is significant to point out that 
neither IgG nor leukocytes were seen permeating the CP choroidal epithelium until D15 
following MOG-CFA/PTX, while changes in both ZO-1 and CLN-2 were observed earlier (D9). 
This time frame is thus consistent with the noted structural changes in CP choroidal epithelial TJ 
proteins having functional consequences that encourage extravasation of IgG and leukocytes. 
 Collectively, these results reinforce the notion that CFA/PTX instigates a series of molecular 
and structural changes associated with neuroinflammation that is augmented when this adjuvant 
combination accompanies MOG immunization. At present, it is unclear whether only one or both 
adjuvants were responsible for the observed effects, as our objective was to specifically highlight 
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changes in TJ protein distribution and IgG/leukocyte extravasation stemming from MOG 
immunization versus collective adjuvant action. CFA and PTX have each been shown to 
separately disrupt TJs and increase permeability at the BBB in other settings (82, 83). However, 
PTX was not found to disrupt barrier function in epithelial Plexus choroideus-derived monolayer 
cultures (84), suggesting that CFA might be responsible for the effects noted here or that the two 
adjuvants cooperate to alter TJs and structural integrity of the CP capillaries and/or choroidal 
epithelium in vivo in support of IgG and leukocyte extravasation. 
 This laboratory previously reported that CFA/PTX alone elicited significant changes in the 
expression of numerous immune response associated genes in both CP capillary and choroidal 
epithelium compartments (42), while MOG-CFA/PTX resulted in super induction of some of 
these genes as well as stimulated a novel cadre of genes in this same functional category. In the 
current report we extend these findings to show CFA/PTX further instigates structural changes in 
the CP that may facilitate the autoimmune response to MOG. Thus, while it has been reported 
that PTX, in particular, can drive CNS autoimmunity via regulation of TLR4 signaling and 
opening up the BBB (85, 86), CFA/PTX appears to act more broadly to “raise the floor” of a 
collective of inflammatory processes in the CP necessary for neuroinflammatory disease, like 
EAE, to develop.  A couple of implications are worth noting here.  Attempts to attribute gene or 
histological changes seen in EAE as being a specific autoimmune response to MOG, might 
overlook significant contributions by CFA and/or PTX.  Also, the fact that CFA/PTX exerts 
prominent effects in the CP – considered a possible gateway for leukocytes to invade the 
uninflamed CNS (8, 9, 87) – calls attention to the prospect that other environmental toxins with 
activities like CFA or PTX might target this brain structure to help trigger cases of CNS 
autoimmunity (88) 
	   26	  
 Further clarification of the modes of leukocyte trafficking through the CP should enable 
more efficient drug targeting to this organ and significantly broaden the prospects to treat 
neuroinflammatory disease (89, 90).  
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FIGURE 1.  LCM analysis of tight junction gene expression in choroidal epithelial cells. The CP of a naïve 
mouse was double immunostained for LCM analysis. (a) CP tissue section before LCM retrieval. Capillaries 
were stained by immunohistochemistry for CD31, employing alkaline phosphatase detection and NBT/BCIP 
substrate (dark purple); choroidal epithelial cells were stained by immunofluorescence using FITC-conjugated 
antibody to pan-cytokeratin (green). (b) Laser shots showing the retrieval of choroidal epithelial cells and their 
deposition on the cap (c). (d) CP tissue section after LCM retrieval of epithelial cells, showing capillaries left 
behind. (e) Collection of LCM shots of epithelial cells on the cap used for gene expression analysis.  (f) qRT-
PCR analysis of LCM-derived CP epithelial tissue, indicating expression of the epithelial marker K8, and several 
tight junction proteins.	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FIGURE 2. Distribution of tight junction proteins, IgG and leukocytes in normal CP tissue. Representative 
sections of the CP of naïve mice are depicted. Capillaries were immunostained for CD31 (red) in all images, 
and isosurface rendered in images (a – c). Nuclei of the choroidal epithelial cells were stained with DRAQ5 
(blue) in images (a – c). (a) ZO-1 immunostaining (green) and (b) CLN-2 immunostaining (green) appear 
uniform and smooth along the inter-epithelial junctions, as highlighted in the insets. (c) IgG immunostaining 
(green) is scant and seen in only focal deposits apparently within the stroma (white arrow, insert). (d) 
Choroidal epithelial cells were immunostained for cytokeratin (green); leukocytes were immunostained for 
CD45 (blue), and isosurface rendered to highlight their 3D appearance and spatial relation to the different 
compartments of the choroid plexus. A few leukocytes are clearly present, seemingly associated with 
capillary network or in the stroma (insert)  	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FIGURE 3. 3D quantification of CP tight junction protein, IgG and leukocytes during evolving EAE. Representative 
sections of the CP of mice at D15 EAE are depicted to elaborate the approaches used for quantification of disease-
associated changes in CP tight junction protein and IgG leakage. (a, d, g) show composite 3D data sets of confocal z-
stacks. The 3D frames are presented to display the holistic acquisition of the data.  (b, c), (e, f) and (h-i) show 2D 
depictions of the images in (a), (d) and (g), respectively. Such 2D projections of 3D images served as the sources 
from which quantitative data were obtained. Isosurface rendering was performed to highlight the tortuous nature and 
3D disposition of the respective CP compartments. Capillaries were immunostained for CD31 (red) and isosurface 
rendered throughout. ZO-1, shown as an example of tight junction protein within the choroidal epithelium, was 
immunostained (green) in (a – c), and isosurface rendered in (c). IgG was also shown immunostained (green) to 
exemplify serum protein leakage (d – f) , and isosurface rendered in (f). Choroidal epithelial nuclei were stained with 
DRAQ5 (blue) in (a-f) while leukocytes were stained for CD45 (blue) in (g-i); DRAQ5- and CD45-stained 
structures were reconstructed as “spheres” in (c) and (i) respectively.  Inserts in (c) show the total ZO-1 staining 
(top) and nuclei staining (bottom) used to calculate relative amount of tight junction protein/choroidal epithelial cell. 
Inserts in (f) show total IgG staining (top) and capillary staining (bottom) used to calculate relative amount of leaked 
IgG/capillary mass. Inserts in (i) show the total number of leukocytes (top) and total capillary staining (bottom) used 
to calculate relative number of leukocytes/ capillary surface area.  	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FIGURE 4. ZO-1 distribution in the choroid plexus during evolving EAE. (A) Representative sections of the CP 
were collected at the indicated time-points in control mice (CFA/PTX) or in mice following EAE induction 
(MOG-CFA/PTX). Capillaries were immunostained for CD31 (red), and isosurface rendered in all images to 
highlight the swelling of these microvessels during disease. Choroidal epithelial cells were stained with DRAQ5 
(blue) to identify their nuclei and immunostained for ZO-1 (green). Insert highlights area of extensive crenulation 
of ZO-1 immunostaining in mice at D15 EAE. (B) 3D quantification and analysis of the changes in total area of 
ZO-1 per epithelial cell nuclei for both the groups: CFA/PTX and MOG-CFA/PTX. A significant increase in area 
is seen in D9 and D15 EAE compared to naïve ZO-1 staining, *p<0.05, ***p <0.001 	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FIGURE 5. CLN-2 distribution in the choroid plexus during evolving EAE. (A) Representative sections 
of the CP were collected at the indicated time-points in control mice (CFA/PTX) or in mice following 
EAE induction (MOG-CFA/PTX). Capillaries were immunostained for CD31 (red), and isosurface 
rendered in all images to highlight the swelling of these microvessels during disease. Choroidal epithelial 
cells were stained with DRAQ5 (blue) to highlight their nuclei and immunostained for CLN-2 (green).  
White arrows show focal disruptions in CLN-2 staining by D15 EAE. (B) 3D quantification and analysis 
of the changes in total area of CLN-2 per epithelial cell nuclei for both the groups: CFA/PTX and MOG-
CFA/PTX. A significant decrease in area corresponding to the loss in focal staining is seen in D9 and D15 
EAE compared to naïve CLN-2 staining, **p<0.01, ***p<0.001. CFA/PTX group showed a significant 
decrease in area by D15 as well, *p<0.05 	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FIGURE 6. IgG distribution in the choroid plexus during evolving EAE. (A) Representative sections of the 
CP were collected at the indicated time-points in control mice (CFA/PTX) or in mice following EAE induction 
(MOG-CFA/PTX). Capillaries were immunostained for CD31 (red), and isosurface rendered in all images to 
highlight the swelling of these microvessels during disease. Choroidal epithelial cells were stained with 
DRAQ5 (blue) to highlight their nuclei, and IgG was immunostained (green). IgG can be seen extravasating 
across the choroidal epithelium in mice increasing with extending timepoints in CFA/PTX and with increased 
severity in MOG-CFA/PTX (white arrows, insert). (B) 3D quantification and analysis of the changes in total 
IgG per total capillaries for both the groups: CFA/PTX and MOG-CFA/PTX. A significant increase in 
extravasating IgG can be seen in D15 Control and, D9 and D15 EAE compared to naïve IgG staining, *p<0.05, 
**p<0.01 and ***p<0.001 
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FIGURE 7. Leukocyte extravasation in the choroid plexus during evolving EAE.  Representative sections of the 
CP were collected at the indicated time-points in control mice (CFA/PTX) or in mice following EAE induction 
(MOG-CFA/PTX). Capillaries were immunostained for CD31 (red). Choroidal epithelial cells were 
immunostained for cytokeratin (green). Leukocytes were immunostained for CD45 (blue), and isosurface rendered 
in all images to highlight the 3D appearance of these cells and their spatial relation to the different compartments 
of the choroid plexus. In control choroid plexus, the number of leukocytes appears to increase at D6 but returns to 
near naïve level by D9 and D15. The leukocytes in these mice appear to remain associated with the capillaries or 
stroma. In choroid plexus of mice with EAE, an increase in leukocytes is apparent at D6 and D9, which reverses to 
naïve level by D15.  Insert highlights leukocytes that can be seen associated with the apical surface of the 
choroidal epithelium, likely extravasating into the CSF at D15 EAE. (b) 3D quantification and analysis of the 
changes in total number of leukocytes per total surface area of capillaries for both the groups: CFA/PTX and 
MOG-CFA/PTX. A significant increase in accumulation of leukocytes can be seen in D6 Control and, D6 and D9 
EAE compared to naïve CD45 staining, *p<0.05, **p<0.01 and ***p<0.001. 	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FIGURE 8. Schematic diagram of the Choroid Plexus. “Leaky” fenestrated capillaries (1) are surrounded by a 
“tight” layer of epithelial cells (2) that express tight junctions (3), forming the BCSFB. The stroma (4) lies in 
between the two layers. Loss of BCSFB integrity during neuroinflammation is associated with alteration of tight 
junctions (3), leakage of serum protein IgG (5) and extravasation of leukocytes (6) across the BCSFB into the 
CSF.  Leukocyte extravasation is depicted as occurring paracellularly; i.e., between choroidal epithelial cells, as 
it accompanies junctional disruption, though the precise mode has not been established.	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Supplemental Fig. 1 Measurement of inter-nuclei distances between CP choroidal epithelial cells. (a) 
Representative sections of the CP from naïve and MOG-CFA/PTX-treated mice at D15. Scale bars represent 
5µm (naïve) and 10µm (MOG-CFA/PTX). Capillaries were immunostained for CD31 (red) and isosurface 
rendered. Choroidal epithelial cells were stained with DRAQ5 (blue) to highlight nuclei, and immunostained 
for ZO-1 (green). Inter-nuclei distances were calculated by placing a measurement point in the center of each 
epithelial cell nucleus and measuring the distance between adjacent points, as highlighted in the inserts and 
described in Materials and Methods. Note that the distance bars connecting the adjacent center points are in all 
three planes; this, together with the different scales, makes some longer distance bars in the MOG-CFA/PTX 
sample ‘appear’ artificially smaller than shorter distance bars in the naïve sample. (b) A significant increase in 
inter-nuclei distances between CP epithelial cells was found in MOG-CFA/PTX-treated (EAE) mice compared 
to naïve mice, *p<0.001. 	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Supplemental Fig. 2 Measurement of the perimeter of ZO-1 staining in choroidal epithelial cells. (a) 
Representative sections of the CP from naïve and MOG-CFA/PTX-treated mice at D15. Scale bars represent 
5µm (naïve) and 10µm (MOG-CFA/PTX). Choroidal epithelial cells were immunostained for ZO-1 (green). 
Measurement points were placed along epithelial ZO-1 staining to recreate the ZO-1 staining boundary as 
described in Materials and Methods. The sum of the all the distances between adjacent points provided an 
estimate of the perimeter of ZO-1 staining. (b) A significant increase in ZO-1 perimeter was found between 
naïve and MOG-CFA/PTX-treated (EAE) mice, consistent with cellular enlargement, *p<0.001. (c) Schematic 
showing effects of inflammation on choroidal epithelial cell TJ proteins, ZO-1 and CLN-2, in association with 
disruption of the cytoskeleton (CSK). An increase in epithelial cell size is concomitant with visible distortion of 
ZO-1, and fragmentation of CLN-2, immunostaining patterns. 	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Supplemental Figure 3.  ZO-2 and CLN-3 distribution in the choroid plexus during evolving EAE. (a) 
Representative sections of the CP from naïve and MOG-CFA/PTX-treated mice at D15. Choroidal epithelial 
cells were immunostained for ZO-1 (green) and epithelial nuclei were stained with DRAQ5 (blue). Insets 
highlight the smooth TJ staining in naïve CP, which begins to rearrange into a crenulated pattern by D15. (b) 
Choroidal epithelial cells were immunostained for CLN-3 (green) and epithelial nuclei were stained with 
DRAQ5 (blue). Insets highlight the smooth TJ staining in naïve CP, which drastically decreases by D15.  
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Spatiotemporal resolution of spinal meningeal and parenchymal inflammation 
during experimental autoimmune encephalomyelitis 
 
1. Abstract 
 
Experimental Autoimmune Encephalomyelitis (EAE), animal model suggestive of 
neuroinflammatory events similar to that of Multiple Sclerosis, has a very typical course of 
disease. The inflammation is known to predominantly localize to the spinal cord with disease 
pathology known to begin from the caudal most end of the cord, as indicated by the clinical 
exacerbations following EAE induction in C57BL6 mice. EAE induced mice regress from 
showing no clinical signs to partial limp tail followed by a paralyzed tail. The paralysis gradually 
moves towards the hind limbs, followed by the forelimbs and finally to a moribund state at the 
peak of the disease. However, how the patterns of inflammation propagate within and along the 
length of the cord is relatively unknown. Lesser known still is the extent and pattern of 
meningeal inflammation within the cord, which reportedly has been associated with the 
pathology within the spinal cord parenchyma including axonal loss and increasingly recognized 
co-relation to the clinical evolution of the disease. This report provides a detailed 
immunohistochemical analysis of the patterns of inflammation including the waves of immune 
cells along the cord throughout the course of the disease. Results indicate that meningeal 
inflammation precedes parenchymal inflammation at all levels of the spinal cord, but does not 
develop equally or simultaneously throughout the SAS, beginning at the caudal end and working 
its way to the rostral extreme of the spinal cord.  These differences in inflammation patterns 
within the sections of the spinal cord was further illustrated by immune-LCM assisted selective 
capture and immune gene profiling of the meningeal and parenchymal vessels within the cervical 
Chapter III: Spinal cord in evolving EAE 
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and lumbar sections of the spinal cord. Each of these segments, meningeal and parenchymal 
vessels within the cervical and lumbar regions showed a varied pattern in expression of 
significantly regulated immune genes along the course disease progression. 
2. Introduction 
 
As mentioned in earlier chapter II, multiple sclerosis (MS) and its surrogate animal model, 
experimental autoimmune encephalomyelitis (EAE), are widely considered chronic, immune-
mediated, demyelinating diseases of the central nervous system CNS, with CD4+ T cells most 
commonly accused of being the major suspects (1-5, 91, 92). Dysfunction of the blood-brain 
barrier (BBB) - the specialized microvascular endothelium that normally restricts passage of 
soluble and cellular elements between the CNS and circulation, and accompanying leukocyte 
infiltration of the CNS parenchyma are noted hallmarks of both diseases (6, 7, 93). Such 
leukocyte infiltrates in the CNS have long begged the question: How do the earliest myelin-
reactive T cells initially breach the formidable BBB of the uninflamed brain? 
 The “two-wave” model of neuroinflammation offers some possibilities (8, 9), 
highlighting a previously unappreciated role for the choroid plexus (CP). A specialized out-
pocketing of the roofs of the third, fourth, and lateral ventricles, the CP is comprised of two 
distinct tissue layers: a highly vascularized core of “leaky” fenestrated capillaries with resident 
perivascular macrophages and dendritic cells entwined in a stromal matrix, encapsulated by a 
“tight” layer of epithelial cells (94, 95). Because of this arrangement of apparently permeable 
capillaries closely opposed to a relatively impermeable epithelium, CP is the designated part of 
the blood-cerebrospinal fluid barrier (BCSFB)(23, 68). The CP has further long been recognized 
as the major site of production of cerebrospinal fluid (CSF), within which it hangs suspended(19, 
35). However, more recent studies have also identified this structure as the locale where pioneer 
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T cells first gain a foothold in CNS territory (22, 27, 96). It is thought that following 
extravasation across the CP capillaries and choroidal epithelium into the CSF, T cells are 
gathered up by bulk CSF flow, and exit the fourth ventricle via the lateral foramina of Lushka 
and medial foramen of Megendie.  They then travel within the CSF stream to the subarachnoid 
space (SAS) between the arachnoid and pial meningeal membranes covering the brain and spinal 
cord. Once in the SAS, T cells can forge immune synapses with resident dendritic cells as part of 
normal immune surveillance, thus concluding the “first wave” of neuroinflammation.   The flare 
of cytokines resulting from these T cell: dendritic cell interactions, in turn, activates endothelial 
surfaces of nearby microvessels within the SAS, fostering adhesion and extravasation of 
leukocytes circulating in the bloodstream. Subsequent interactions between these invading 
leukocytes and other dendritic cells in the SAS and Virchow-Robbins space (with which the SAS 
is continuous) are thought to follow, ultimately propagating a “second wave” of non-specific 
leukocyte infiltration along the surface-penetrating microvessels that enter the CNS parenchyma. 
In this manner, the two-wave model consists of a neuroinflammatory “impulse” that originates in 
the SAS (first wave) and then is transmitted to the parenchyma (second wave).  
   While the animal model EAE has provided vast opportunity to gauge the significant role of 
meningeal inflammation in MS and other neuroinflammatory conditions (97), it obliges still 
other questions. Why does conventional EAE result primarily in spinal cord inflammation with a 
trajectory of ascending paralysis(5, 98-100)? Does the most caudal region of the spinal cord 
parenchyma display the first signs of inflammation? If so, is this because meningeal 
inflammation begins first at the caudal region as well? Or, might it be that meningeal 
inflammation is equally florid throughout the spinal cord from disease onset, but the 
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neuroinflammatory impulse is first conducted to the caudal parenchyma from which it then 
spreads rostrally?  
   To address these questions, studies were carried out to document when and where the first 
signs of inflammation appear in both the meninges and parenchyma along the entire spinal axis. 
Specifically, high-resolution 3-dimensional (3-D) confocal microscopy was performed to 
visualize, in detail, the development of leukocyte infiltration at distinct regions of the spinal 
cord. In addition, holistic examination of the entire spinal cord by “virtual slides” was also 
conducted using fluorescence microscopy to reveal the direction and relative magnitude of the 
propagation of inflammatory intensity along the length of the same spinal cord.  To further 
determine whether a difference in inflammatory gene expression by meningeal and parenchymal 
microvessels along the spinal axis reflects the course of ascending paralysis in EAE, laser 
capture microdissection (LCM) coupled with gene expression profiling was performed.  
   Results indicate that meningeal inflammation precedes parenchymal inflammation at all 
levels of the spinal cord, but does not develop equally or simultaneously throughout the SAS.  
Instead, meningeal inflammation is initially most obvious in the caudal SAS, from which it then 
proceeds to the directly underlying parenchyma, paralleling the first signs of clinical disease in 
the tail and hind limbs. Meningeal inflammation then extends in the caudal-to-rostral direction, 
followed by a similar, but delayed, trajectory of parenchymal inflammation. LCM further 
allowed selective profiling of immune genes within the meningeal and parenchymal vessels of 
the different regions of the spinal cord in its extremes: cervical and lumbar spinal cord.  
3. Materials and methods 
3.1 Animals 
Female C57BL/6 mice, age 8–10 weeks were obtained from Charles River Laboratories, Inc. 
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(Wilmington, MA). A total of n = 3 animals/group were used for each treatment and time-point 
assessed. All animal experimental procedures were performed following Animal Care and Use 
Guidelines of the University of Connecticut Health Center (Animal Welfare Assurance # A3471-
01), and approved under protocol # 100937-0917. 
3.2 EAE induction 
EAE was induced in mice by active immunization with MOG35-55 peptide 
(MEVGWYRSPFSRVVHLYRNGK), of murine origin (W. M. Keck Biotechnology Resource 
Center, Yale University), as described [21], following Animal Care and Use Guidelines of the 
University of Connecticut Health Center (Animal Welfare Assurance # A3471-01).  Briefly, on 
day 0 (D0), mice were injected subcutaneously with 300 µg of MOG peptide in complete 
Freund’s adjuvant (DIFCO, BD , Sparks MD) into the right and left flank, 100 µl per site. On D0 
and D2 mice were also injected intraperitoneally (i.p.) with 500 ng pertussis toxin (List 
Laboratories, Campbell CA) in PBS. Another group of age-matched mice was left untreated 
(referred to as “naïve” mice), and represented “normal” tissue. Mice typically showed 
development of acute clinical symptoms at ~ D12, followed by ascending paralysis and chronic 
disease (44). Animals were killed at D0 (naïve), D9 and D15 post-injection. Animals were 
monitored daily for clinical disease severity and scored as follows: 0 = normal; 1 = tail limpness; 
2 = limp tail and weakness of hind legs; 3 = limp tail and complete paralysis of hind legs; 4 = 
limp tail, complete hind leg and partial front leg paralysis. The time-points selected for both 
histological and gene expression a 
3.3 Tissue preparation and sectioning for 3D imaging  
Mice were anesthetized by i.p. injection of Ketamine (80 mg/kg) and Xylazine (10mg/kg) in 
PBS. Animals were then transcardially perfused first with Heparin-PBS (10 usp/ml) to 
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eliminate vascular blood content, and then with fixation buffer (2% paraformaldehyde in 0.1 M 
phosphate buffer) as described previously [20]. Spinal columns were harvested and the 
vertebrae removed via laminectomy (41). Spinal cords were then embedded in OCT 
cryomatrix compound (Thermo Fisher Scientific, Waltham, MA) for cryosectioning. 
Cryosections of 60µm thickness were obtained using a Microm HM 505M cryostat (Mikron 
Instruments; Oakland, NJ) maintained at -25°C, and deposited onto poly-L-lysine-coated slides 
for 3D confocal imaging.  
 
3.4 Tissue preparation and sectioning whole spinal cord scan imaging 
Spinal cords were harvested after identical perfusion fixation to that used for 3D imaging, 
except that laminectomy was not performed. Instead, whole spinal cord with intact vertebrae 
were embedded in OCT cryomatrix compound prior to sectioning. It was important to maintain 
the vertebrae to preserve the integrity of the meninges lying underneath. Due to the brittleness of 
the vertebrae, individual 7 µm-thick sections were captured on to an adhesive tape (Cryofilm 
type IIC, Section-Lab, Japan) and rolled for a smooth, intact cut. Adhesive tape strips were then 
glued (sections facing up) onto glass sides using an optical adhesive (Norland products, 
Cranbury, NJ) under UV light for 10 min. The glass slides with the sections were then used for 
whole spinal cord scan imaging.  
 
3.5 Immunostaining and Image acquisition for 3D analysis and whole image scan 
Sections (both for 3D analysis and whole image scans) were permeabilized with 1% Triton X-
100 in PBS for 30 min, and non-specific binding blocked by incubation with Power block® for 
10 min in Ultrapure (GIBCO) distilled water (41). The spinal cord vessels were stained with rat 
anti-mouse CD31 antibody (BD Pharmingen) at 1:160 dilution, followed by incubation with 
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goat anti-rat Alexa Fluor® 555 antibody (Life Technologies) at 1:250 dilution. Epithelial cells 
were stained with monoclonal pan-cytokeratin-FITC antibody (Sigma) at 1:160 dilution. 
DRAQ5 (Biostatus Ltd., Leicestershire, UK) was used to stain nuclei at 1:1000 dilution. Alexa 
Fluor® 647 anti-mouse CD45 (Biolegend) at 1:160 dilution was used to stain leukocytes. 
Sections were mounted in Mowiol (Sigma-Aldrich). Confocal z-stacks (multi-track scan) were 
acquired using a Zeiss LSM 510 Meta equipped with a Zeiss Fluar 40X/1.30, 63X Plan-
neofluar/1.25 and 100X Plan-apochromatic/1.4 oil immersion objective lens. Thereafter, z-
stacks were imported into Bitplane Imaris® suite version 7.1 x64 software (Bitplane Inc., South 
Windsor, CT), as described previously (41).  Whole scan spinal cord images were acquired 
using a Zeiss Axioscan.Z1 at 10X and images imported into Ziess microscope software Zen 
(Thornwood, NY, USA) for analysis.  
 
3.6 Tissue preparation and immunostaining for LCM  
Immunohistochemistry-guided LCM was performed as recently detailed (42, 96).  Naïve animals 
were euthanized by CO2 inhalation. Spinal cords were immediately removed, cleaned off of extra 
tissue and dissected into cervical (C1-C8) and lumbar (L1-L5) sections with the vertebrae intact.  
The spinal cord segments were then snap-frozen in dry ice-cooled 2-methylbutane (Acros; Geel, 
Belgium), and embedded in cryomatrix compound (Thermo Fisher Scientific, Waltham, MA) for 
cryosectioning. Longitudinal sections (7µm) were cut on a Microm HM 505 M cryostat (Mikron 
Instruments; Oakland, NJ) and affixed to uncoated, pre-cleaned glass slides (Fisher Scientific, 
Pittsburgh, PA). The spinal cord vessels were stained using a substrate combination, nitro-blue 
tetrazolium chloride/5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt (Vector Labs, 
Burlingame, CA), to detect the endogenous alkaline phosphatase activity in endothelial cells. 
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3.7 Laser Capture Microdissection (LCM) and cDNA synthesis 
A PixCell IIe laser capture microscope (Life Technologies, Foster City, CA) was used to retrieve 
the meningeal and parenchymal vessels. Obtained LCM tissue was solubilized in Cell Lysate 
Buffer (Signosis; Sunnyvale, CA). Cell Lysate Buffer® extracts were treated with Turbo DNase 
and inactivation reagent (Ambion; Austin, TX) according to the manufacturer’s instructions. 
Samples were then reverse transcribed using the SuperScript III (Invitrogen) standard protocol 
with random hexamers (Roche; Indianapolis, IN).  
 
3.8 Pre-amplication of cDNA and qRT-PCR  
Pre-amplification was carried out for array analysis out using TaqMan® PreAmp Master Mix 
and a PreAmp Pool containing all the primers for detection by the Mouse Immune Panel 
TaqMan® Low density Array (TLDA; Life Technologies Corp., Foster City, CA) as previously 
described (42). This panel contains 93 immune-related genes plus three housekeeping control 
genes. Pre-amplification was carried out with an initial hold at 95°C for 10 min, followed by 14 
cycles at 95°C for 15 sec and 60°C for 4 min. Relative cDNA levels were quantified by qRT-
PCR using an an ABI 7900HT Fast Real-Time PCR System (Life Technologies Corp, and 
normalized to housekeeping gene GAPDH as described previously (34). Expression of genes 
relative to GAPDH was then represented as percent expression of GAPDH. Custom TaqManW 
primers/probes were used for the Mouse Immune Panel TLDA.  
3.9  Statistical Analysis 
All statistical analyses were performed using GraphPad Prism 5 (GraphPad, La Jolla, CA). For 
all sets of comparisons (meningeal vs parenchymal vessels in cervical and lumbar regions, and 
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cervical vs lumbar regions within meniges and parenchyma) individual genes from the two sets 
being compared were first subjected to Shapiro-Wilk normality test. Genes that passes the 
normality test were then compared for significance using paired, 2-tailed T-test, or Mann-
Whitney U test was used for genes that did not pass the normality test. Results were considered 
significant at P≤0.05.  
4. Results 
4.1 Regional sections of spinal cord show varying levels of leukocyte infiltration during 
EAE  
Fig. 9a highlights the extent of leukocytes in the respective meningeal and parenchymal 
compartments of the spinal cord during EAE, as revealed by CD45 staining, is dependent on 
time and segmental level.  At D6, several days before clinical disease is typically manifest, CD45 
staining is barely detectable in the meninges of the cervical spinal cord, and undetectable within 
the parenchyma at this time. Similarly, meningeal and parenchymal leukocyte infiltration of the 
lumbar spinal cord is sparse as well. Just prior to commencement of clinical disease at D9, the 
cervical spinal cord reveals limited leukocyte infiltration of the meninges but as yet no readily 
discernible leukocytes in the parenchyma.  The lumbar spinal cord also demonstrates scant 
leukocytes in both the meninges and parenchyma at this time. By day 15, during the acute phase 
of clinical EAE disease, the cervical spinal cord displays extensive meningeal leukocytes, while 
the underlying parenchyma just shows signs of incipient leukocyte infiltration. Meningeal 
leukocyte infiltration within the lumbar cord is even more florid at this time, and appearance of 
leukocytes in the parenchyma, while apparently less than that of the overlying meninges, is still 
vast and far more pervasive than that seen at the cervical level.  Fig. 9b confirms the differential 
extent of leukocyte infiltration in the meningeal and parenchymal compartments at the cervical 
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and lumbar levels of the spinal cord at D15. Nuclear staining shows there is much denser 
perivascular cellularity in the lumbar versus cervical meninges, as well as in the lumbar 
parenchyma compared to the cervical parenchyma.  Additionally, perivascular cellularity is 
greater in the meninges versus the parenchyma at both levels of the spinal cord. The differential 
cellularity within the respective meningeal and parenchymal compartments at the cervical and 
lumbar levels of the spinal cord during the progression of EAE is depicted in Suppl. Fig. 4.  
 
4.2 Whole spinal cord image scans reveal an ascending wave of leukocyte infiltration  
To acquire better appreciation of the segmental distribution of leukocytes along a single spinal 
cord at different time-points of EAE, whole spinal cords with intact vertebrae and preserved 
underlying meninges were analyzed.  Fig. 10 shows the immunostaining patterns of several 
marker proteins in the spinal cord of a naïve mouse, as a reference. Notably, CD45 staining is 
restricted to the vertebral column, most likely representing leukocytes of the spinal marrow 
(Kenyon et al., 1997).  Absent from the naïve cord is any clear leukocyte infiltration of the spinal 
meninges or parenchyma.  The method of sectioning and attachment of a longitudinal section of 
whole spinal cord to adhesive film is depicted in Suppl. Fig. 5.  Leukocyte distribution patterns 
along the entirety of spinal cords from animals at the acute (D15) and chronic (D23) stages of 
EAE are seen in Fig. 11a.   At D15, CD45 staining is apparent in the lateral meninges of the 
lumbar and thoracic levels of the cord, and in the dorso-medial sulcus where the penetrating 
meninges bisect the spinal parenchyma into the dorsal white matter columns and grey matter 
horns. Some CD45 staining of the lumbar parenchyma is also seen at this time. By D23, a wave 
of CD45 staining appears to proceed up the cord and is concentrated at the thoracic level in and 
around the dorso-medial sulcus. This wave appears more obvious in the intensity charts shown in 
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Fig. 11b. In the spinal cord of a naïve mouse CD45 staining is confined to the vertebral column – 
likely reflecting hematopoietic activity of spinal bone marrow (Shah and Hanrahan, 2011) – with 
no discernible signs of leukocyte infiltration into spinal tissue. At D15 EAE, leukocyte 
infiltration is overt in the meninges (including the dorso-medial sulcus) of the lumbar region with 
comparatively sparse CD45 staining seen in the upper levels of the cord. By D23, intensity of 
CD45 staining of the lateral meninges of the lumbar region is even more florid and manifest 
diffusely in the parenchyma as well.  Severely heightened staining in the dorso-medial sulcus at 
the thoracic level is also observed at this later stage. The clear distinction in degree of cellularity 
in the spinal meninges versus parenchyma, and between cervical and lumbar levels, is seen at 
higher magnification in Fig. 12, along with what appears to be meningeal leukocyte clusters at 
D15. Fig. 13 shows the disparity in regional parenchymal cellularity becomes even more 
pronounced by D23, as the most caudal spinal cord becomes suffused with nuclear and CD45 
staining, while increased cellularity in the meninges has progressed to the cervical level.  
 
4.3 Varying patterns in immune profiling of meningeal and parenchymal vessels of the 
cervical and lumbar spinal cord. 
Further analysis of differences between the cervical and lumbar regions of the spinal cord within 
the meningeal and parenchymal vessels was done using LCM. Site-specific isolation of these 
vessels coupled with TLDA arrays allowed probing of immune genes including adhesion 
molecules, cytokines, chemokines, statins, interleukins, T cell activation markers, co-stimulatory 
molecules, transcription factors and apoptotic markers. As the disease progressed from a naïve 
state to clinical acute EAE at D15, varying patterns of immune gene expressions was seen. Pro-
inflammatory gene expression in the naïve spinal cord was very minimal and not significantly 
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different in between either the meningeal and parenchymal sections or cervical and lumbar 
regions of the spinal cord. Fig. 14 highlights the genes that were significantly different in these 
regions in D9 of evolving EAE. Comparisons were made between two distinct sets. 1. Meningeal 
versus parenchymal vessels separately within first, the cervical region followed by the lumbar 
region (Fig. 14a-b): Fig 14a depicts cervical region has significant differences in expression of 
Ptgs2, CCR2, STAT1, VEGFa, Col4a5, Cd68 and Ski 2 between the meningeal and parenchymal 
vessels. In Fig 14b lumbar region shows significant differences in Ski, STAT1. VEGFa, STAT3, 
Socs2, Ece1, Edn1, Bax between the meningeal and parenchymal vessels. 2. Cervical versus 
lumbar regions separately within the meninges and then the parenchyma (Fig. 14c-d): Fig 14c 
highlights significant differences between the meninges of cervical and lumbar regions observed 
for Socs2, Ski, CCR2, IL18, STAT1, VEGFa, Bax, CD8a, Csf1, H2-Ea. Fig 14d shows that 
cervical and lumbar regions have significant differences in CD28, Cxcr3, CD3e, Bcl2, Il2ra, 
CCR2 and Col4a5.  Similarly, the same set of comparisons was carried out for D15 EAE spinal 
cord in Fig. 15(a-d). Fig. 15a shows the differences between meningeal and parenchymal vessels 
in the cervical region in CD38, CD86, Socs2, TGFβ1, STAT1, CD68, Il18 and Gzmb while 
lumbar region shows differences in VEGFa, VCAM1, Csf1, Ikbkb, Ski, Stat3, CCL2, Edn1 and 
CCR2 as depicted in Fig 15b. As shown in Fig 15c, meninges between the cervical and lumbar 
regions differed significantly in expression of Socs2, CD80, Stat1 and CD38 while meninges in 
the parenchyma showed significant differences in NOS2, Nfkb2,Tgfb1, Smad3, VCAM1, Ptprc, 
STAT3, Col4a5 and Cxcl1 as shown in Fig. 15d.  
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5. Discussion 
Results from this study reinforce and advance awareness that the meninges are sites of 
significant immune activity and feature prominently in the development of neuroinflammation in 
MS (101) and its animal model, EAE(10, 13, 102, 103).  Specifically, our findings provide new 
histological evidence of a progressive, spinal meningeal inflammation that proceeds in the 
caudal-to-rostral direction during development of EAE. A similar trajectory of parenchymal 
inflammation was also observed, but delayed compared to that of the meninges at all levels of 
the spinal cord. This scenario is consistent with inflammation being propagated from meninges 
to parenchyma (8, 9).  The possibility remains, however, that once parenchymal inflammation 
takes hold in the caudal spinal cord, it can then spread rostrally through both parenchymal and 
meningeal channels.  
  Whole spinal cord intensity scans most clearly exposed what appears to be an ascending 
pulsatile wave of leukocyte infiltration in both the meningeal and parenchymal compartments of 
the spinal cord during EAE progression.  While particular sensitivity of the lumbar (L5) region 
of the spinal cord to autoimmune inflammation has been resolved by ultrahigh-field MRI (104) 
and reported to be mediated by regional neural stimulation (105, 106), this is the first report we 
are aware of that documents preferred sites of meningeal involvement during evolving EAE.  
Moreover, whole spinal cord intensity charts reflect a conspicuous ascending wave of leukocyte 
infiltration in the meninges, which precedes an underlying parenchymal infiltration that advances 
in the same direction during EAE progression. The order of these similar, advancing patterns of 
meningeal inflammation and parenchymal inflammation is consistent with the interpretation that 
the former helps drive the latter.  
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 Immune gene profiling of selectively isolated meningeal and parenchymal vessels by 
immune LCM further correlated the differences in the inflammatory gene patterns between the 
sections of the spinal cord. The distinctly different set of genes expressed by the meningeal 
vessels in the lumbar versus the cervical region, depict the possible variations in immune 
regulation depending on the level of the spinal cord. As evidenced by the individual regional 
spinal cord and whole scan images, accumulation of CD45 positive cells were first visible within 
the meninges of the lumbar spinal cord by D15, and minimally present during D9.  This could 
correlate with the majority of significantly different genes (Socs2, Ski, CCR2, IL18, Stat1, 
Vegfa, Bax and Csf1) highly expressed in the meninges of the lumbar region when compared to 
the cervical region during D9 (Fig 14c). Although immune cell accumulations are not very 
evident during D9, the differential expression could provide factors increasing the susceptibility 
of this region to be inflamed first at a later stage in D15.  Comparisons also show that meningeal 
vessels have significantly higher expressed genes-Ski, Stat1, VEGFa, Stat3, Socs2 and Bax than 
parenchymal vessels at this time point. This could point toward genes such as VEGFa, STAT1 
and Ski possibly aiding in the earliest inflammation first noted within the meninges of the lumbar 
spinal cord evidenced by clusters of CD45. Parenchymal vessel inflammation is minimal at this 
point as evidenced by the spinal cord images. Differential set of genes is significantly expressed 
during this time in the parenchymal vessels of the lumbar region versus cervical region and in 
comparison with the meningeal vessels of both within the cervical and lumbar regions. CCR2 
seems to be highly expressed in the parenchymal vessels of the cervical region, more so that the 
meningeal expression.  
  Figures 9, 11 and 12 show the florid meningeal inflammation all along the cord including 
immune cell accumulations seen infiltrating into the sub-pial parenchyma within the lumbar 
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region. Immune profiling of D15 EAE meningeal and parenchymal vessels highlights gene 
differences that co-relate with this pattern of inflammation as shown in Fig. 15. Only a limited 
number of genes, minimally expressed (Socs2, CD80, Stat1, CD38) are significantly higher in 
the meninges of the lumbar regions compared to the cervical region. Whereas, the parenchyma 
demonstrates significant differences between the cervical and lumbar regions, with STAT3, 
Ptprc, Nos2, Nfkb2, Tgfb1 and Smad3 highly expressed in the lumbar region. Also to be noted, 
is the entirely different set of genes expressed by the parenchymal vessels within the cervical and 
lumbar regions that prove that each region is unique in its expression of immune genes. 
Interestingly, both CCL2 and CCR2 are significantly higher in the meningeal vessels of the 
lumbar region at D15, relating to the evidenced immuno-modulatory effects of CCL2 (44, 107, 
108). These results point towards the possibility that each region of the spinal cord is unique in 
its immune gene expression pattern, which could be the result of its location and differential 
regulation.  
  Once the immune cells enter the SAS and are triggered to release inflammatory 
cytokines, by nature of the anatomy of meningeal vessels lying within the CSF filled SAS (109), 
inflammation within these vessels could be swift and rampant as reported by Kivisakk et al. by 
detection of meningeal T cell infiltration through out the CNS(11). Parenchymal vascular 
inflammation of the underlying white matter tracks that succeeds SAS inflammation however, 
could be subject to segmental vulnerability. Intimate and convoluted arrangement of meninges 
within the cauda equina (hair-like endings of the lumbar spinal cord) could uniquely allow 
inflammatory signals to be readily relayed from SAS meningeal vessels to parenchymal vessels 
in the lumbar segment. In support, reports by Arima et al. show that autoreactive T cells access 
the CNS parenchyma via the fifth lumbar spinal cord, this region being defined by an 
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upregulated CCL20, CCL2 and IL6 (105), important players in inflammation in EAE. Hence, the 
parenchymal vessels in the lumbar region compared to cervical region showed   different 
immune profile with earlier signs of inflammation by up-regulating their immune profile. We 
noticed heightened immune response within the meningeal compared to parenchymal vessels 
during earlier stages (D9), followed by inflammation in the parenchymal vessels in the later 
stages (D15) beginning from the lumbar segment.  
  In summary, results obtained from imaging and further validated by immune profiling of 
meningeal and parenchymal vessels from cervical and lumbar regions give a sense of directed 
progression of immune cells accumulation and inflammation during evolving neuroinflammation 
summarized in a schematic (Fig. 18). The sequence of events in developing EAE begin with 
CD45 cells accumulating within the CP and crossing through the BCSFB into the CSF flowing 
within the SAS (96) typically around D6 to D9 with the clinical score ranges from 0-0.5. This is 
followed by the accumulation of infiltrating immune cells seen within the meninges, more 
distinct within the lumbar region due to these cells penetrating the pial membrane and 
accumulating within the parenchyma as well, typically evidenced around D15, where EAE 
induced animals display a clinical score ranging from 0.5-2. By D23, the animals display 
symptoms of peak disease with a score from 2-3 with increased accumulations of infiltrating 
immune cells seen within the cervical meninges and added infiltration into the underlying 
parenchyma. Results from this report highlight the role of meningeal inflammation in initiating 
the disease course leading to propagation of disease pathology. Reports have shown similar 
instances that support the idea that the meninges are a gateway for immune cell access into the 
CNS corresponding with clinical exacerbations in EAE (102). This brings into light the 
importance of therapies possibly targeted directly to the meninges that might prove more 
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effective with controlling disease progression. Drug delivered regionally within the meninges of 
a section of the spinal cord, would be able to modulate the disease and contain the inflammation 
before it propagates to other regions of the spinal cord. In addition, meningeal targeted therapies 
would allow drug delivery without the Blood Brain Barrier (BBB) permeability concerns or the 
need for a systemic immunosuppression as seen with the current FDA approved drugs for MS 
treatment, hence allowing for novel therapeutic interventions.  
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Figure 9: Spinal cord regions (cervical and lumbar) showing leukocyte extravasation within the meninges and 
parenchyma during evolving experimental autoimmune encephalomyelitis (EAE). (a) Representative sections of 
spinal cord regions were collected at days 6, 9, 15 (D6, D9, D15)  from mice affter EAE induction. Vessels are 
immunostained for CD31 (red) and isosurface rendered to highlight the meningeal vessels penetrating into the 
parenchyma; leukocytes are immunostained for CD45 (blue) and CytoK (green) was used to immunostain for any cells of 
epithelial nature. White arrows in D15 cervical spinal cord meninges show the cytokeratin positive CD45 cells 
accumulated within the meninges and infiltrating into the parenchyma across the pial membrane. (b) Cervical and lumbar 
regions showing meningeal and parenchymal cellularity collected on D15 at 20x magnification with nuclei stained for 
DRAQ5 highlighting differences in cellularity between cervical and lumbar sections. White arrowheads show increase in 
cell accumulations around deeper parenchymal vessels. 
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Figure 10: Whole spinal cord image scans in different channels. Representative sections of whole spinal 
cords collected on day 0 (Naïve) mice are shown. DIC shows the differential interphase contrast, CytoK was 
used to immunostain for epithelial cells, CD45 for leukocytes, DAPI for cellularity, CD31 for vessels and 
Merge for all the channels together. Same pattern of scans was carried for the timepoints in the study-D9,D15 
and D23. 
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Figure 11: Changes in leukocyte distribution patterns within the meninges and parenchyma along the 
spinal cord during evolving experimental autoimmune encephalomyelitis (EAE). (a) Representative 
sections of whole spinal cords were collected on day 0 (Naïve) 15 and 23 (D15 and D23) from mice after EAE 
induction. Sections were immunostained for CD45 to highlight the distribution patterns during developing 
stages of disease. (b) Quantitative distribution of CD45 shown in intensity plots. 
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Figure 12: Whole spinal cord showing leukocyte extravasation within the meninges during D15 EAE. 
(a)Representative section of spinal cord collected on day 15 (D15) showing CD45 +ve leukocyte infiltration 
within the meninges along the entire spinal cord during evolving EAE. (b)and (c) Insets from the cervical and 
lumbar regions of the spinal cord showing CD45 cells within the meninges and parenchyma highlighted with 
brackets. White arrowhead in (b) showing a meningeal vessel and in (c) showing clusters of CD45 cells 
accumulating within the meninges of the lumbar spinal cord. 
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Figure 13: Whole spinal cord showing leukocyte extravasation within the meninges during D23 EAE. 
(a)Representative section of spinal cord collected on day 23 (D23) showing CD45 +ve leukocyte infiltration 
within the meninges and parenchyma along the entire spinal cord during evolving EAE. (b)and (c) Insets from 
the cervical and lumbar regions of the spinal cord showing CD45 cells within the meninges and parenchyma. 
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Figure 14: Differential expression of immune genes within spinal cord regions during D9 EAE. (a), 
(b)Comparison between meningeal and parenchymal vessels within the Cervical and Lumbar regions in their 
immune gene expression profile during D9 of evolving EAE.  (c), (d) Comparison between Cervical and Lumbar 
regions within meningeal and parenchymal vessels  in their immune gene expression profile.  
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Figure 15: Differential expression of immune genes within spinal cord regions during D9 EAE. (a), 
(b)Comparison between meningeal and parenchymal vessels within the Cervical and Lumbar regions in their 
immune gene expression profile during D15 of evolving EAE.  (c), (d) Comparison between Cervical and 
Lumbar regions within meningeal and parenchymal vessels  in their immune gene expression profile.  
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Figure 16: Schematic showing the directed progression of inflammation during evolving neuroinflammation 
in EAE. Inflammation begins with the accumulation of leukocytes in the Choroid Plexus, followed by entry into 
the CSF and regional accumulation within different regions of the spinal cord. Immune cells are first seen within 
the meningeal spaces of the subarachnoid space then with the progression of the disease, into the parenchymal 
spaces.  The events in disease progression from D6 through D23 have been shown in correlation with 
corresponding scores in the table within the schematic.  
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  Supplemental figure 4: Spinal cord regions (cervical and lumbar) showing cellularity within the meninges 
and parenchyma during evolving experimental autoimmune encephalomyelitis (EAE). (a)Representative 
sections of spinal cord regions were collected on days 6, 9, 15 (D6,D9,D15)  from mice affter EAE induction 
with myelin oligodendrocyte glycoprotein(MOG) at 63X magnification. Vessels are immunostained for 
CD31(red) and isosurface rendered to highlight the meningeal vessels penetrating into the parenchyma and 
DRAQ5 (blue) stains for cell nuclei.  
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  Supplemental figure 5. Spinal cord sectioning for whole spinal cord image scans. (a)Whole spinal columns 
were embedded in OCT and sectioned to expose the spinal cord. (b)An adhesive tape was then applied on top of 
the section and rolled in place. (c) Adhesive tape post sectioning containing the entire spinal cord with 
surrounding vertebrae remaining intact. 
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Supplemental figure 6. Inflammation within the lumbar spinal cord region during D15 EAE. (a) Representative 
section of lumbar spinal cord collected on day 15 (D15) showing CD45 +ve leukocyte infiltration within the 
meninges evolving EAE. Insets (b)-(e), from left to right, focus on regional CD45 clusters. (b) and (e) showing 
the spinal fissure being populated with CD45 cells. (e) Green arrowheads show meningeal vessels within the 
fissure and red arrowheads show parenchymal vessels being inundated with infiltrating leukocytes. (c) and (d) 
show meningeal accumulations of CD45 cells during disease. 
	   66	  
	  	  
 
  
	  
Supplemental figure 7. Inflammation within the lumbar spinal cord region during D23 EAE. (a) Representative 
section of lumbar spinal cord collected on day 23 (D23) showing CD45 +ve leukocyte infiltration within the 
meninges evolving EAE. Insets (b)-(d), from left to right, focus on regional CD45 clusters. (b) and (e) showing 
the spinal fissure being populated with CD45 cells. (e) Green arrowheads show meningeal vessels within the 
fissure and red arrowheads show parenchymal vessels being inundated with infiltrating leukocytes. (c) and (d) 
show meningeal accumulations of CD45 cells during disease. 
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Resolution of central nervous system astrocytic and endothelial sources of 
CCL2 gene expression during evolving neuroinflammation 
 
1. Abstract 
The chemokine CCL2 is a critical mediator of neuroinflammation in diseases such as 
multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis 
(EAE). CCL2 drives mononuclear cell infiltration into the central nervous system (CNS), alters 
expression and distribution of microvascular endothelial tight junction proteins, and disrupts the 
blood-brain and blood-spinal cord barriers. Immunohistochemistry has consistently revealed 
astrocytes to be a source of this chemokine during neuroinflammation, while providing less 
uniform evidence that CNS endothelial cells may express CCL2 as well. Moreover, the relative 
contributions of these cell types to the CNS pool of CCL2 during MS/EAE are unclear and 
require further investigation. CCL2 gene expression was determined by qRT-PCR in different 
populations of CNS cells at different times following EAE induced by immunization with 
MOG35-55 peptide and adjuvants, or after injection with adjuvants alone. CNS cells types were 
isolated by two different protocols: bulk isolation to yield crude microvascular and parenchymal 
fractions (containing astrocytes, other glia, and neurons), or laser capture microdissection (LCM) 
to more precisely acquire microvascular endothelial cells, astrocytes or other parenchymal cells. 
Both CNS microvessel and parenchymal populations isolated by crude bulk isolation showed up-
regulation of CCL2 mRNA following MOG immunization or injection of adjuvants alone. More 
exact dissection by LCM revealed microvascular endothelial cells and astrocytes to be the 
specific sources of CCL2 gene induction following MOG immunization, while only astrocytes 
Chapter IV: CCL2 sources in evolving EAE 
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showed elevated CCL2 mRNA in response to just adjuvants. Astrocytes displayed the greatest 
degree of stimulation of CCL2 gene expression following EAE induction. High precision LCM 
affirmed both microvascular endothelial cells and astrocytes as the major CNS sources of CCL2 
gene expression during EAE.  Given the high accessibility of the CNS microvascular 
endothelium, endothelial-derived CCL2 could prove a viable target for therapeutic intervention 
in neuroinflammatory disease.  
4. Background 
 
Numerous human and animal studies have highlighted the chemokine CCL2 (formerly known as 
MCP-1 (110)) as a critical mediator of the neuroinflammatory disease multiple sclerosis (MS) 
and its animal model experimental autoimmune encephalomyelitis (EAE)(2, 4, 8). While long 
recognized for its chemotactic properties in guiding leukocyte migration, CCL2 has also been 
shown to destabilize tight junctions of microvascular endothelial cells that comprise the blood-
brain and blood-spinal cord barriers (71, 111-113). This multifunctional status underscores 
CCL2’s value as a potential therapeutic target. However, for therapeutic measures to be most 
effective the sources of CCL2 in the central nervous system (CNS) have to be defined and the 
timing of CCL2 expression during neuroinflammation elaborated. While astrocytes are widely 
recognized in reviews as a major CNS source of CCL2 during MS and EAE, BMEC have 
received only limited acknowledgement as expressing this chemokine (108, 114, 115). The 
scarce recognition of BMEC as a critical CCL2 source in situ may in part stem from the routine 
use of conventional immunohistochemistry to confirm expression, as this technique may not be 
sufficiently sensitive to reliably detect perhaps smaller, vesicular quanta of endothelial CCL2 
(116). The use of adjuvants to induce EAE, e.g., Complete Freund’s Adjuvant (CFA) and 
pertussis toxin (PTX), can affect CCL2 expression in some endothelial cell types (42, 117), and 
	   69	  
might further contribute to ambiguity of BMEC-derived CCL2 during neuroinflammatory 
disease.  Previous reports have not examined the adjuvant issue. The status of BMEC CCL2 gene 
expression in neuroinflammation thus remains equivocal. 
 Herein, we report use of two highly sensitive, qRT-PCR-based approaches to clarify the 
relative contributions of the parenchymal and vascular compartments to CNS CCL2 gene 
expression during evolution of EAE induced by immunization with myelin oligodendrocyte 
glycoprotein (MOG) peptide35-55 along with adjuvants. One approach used a crude separation of 
CNS parenchymal and microvessel fractions, based on a common preparative method from 
homogenized CNS tissue. The other employed the laser capture microdissection (LCM), to more 
precisely retrieve separate BMEC, astrocyte and other parenchymal cell types. Additionally, we 
assessed CCL2 expression levels following MOG immunization as well as after injection of 
these adjuvants alone, to highlight the effects due to MOG immunoreactivity.  
3. Material and Methods 
3.1 Animals 
Female C57BL/6 mice, age 8–10 weeks were obtained from Charles River Laboratories, Inc. 
(Wilmington, MA) and were euthanized by CO2 inhalation, following Animal Care and Use 
Guidelines of the University of Connecticut Health Center (Animal Welfare Assurance # A3471- 
01). All the experimental procedures conducted have been approved under the protocol #100346-
1214.  
 
3.2 EAE induction 
Mice were immunized with MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK; W. M. Keck 
Biotechnology Resource Center, Yale University) as detailed previously (42).  Briefly, on day 0 
(D0), female mice 7-9 weeks of age were injected subcutaneously with 300 µg of MOG peptide 
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in Complete Freund’s adjuvant (CFA) (DIFCO, Detroit, MI, USA) containing 1mg/ml 
Mycobacterium tuberculosis. Mice were also injected intraperitoneally with 200 ng pertussis 
toxin (List Laboratories, Campbell CA, USA) in phosphate buffered saline (PBS) on D0 and D2 
following MOG immunization. Mean clinical scores were calculated from animals monitored for 
clinical disease severity and scored as 0 =normal; 1 = tail limpness; 2 = limp tail and weak- ness 
of hind legs; 3=limp tail and complete paralysis of hind legs; 4 = limp tail, complete hind leg and 
partial front leg paralysis; and 5 = death. The time-points selected for analysis, D9, D15 and 
D23, represent early EAE (score 0-0.5), acute EAE (score 2-2.5) and chronic EAE (score 2.5-
3.5), respectively. 
 
3.3 Bulk isolation of parenchymal and microvessel fractions  
Bulk isolations were prepared from each naïve, control and EAE group at all the time-points 
assessed. Separate parenchymal and microvessel fractions were obtained in bulk from freshly 
dissected brain and spinal cord using a modification of previously described methods (118). 
After removal of meninges and large blood vessels, ½ of the brain and spinal cord tissue was 
homogenized in ice cold PBS using a 7 mL Dounce tissue grinder (Kimble/Kontes,Vineland, NJ, 
USA). Brain and spinal cord tissue were combined for bulk isolation of parenchymal and 
microvessel fractions, in keeping with other reports detailing CNS CCL2 expression during EAE 
(119-121). The remaining spinal cord tissue was snap-frozen in dry ice-cooled 2-methylbutane 
(Acros; Geel, Belgium), and stored at 80°C until used for LCM.   The homogenate was 
centrifuged at 400 x g for 15 min, and the resulting pellet resuspended in 18% (w/v) dextran 
(mwr 60,000 – 90,000) and centrifuged at 4,500x g for 10 min to sediment the crude 
“microvessel” fraction. The dextran supernatant and floating layer of myelinated axons were 
collected together to generate the crude “parenchymal” fraction and diluted in PBS; microvessels 
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were resuspended in PBS and both fractions were washed twice by sedimentation at 720 x g for 
10 min and rinsing in PBS. Microvessels were washed of blood cells by filtering through a 40 
µm cell strainer (Becton Dickinson Labware, Franklin Lakes, IN, USA) and eluting with PBS. 
This procedure eliminated a significant fraction of the smaller capillaries, which passed through 
in the filtrate, while retaining the vast portion of larger venules on the filter (122). The filter-
bound-microvessels were then solubilized with lysis buffer from the RNeasy Mini kit (QIAGEN, 
Valencia, CA).  
 
3.4 Laser Capture Microdissection (LCM) of parenchyma, astrocytes and BMEC 
Frozen spinal cords were embedded in cryomatrix compound (Thermo Fisher Scientific, 
Waltham, MA), and 7µm-thick frozen sections obtained. Immunohistochemstry-guided LCM 
was performed using a PixCell IIe laser capture microscope (Life Technologies Inc., Foster City, 
CA), as previously described by this laboratory (123).  Significantly, this LCM approach has 
been shown to yield highly purified populations of microvascular endothelial cells and 
astrocytes, respectively. Tissue was captured from within the dorsolateral columns along the 
entire length of the spinal cord, as pathology in this EAE model proceeds up the CNS axis in a 
caudal-to-rostral direction (124), with lesions prominent in the spinal white matter. Briefly, anti-
CD31 was used to label endothelial cells, along with alkaline phosphatase detection employing 
NBT-BCIP as chromogenic substrate. The endothelial cells of venules (10 – 50 µm in diameter) 
were specifically acquired (33) as these microvascular tributaries are the preferred sites of 
leukocyte extravasation (125), and were thus reasoned to express the highest CCL2 expression. 
This further allowed for a more equitable comparison with the bulk-isolated microvessels, which 
were enriched in venules. Anti-GFAP immunofluorescence was carried out to identify astrocytes 
in the same tissue sections.  Areas of “other” parenchymal cells selected for LCM were those 
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that did not stain with CD31 or GFAP, and thus contained neurons, oligodendrocytes and/or 
microglia. LCM tissue was solubilized in Cell Lysis Buffer® (Signosis; Sunnyvale, CA). 
 
3.5 RNA isolation, cDNA synthesis and qRT-PCR 
Total RNA was isolated from bulk microvessel and parenchymal fractions using the RNeasy 
Mini kit (QIAGEN), and treated with Turbo DNAse (Ambion, Austin, TX, USA). cDNA was 
generated using SuperScript III (Invitrogen, Carlsbad, CA, USA) and relative CCL2 RNA level 
determined by qRT-PCR using SYBR green (AB Applied Biosystems, Foster City, CA, USA) as 
described previously (44). LCM tissue was subjected to DNAse treatment using Turbo DNAse 
followed by reverse transcription, using SuperScript III. LCM-derived cDNA was then pre-
amplified using TaqMan PreAmp Master Mix and a PreAmp Pool containing all primers for 
detection by the Mouse Immune Panel TaqMan Low density Array (TLDA; Life Technologies 
Corp., Foster City, CA) and probed for CCL2 by qRT-PCR using a single-plex gene expression 
assay (42). An ABI 7900HT Fast Real-Time PCR System (Life Technologies Corp.) was used to 
detect amplicon amount for both bulk and LCM preparations. RPL-19 was used as a reference 
for relative CCL2 gene expression for bulk isolation as detailed previously (44) and GAPDH for 
LCM preparation (42), both genes having been shown to be largely invariant during EAE. 
Relative quantitation was performed using the 2-[Δ][Δ]Ct method of Fleige et al (126). Results 
were analyzed using a one-way non-parametric Kruskal-Wallis test followed by Dunn’s post-test 
analysis using GraphPad Prism 5 (GraphPad, La Jolla, CA). Results were considered significant 
at P≤0.05.   
4. Results and Discussion 
CCL2 expression levels were first evaluated in separate parenchymal and microvessel fractions 
prepared by bulk isolation from brain and spinal cord tissue of either MOG-CFA/PTX-treated 
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(EAE) or CFA/PTX-treated (Control) mice. Analysis was performed at different days after initial 
injection, which represented onset (D9), peak (D16) and chronic (D23) phases of clinical EAE 
disease (Fig. 18). As determined by qRT-PCR, relative expression of CCL2 by microvessels was 
significantly higher in both treatment groups (CFA/PTX and MOG-CFA/PTX) compared to 
naïve animals at D9 and D16, with a return to naïve level by D23 (Fig.18A, C). The parenchymal 
fraction showed a similar trend of significantly increased CCL2 expression in both treatment 
groups compared to naïve animals at D9 and D16 (Fig. 18B, D).  
 Next, we performed a time-course analysis with CNS tissue that was more precisely 
dissected into endothelial cells (CD31), astrocytes (GFAP) and “other” parenchymal cells 
(selected areas devoid of CD31 and GFAP immunostaining) by LCM. As was the case with bulk 
preparation of microvessels, endothelial cells showed elevated CCL2 expression in MOG-
CFA/PTX-treated mice at D16 compared to naïve mice (Fig. 19D). However, corresponding 
endothelial samples from CFA/PTX-treated mice did not show a similar increase (Fig. 19A). 
Astrocytes exhibited significantly elevated CCL2 expression at both D9 and D16 in the MOG-
CFA/PTX-treated group (Fig. 19E), and a significant increase at D9 in the CFA/PTX-treated 
cohort (Fig. 19B). In contrast to that observed with the bulk parenchymal preparations, other 
parenchymal cells isolated by LCM failed to display an increase in CCL2 expression either in 
MOG-CFA/PTX-treated (Fig. 19F) or CFA/PTX-treated (Fig. 19C) mice compared to naïve 
mice at any time-point.  
 These findings underscore several points. Expression of CCL2 is significantly induced in 
both astrocyte and endothelial cell populations in the MOG-induced EAE paradigm. The fact that 
CCL2 mRNA level appeared higher in endothelial cells than in astrocytes in naïve mice may 
reflect the capture of some circulating leukocytes along with endothelial cells, as the mice were 
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not perfused prior to LCM.  Interestingly, while CFA/PTX injection resulted in elevated CCL2 
expression in isolated microvessels, it did not do so in LCM-acquired endothelial cells.  This 
suggests that sources other than endothelial cells contributed to the altered CCL2 mRNA level in 
the bulk microvessel fraction.  As astrocytes lie in close proximity to endothelial cells within the 
neurovascular unit (NVU) (127, 128) and can contaminate microvessel preparations (129, 130), 
a priori these particular glial cells may be a significant source of CCL2 mRNA detected in bulk-
isolated microvessels. This caveat reinforces LCM as a critical technology to more effectively 
resolve sources of gene expression in situ.  
 Our LCM results further suggest astrocytes are the preeminent parenchymal sources of 
induced CCL2 gene expression during EAE, since the other parenchymal cells acquired by this 
technique showed no significant stimulation of CCL2 mRNA. As increased immunostaining of 
CCL2 in microglia has been reported in EAE (131), this may represent up-regulation at the 
protein rather than the RNA level. It may also be that the percentage contribution of microglia in 
the other parenchymal cells acquired by LCM, was not high enough to show overall elevation of 
CCL2 gene expression in these samples from diseased mice. CCL2 mRNA detected in other 
parenchymal cells from naïve mice could possibly reflect a low level of constitutive CCL2 
expression by neurons as well (132).  
 Lastly, CFA/PTX alone can stimulate CCL2 expression in astrocytes (Fig. 19B), possibly 
providing a priming function for supernumerary stimulation due to MOG effects   (Fig. 19E). 
This is consistent with reports that peripheral inflammation induced by CFA or Mycobacterium 
resulted in CNS glial activation (133, 134). Previous results from this laboratory indicated 
CFA/PTX injection also up-regulated expression of CCL2 by choroid plexus capillary 
endothelial cells.  Thus, it is imperative that any measure of gene expression following the 
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typical MOG immunization protocol be compared to effects seen after injection of CFA/PTX 
alone, to discern what gene changes are associated specifically with MOG-induced pathogenesis. 
 These results reinforce the CNS microvascular endothelium as a significant source of CCL2 
[9, 10, 12], as well as spotlight LCM as a critical tool for the selective enrichment of vascular or 
other CNS cell types for gene expression studies (33, 42, 123).  Moreover, given the 
microvascular endothelium is highly accessible from the circulation – as compared to the 
astrocyte population, which lies behind the BBB and BSCB – endothelial-derived CCL2 may be 
a “druggable” target in neuroinflammatory disease (44, 135). 
 
	   76	  
	   	  
Figure 18: CCL2 gene expression in CNS microvessel and parenchymal fractions obtained by bulk 
preparation. Separate, crude microvessel (A, C) and parenchymal (B, D) fractions were prepared by bulk isolation 
from combined brain and spinal cord tissue of mice injected with CFA/PTX (A, B) or immunized with MOG-
CFA/PTX (C, D). Analyses were performed at D9, D16 and D23 following beginning of either injection regime, and 
relative CCL2 mRNA levels are plotted on a log scale. Comparisons were made to naïve mice. * P≤0.05; **P≤0.01; 
and ***P≤0.001. Data has been presented as mean +/- SEM. For each experiment, bulk isolations were performed 
from three individual mice from each naïve, control (CFA/PTX) and EAE (MOG-CFA/PTX) group, and 
experiments were conducted twice. 	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Figure 19: CCL2 gene expression in CNS microvascular endothelial cells, astrocytes and other 
parenchymal cells isolated by LCM. Endothelial cells (A, D), astrocytes (B, E), and other parenchymal 
cells (C, F) were separately acquired by LCM from spinal cord tissue of mice injected with CFA/PTX (A-
C) or immunized with MOG-CFA/PTX (D-F). Analyses were performed at D9, D16 and D23 following 
either injection regime, and relative CCL2 mRNA levels are plotted on a log scale. Comparisons were 
made to naïve mice. *P≤0.05; **P≤0.01; and ***P≤0.001. Data has been presented as mean +/- SEM.  For 
each experiment, LCM was performed on tissue from three individual mice from each naïve, control 
(CFA/PTX) and EAE (MOG-CFA/PTX) group.	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 CP has been established as one of the alternate routes for immune cell entry during 
EAE/MS (15, 18) but the changes within CP anatomy that allow this access to the leukocytes 
was still unknown.  Prior to this work, CP barrier integrity had not been evaluated in MS/EAE to 
the extent of the details as provided by this report. As important was the need to find evidences 
leading to possible changes in permeability of CP that could aid in leukocyte extravasation. Tight 
junction breakdown is co-relative with barrier alterations, since the complexity of TJ between 
adjacent cells constitutes the physical presence of a barrier. There has been very limited work 
addressing the status of TJ within BCSFB. Few preliminary reports were available before this 
work and they had been more suggestive than conclusive. Wohlburg et al. noted altered 
localization of CP TJ proteins claudins 1,2 and 11, occludin and ZO-1 during EAE (24). These 
reports are more qualitative and did not address progressive changes in TJs through developing 
stages of disease.  Changes in CP TJs following peripheral inflammation have also been reported 
by Marque et al. (20) and Mitchell et al. (136), providing further evidence that CP TJs are thus 
subject to alterations in an inflammatory scenario. 
 Other reports provide indirect links to possibly altered integrity of CP during disease. 
Severe cerebrospinal venal insufficiency (CCSVI); an abnormality in blood drainage in the brain 
and spinal cord associated with MS (137), has been linked to altered CSF dynamics (138) which 
could be due to a disrupted BCSFB. Invitro evidence shows BCSFB alterations in trans epithelial 
electrical resistance and increase of para cellular flux after TNF stimulation, a potent 
inflammatory cytokine, which is markedly increased during inflammation (139). These reports 
point toward changes in BCSFB integrity and permeability during inflammation. We proposed to 
CHAPTER V: Conclusion  
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quantify these changes using novel 3D quantification technique previously standardized by the 
lab (41). 
Previous reports with the proposed claudins in CP have provided suggestive evidence that 
they are altered during disease (24, 25). Quantification of TJs in naïve, control and EAE groups 
painted a similar picture of stable expression in the naïve group, slightly altered levels in the 
control groups (CFA/PTX alone without the MOG peptide may not have significant effects on 
TJ regulation), with EAE mice showing the most altered values due to barrier changes and 
breakdown in disease. The quantification protocol of the TJs was previously used in the lab with 
experience in IMARIS based applications and has standardized the procedures (41). However, 
given that the CP epithelial cells are a lot more tortuous (19) than the parenchymal vessels 
where the quantification method was previously standardized. This opened new challenges in 
imaging as well as quantification allowing us to add novel modules and techniques into 
addressing the quantification of tight junctions, permeability of the barrier and leukocyte 
extravasation.   
TJ protein dynamics such as linkage with cytoskeleton and the interactions between the 
dimers of TJ complex could be subject to changes during the process of disease (140-142). 
However, imaging molecular changes at this level is beyond the scope of the type of imaging 
and quantification carried out within this report. Nevertheless effects of such structural 
alterations can be linked to increase in trans epithelial transport (143) and hence, to changes in 
permeability, which we have assessed and quantified in our study as well. 3D quantification of 
IgG diffusion across the CP had never been done before and quantification advances in other 
systems have only been in 2D (144).  
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Inflammation of the meninges, another established route of immune cell entry into the SAS  
has been shown to precede that of the underlying parenchyma, which leads to lesions causing 
neuroinflammation in EAE/MS (145, 146). This suggests an important role of this compartment 
in the development of neuroinflammation within the CNS. More recent evidences point out that 
inflammatory cells are localized around the meningeal venules within this specialized SAS 
compartment (10, 11, 27). However, it is not clear as to why the SAS meningeal venules are 
inflamed earlier than the parenchymal vasculature or why does the inflammation progresses from 
the SAS into the parenchyma. Constitutive expression of P-selectin (required for initial 
attachment of leukocytes with the vascular endothelial cell) in meningeal vasculature but absent 
within the resting parenchymal vessels is a possible direction suggesting differential expression 
of immune genes in different types of vasculature (13, 147). Kivisakk et al. reports suggestive 
differential expressions of E-selectin and adhesion molecules such as ICAM and VCAM as well 
(13). Moreover, our reports show that extensive arrays of genes that are important contributors in 
inflammation are differentially expressed within these vascular locales. This study probed into an 
array of adhesion molecules, cytokines, chemokines, statins, interleukins, T cell activation 
markers, co-stimulatory molecules, transcription factors and apoptotic markers investigating 
their possible differential regulation between meningeal and parenchymal vessels. 
Differential expression pattern of immune genes in meningeal and parenchymal venules 
as shown by this study provide supportive evidence to explain why some regions of the spinal 
cord are more prone to lesions in EAE. Reports of ascending paralysis have long been around 
(148) but the reasons for this ascension from lumbar to cervical segment of the cord has 
remained unexplained. A detailed segmental analysis of immune profiling of both these vessel 
	   81	  
types was done, the technique perfected by the group and shown in varied LCM applications (30, 
31, 33) in addition to recent reports on coupling it with TLDA analysis (42, 149).  
Reports included in this work investigated how the tight junctions between the epithelial 
cells of BCSFB changed during disease. We assessed the status of junctional integrity and 
permeability of CP choroidal epithelium at different timepoints during developing EAE using 
immunostaining, 3D imaging and quantification. We then continued to study the effects of EAE 
within the meningeal venules that reside in the SAS and the underlying parenchymal venules via 
regulation of inflammatory genes within these vessels. This allowed a unique opportunity to 
study the differential inflammation patterns between the venules of the two regions- meninges 
and parenchyma and the possibility of relay of inflammatory signals between the cervical, 
thoracic and lumbar spinal cord segments. We were able to characterize and compare the 
inflammatory gene expression patterns between meningeal and underlying parenchymal venules 
from three distinct spinal cord segments (lumbar, thoracic and cervical) at different timepoints 
during developing EAE using immune-LCM coupled to TLDA array analysis.  
Studies within this report helped fill in the gaps that are crucial to understanding the 
initial sequence of events that trigger inflammation and spread of immune cascade as the disease 
progresses. With an unknown etiology, the main trigger behind MS remains enigmatic. It is 
probable that more than one factor, a culmination of genetics and environmental players are 
accountable for the susceptibility of this disease. The field has progressed in terms of identifying 
the alternate routes other than the BBB that usher in immune cells, which could eventually lead 
to the breakdown of the BBB, the known hallmark of this neurodegenerative disease. However, 
the sequence of events that makes the alternate routes-CP and SAS susceptible in the first place 
has largely been unknown. As puzzling are the events that guide inflammation from these initial 
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sites to inner parenchyma where the BBB resides. This project aimed to cover these critical 
questions, answers to which provide a fundamental basis in identifying possible therapeutic 
avenues within the earliest events of the disease, perhaps the most sensitive to drug interventions 
as well.  
This project assessed TLDA gene analysis of 93 immune genes through EAE progression: 
from earliest pre-clinical to late chronic disease phase. Results have provided us with an array of 
information on gene regulation from onset through progression of inflammation, highlighting the 
genes significantly regulated at different stages of inflammation in different regions of the spinal 
cord. This data provides us with valuable early and late disease stage biomarkers that could be 
further co-related with disease pathology. This is important because an ideal biomarker would be 
an early and accurate indicator of immunological activity and would co-relate with key endpoints 
in MS patients such as relapse activity, disability and disease progression and possibly early 
detection. Although this concept is in its incipient pre-clinical stage, further confirming 
experiments with these markers, could help us screen MS patients and relate them with the stage 
of the disease they might be in, as well as foresee the possible progression of their inflammation 
or relapses. With this valuable information of disease stages, we could design targeted anti-
inflammatory therapies against co-relating genes in developing inflammation, and successfully 
impede the looming relapses.  
The current measure of disease for MS patients are MRI images of brain and spinal cord 
lesions, which are essentially end stage results of disease progression. Genetic biomarkers can 
provide a much-needed shift in gauging the disease, possibly finding it as early as possible, 
earlier than the manifestation of inflammation resulting in lesions as captured by imaging 
diagnostics. This late stage is far along the damaging inflammatory cascade for effective 
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prophylactics leaving room only for therapies targeted to symptomatic relief, as is the case with 
current FDA approved treatments for MS patients.  These treatments could also possibly be 
paired with new targets of inflammation identified by the study, which would provide a multi-
directional approach to treating MS. In another light, the current treatments have a holistic 
immune-suppressive effect subjecting patients to novel infections they were protected against 
with an otherwise functional immune system. This study could highlight inflammatory markers 
related to a particular subset of immune pool, allowing targeted suppression instead of an entire 
immune pool ablation. 
An extension to the CP work, future in-vitro experiments can be carried out to confirm 
changes in TJs using BCSFB culture mediums. Reports have provided convincing epithelial 
culture systems with BCSFB properties (150-152) that can be manipulated with inflammatory 
cytokines and transcription factors to study TJ changes due to inflammation. CP TJs have been 
assessed with whole tissue extracts as well (25, 136). This system of tissue isolation however 
defies our purpose of resolving the changes in the choroidal epithelium within the complex 
layers of the CP (i.e. the inner capillary endothelial layer surrounded by a stroma and outlined 
by the outermost epithelial layer). None-the-less, this approach can provide overall changes or 
effects of inflammatory markers on the CP as a whole.  
A probable alternative to LCM of meningeal and parenchymal vessels could be vessel 
isolation from the extracted spinal cord, for which the lab has previous reports with vessel 
isolation protocols (118, 122, 153). However, those isolations were using brain tissue providing 
more material to work with, while spinal cord vessel extraction has proved to be more 
problematic in terms of yield. Working with smaller segments of spinal cord as needed for the 
purpose of this study, would provide lesser material to work with. Vessel isolation from 
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extracted meninges of these individual sections of spinal cord segments can prove further 
problematic in terms of isolation as well as the amount of material that can be extracted from 
these thin sheets of meninges from small sections. A proper and successful extraction would 
however provide an invaluable method to understand the gene expression within these unique 
sections as well as provide an opportunity to co-relate and validate our LCM- gene expression 
analysis.   
Also as a possible future direction from this project, potential therapeutic targets could be 
narrowed down from the pool of regulated genes changed in inflammation to the most potent 
regulators, by successive invitro analysis that can analyze the extent of inflammatory roles 
played by individual up regulated markers. Invitro analysis can be carried out in similar vascular 
in-vitro systems including but not limited to murine BMECs (Brain Microvascular Endothielial 
Cells), both on primary and commercially available cell lines and moving translating it further 
with Primary Human Brain Microvascular Endothelial Cells (ACBRI 376). This will provide a 
sharper focus in identifying a potential effective biomarker of inflammatory stages. We could 
also potentially be looking at a novel route of drug delivery. Our results reveal that inflammation 
primarily begins in the meningeal vessels compared to the parenchymal vessels, so targeted drug 
delivery into the meningeal compartment, directly into the CSF via intrathecal delivery could 
prove to be more beneficial rather than an intravenous or subcutaneous method of drug delivery, 
although this route does pose the risk of being more invasive. Hence future directions to the 
continuation of this concept of biomarkers will make strides in understanding MS pathology and 
regulation providing possible avenues for therapeutic interventions. 
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List of abbreviations:  
BBB: Blood Brain Barrier 
BCSFB: Blood Cerebrospinal Fluid Barrier 
CFA: Complete Freund’s Adjuvant 
CLN- Claudin 
CSF: Cerebrospinal Fluid 
CNS: Central Nervous System 
Col4a5: Collagen type IV alpha 5. 
CP: Choroid Plexus 
EAE: Experimental Autoimmune Encephalomyelitis 
Ece 1: Endothelin Converting Enzyme 1 
Edn1: Endothelin 1 
H2-Ea: Histocompatibility 2 class II antigen E alpha 
LCM: Laser Capture Microdissection 
MCP: Monocyte Chemoattractant Protein 
MOG: Myelin Oligodendrocyte Glycoprotein 
MS: Multiple Sclerosis 
NOS2- Nitric Oxide Synthase 2 
PTX: Pertussis Toxin 
SAS: Sub Arachnoid Space 
SKI-2: Super Killer-2 
SOCS-2- Supressor Of Cytokine Signaling-2 
STAT 1: Signal Transducers and Activators of Transcription-1 
TJ: Tight Junctions 
TGFβ: Transforming Growth Factor β 
VEGF: Vascular Endothelial Growth Factor 
VCAM: Vascular Cell Adhesion Molecule 
ZO: Zonula Occludens 
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Abstract
Background: Production of the chemokine CCL2 by cells of the neurovascular unit (NVU) drives critical aspects of
neuroinflammation. Suppression of CCL2 therefore holds promise in treating neuroinflammatory disease.
Accordingly, we sought to determine if the compound bindarit, which inhibits CCL2 synthesis, could repress the
three NVU sources of CCL2 most commonly reported in neuroinflammation – astrocytes, microglia and brain
microvascular endothelial cells (BMEC) – as well as modify the clinical course of neuroinflammatory disease.
Methods: The effect of bindarit on CCL2 expression by cultured murine astrocytes, microglia and BMEC was
examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Bindarit action on mouse brain
and spinal cord in vivo was similarly investigated by qRT-PCR following LPS injection in mice. And to further gauge
the potential remedial effects of bindarit on neuroinflammatory disease, its impact on the clinical course of
experimental autoimmune encephalomyelitis (EAE) in mice was also explored.
Results: Bindarit repressed CCL2 expression by all three cultured cells, and antagonized upregulated expression of
CCL2 in both brain and spinal cord in vivo following LPS administration. Bindarit also significantly modified the
course and severity of clinical EAE, diminished the incidence and onset of disease, and evidenced signs of disease
reversal.
Conclusion: Bindarit was effective in suppressing CCL2 expression by cultured NVU cells as well as brain and spinal
cord tissue in vivo. It further modulated the course of clinical EAE in both preventative and therapeutic ways.
Collectively, these results suggest that bindarit might prove an effective treatment for neuroinflammatory disease.
Keywords: CCL2, Neuroinflammation, Blood–brain barrier, Neurovascular unit, Brain microvascular endothelial cells,
Astrocytes, Microglia
Background
The chemokine CCL2 (formerly called MCP-1) is a crit-
ical mediator of neuroinflammation in a myriad of dis-
eases states, including multiple sclerosis (MS) and its
animal model experimental autoimmune encephalomy-
elitis (EAE) [1], HIV-1 encephalitis [2], Guillain-Barré
Syndrome [3], Alzheimer’s disease [4], ischemia [5], neu-
rotrauma [6], epilepsy [7], neurogenic hypertension [8]
and alcoholism [9]. While its precise mechanisms of
action remain to be elaborated, among CCL2’s widely
recognized effects are disruption of the blood–brain bar-
rier (BBB) [10-12] and stimulated migration of mono-
nuclear leukocytes into the central nervous system
(CNS) [13-17].
These actions and pathogenic role, along with the fact
that constitutive expression of CCL2 in the healthy cen-
tral nervous system is severely limited [18], render CCL2
an ideal target for therapeutic intervention in neuroin-
flammatory disease [17,19,20]. Indeed, there is already
strong suggestion that pharmacological suppression of
CCL2 expression [21,22], oligomerization [23,24] or
binding to its cognate receptor, CCR2 [25,26], can
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mitigate aspects of EAE. Pharmacologic blockade of
CCL2 binding to glycosaminoglycans (GAGs) has also
been reported to antagonize an autoimmune inflamma-
tory condition of the neural retina, experimental auto-
immune uveitis [27].
While highly effective in moderating neuroinflamma-
tion experimentally, many pharmacological agents that
abrogate CCL2 expression and/or activity have neverthe-
less failed clinically. This disappointing performance in
clinical trials might stem, in part, from overly broad sup-
pression of microglia and astrocytes, a potential caveat
that could curtail beneficial action of these cells in re-
solving neuroinflammation [28,29], as well as redun-
dancy of chemokine binding sites and targets [30,31]. An
alternative approach that more selectively targets CCL2
synthesis might therefore hold therapeutic promise in
the treatment of human neuroinflammatory disease.
An attractive candidate in this regard is the well-char
acterized compound 2-((1-benzyl-indazol-3-yl) methoxy)-
2-methyl propionic acid (bindarit) [32]. A small, synthetic
indazolic derivative that preferentially inhibits transcrip-
tion of the monocyte chemoattractant subfamily of CC che-
mokines (MCP-1/CCL2, MCP-2/CCL8 and MCP-3/CCL7)
[33], bindarit has shown clinical efficacy in a broad array
of experimental inflammatory, autoimmune and vascular
disorders involving peripheral organ beds [34-38], as well
as success in recent clinical trials for diabetic nephropathy
[39] and lupus nephritis [40]. Such efficacy has been asso-
ciated with bindarit’s ability to interfere with monocyte
recruitment, which is also a critical feature in neuroin-
flammatory disease [13-17].
Given this clinical history of bindarit suppressing vari-
ous examples of peripheral inflammation, we investigated
its effect on expression of CCL2 in culture by the three
cell types that represent the most frequently reported
CNS sources of this chemokine during neuroinflamma-
tion: astrocytes, microglia and brain microvascular endo-
thelial cells (BMEC). These cells serve as integral
components of the neurovascular unit (NVU) [41] and,
via their expression of CCL2, can impact the BBB and
course of neuroinflammatory disease [42,43]. As a com-
plement to these culture studies, the ability of bindarit to
suppress LPS induction of CNS CCL2 expression in vivo
was well determined. And to gauge bindarit’s potential
clinical efficacy, its effect on EAE, a prototypical neuroin-
flammatory disease [44,45], was also examined. Results
indicate bindarit significantly suppressed CCL2 gene ex-
pression in culture, as well as blunted lipopolysaccharide
(LPS)-induced expression of CCL2 in the CNS. It also
inhibited various facets of clinical EAE, and showed signs
of promoting disease recovery. Collectively, these data
suggest that bindarit might offer promise, either alone or
in conjunction with other therapies, in the treatment of
human neuroinflammatory disease.
Methods
Reagents
All reagents and antibodies were purchased from Sigma-
Aldrich (St. Louis, MO, USA), unless specified other-
wise. Bindarit was synthesized by and obtained from
Angelini (Angelini Research Center-ACRAF, Italy).
MOG peptide35-55 was synthesized by the WM Keck
Biotechnology Resource Center at Yale University,
New Haven, CT, USA.
Preparation of bindarit
For experiments with cultured cells, a stock solution of
100 mM bindarit was prepared in dimethyl sulfoxide
(DMSO), and dilutions (50, 100, 300 and 500 μM) of the
DMSO stock were made in culture medium. For in vivo
experiments, bindarit was prepared as a suspension in
0.5% methylcellulose (MTC) at a concentration of
20 mg/ml as previously described [37].
Mice
C57BL/6 mice were obtained from the Charles River
Laboratories, Inc. (Wilmington, MA, USA). All animal
studies were performed, and CO2-mediated euthanasia
carried-out, according to the Animal Care and Guidelines
of the University of Connecticut Health Center (Animal
Welfare Assurance #A3471-01).
Isolation and culture of mouse astrocytes and microglia
Brain tissue obtained from mice at postnatal days 2 to 3
was used as the source of astrocytes and microglia. After
decapitation, brains were removed immediately and sep-
arate astrocyte and microglial cultures prepared follow-
ing a modified version of the protocol described by Ge
and Pachter [46]. Cerebral cortices were first cut into
small pieces (approximately 1 mm), and the minced tis-
sue incubated in dissecting medium (Hank’s Balanced
Salt Solution, from Gibco/BRL, Rockville, MD, USA),
containing 0.5% glucose, 0.7% sucrose, 20 mM: hydro-
xyethyl piperazineethanesulfonic acid (Hepes) (pH 7.4)
with 0.03% trypsin at 37 °C for 20 to 30 minutes. The
tissue extract was then centrifuged at 1000 × g for 5 min-
utes and the resulting pellet washed and resuspended in
astrocyte culture medium (Earl’s Modified Eagle Medium,
from Gibco/BRL) containing 10% fetal bovine serum, 10%
horse serum, 2 mM glutamine, 20 mM D-glucose, 4 mM
sodium bicarbonate, 100 μg/ml penicillin and 100 μg/ml
streptomycin. The tissue was mildly triturated to produce
a single cell suspension, and the dissociated cells plated
onto tissue culture flasks (T-75 cm2) coated with poly-
lysine (BD Biosciences, Bedford, MA, USA). Cultures were
maintained up to 1 week in plating medium in a humidi-
fied atmosphere (5% CO2) at 37 °C. After this time, cul-
tures were shaken at 200 rpm for 2 hr at 4 °C, and
supernatants containing dislodged microglia collected.
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Supernatant material was then centrifuged at 1000× g for
5 minutes to pellet microglia. Microglia were then resus-
pended in microglia culture medium (Dulbecco’s modified
Eagle Medium, from Gibco-BRL) supplemented with 10%
heat-inactivated fetal calf serum, 100 μg/ml penicillin and
100 μg/ml streptomycin) and cultured in a 24-well plate.
Following removal of microglia from the initial mixed glial
cultures, the latter were shaken for an additional 18 hr at
37 °C to remove residual neurons. The enriched astrocyte
population that remained was further depopulated of
remaining microglia by treatment with L-leucine me-
thyl ester (LME) [47]. LME was dissolved in astro-
cyte culture medium, and the solution adjusted to
pH 7.4 and filtered prior to adding to cultures to
achieve a final concentration of 50 mM. After 90
minutes of LME treatment, astrocyte-enriched cul-
tures were washed thoroughly and re-incubated with
fresh astrocyte culture medium. Cell purity was deter-
mined by immunocytochemistry using a monoclonal anti-
human glial fibrillary acid protein (GFAP) antibody, and
cultures assessed to be≥ 98% astrocytes (GFAP+).
Isolation and culture of mouse brain microvascular
endothelial cells
BMEC were isolated as previously detailed by this la-
boratory [10,48]. Primary cultures were typically grown
for approximately five days prior to sub-culturing for
experiments. At that time, purity was gauged to be ≥ 98%
BMEC, according to diI-acetylated LDL uptake [48].
BMEC also exhibited common endothelial characteris-
tics, e.g. CD31 and vWF immunostaining, plus displayed
expression of the tight junction-associated proteins ZO-1
and occluding, found enriched at the BBB.
Treatment of cultured cells
To examine effects of bindarit on basal CCL2 expres-
sion, cultured microglia and BMEC were incubated with
different concentrations of bindarit for 4 hr or exposed
to 300 μM bindarit for different time. To gauge effects
of bindarit on LPS-stimulated CCL2 expression, astro-
cytes and microglia were pretreated with 300 μM bin-
darit for 1 hr; then cells were incubated with± 100 ng/ml
LPS (Escherichia coli Serotype 026:B6) for 4 or 20 hr in
the continued presence of bindarit. After treatments, cells
were extracted for RNA purification.
Separation of brain microvessels and parenchyma
Distinct brain microvessel and parenchymal fractions
were obtained using a modification of the method to
prepare BMEC [10,48]. In brief, after removal of the
brain from the cranium, the meninges and big vessels
were discarded, and the whole brain diced into approxi-
mately 1 mm pieces. Brain tissue was then homogenized
with a 7 mL Dounce tissue grinder (Kimble/Kontes,
Vineland, NJ, USA) in PBS. The homogenate was then
transferred to a 15 ml conical tube and centrifuged at
400 × g for 15 minutes in an Eppendorf Model 5804R
centrifuge/A-4-44 rotor. The resulting pellet was resus-
pended in 18% dextran (v/v, molecular weight 60 000 to
90 000; USB Corporation, Cleveland, OH, USA) and
centrifuged at 4,500 × g for 15 minutes to pellet the
crude microvessel fraction. The dextran supernatant and
floating layer of myelinated axons were separated from
the crude microvessel pellet, then diluted 1:2 with PBS
and centrifuged at 720 × g for 10 minutes to sediment
the parenchymal fraction. Both microvessel and paren-
chymal fractions were washed twice with PBS to elimin-
ate traces of dextran. Microvessels were further washed
free of blood cells by filtering through a 40 μm cell
strainer (Becton Dickinson Labware, Franklin Lakes, IN,
USA) and eluting with PBS. Eluted microvessels were
pelleted by centrifugation at 16,000 × g in a table-top
microcentrifuge.
Treatment of animals
To determine effects of bindarit on LPS-stimulated
CCL2 expression in brain and spinal cord, C57BL/6 fe-
male mice were given intraperitoneal (i.p.) injection of
bindarit (200 mg/kg) or methylcellulose vehicle, once a
day, for 4 consecutive days. At 30 minutes following the
last bindarit injection, mice were given i.p. injection of
LPS (5 mg/kg; Escherichia coli Serotype 026:B6). Then,
4 hr after LPS injection, mice were euthanized and brain
and spinal cord dissected for CCL2 mRNA and protein
analysis.
For active induction of EAE, C57BL/6 female mice
were immunized with MOG35-55 peptide (MEVG-
WYRSPFSRVVHLYRNGK) of rat origin, by a modification
of the method previously described [49]. Briefly, on day 0
female mice 7 to 9 weeks of age were injected sub-
cutaneously with 150 μg of MOG peptide and 300 μg
of Mycobacterium tuberculosis (DIFCO, Detroit, MI, USA)
in complete Freund’s adjuvant (CFA) (DIFCO) into the
right and left flank, 100 μl per site. Mice were also injected
i.p. with 200 ng pertussis toxin (List Laboratories,
Campbell CA, USA) in PBS on days 0 and 2 following the
first immunization. Animals were monitored and scored
daily for clinical disease severity according to the following
scale: 0 = normal; 1 = tail limpness; 2 = limp tail and weak-
ness of hind legs; 3 = limp tail and complete paralysis of
hind legs; 4 = limp tail, complete hind leg and partial front
leg paralysis; and 5=death. Several disease parameters
were calculated as described [49]. The mean day of onset
was calculated by averaging the time when clinical symp-
toms, that is, a clinical score≥ 1, were first observed for
two consecutive days in each mouse. The mean maximum
clinical score was calculated by averaging the highest score
for each mouse. The disease index was calculated by
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adding the daily average clinical scores in each group, div-
iding by the mean day of onset, and multiplying by 100. In
the case that an animal showed no disease, the day of
onset was arbitrarily counted as one day after the last day
of the experiment (for example, day 22). And the disease
incidence was the fraction of mice experiencing EAE.
To investigate the effects of bindarit on both the clin-
ical course of EAE and CCL2 level during disease, mice
were given daily i.p. injection of bindarit (or vehicle
MTC) at 200 mg/kg for three consecutive days, begin-
ning the day before MOG immunization (day −1), then
injections every other day till day 20. This schedule was
designed to mitigate, as much as possible, trauma asso-
ciated with daily injections at times of peak neurologic
disease and physical compromise.
RNA purification from cell cultures
Total RNA was extracted from cell cultures using the
RNeasy kit according to the manufacturer’s instructions.
RNA was treated with Turbo DNAse (Ambion, Austin,
TX, USA) according to the protocol provided by the
manufacturer. RNA yield and purity were determined by
spectrophotometry absorption at 260 and 280 nm.
RNA purification from CNS tissue
RNA and protein were differentially extracted from the
same mouse brain and spinal cord samples using the
AllPrep RNA/Protein kit (QIAGEN, Valencia, CA) fol-
lowing the manufacturer’s instructions. RNA was treated
with Turbo DNAse (Ambion, Austin, TX, USA) accord-
ing to the protocol provided by the manufacturer. RNA
yield and purity were determined by spectrophotometry
absorption at 260 and 280 nm. Protein level was deter-
mined using the Micro BCA protein assay kit (Pierce,
Rockford, IL, USA), using bovine serum albumin as a
standard.
Reverse transcription
cDNA was synthesized from the total RNA using a
SuperScript III (Invitrogen, Carlsbad, CA, USA) First-
strand synthesis system for RT-PCR with a standard
protocol. The resulting cDNA was stored at −80 °C until
used for further analysis.
CCL2 RNA determination by quantitative RT-PCR
Measurements of cDNA levels were performed by quan-
titative (q) RT-PCR using an ABI PRISM 7500 Sequence
Detection System Version 1.3, and SYBR green (AB
Applied Biosystems, Foster sity, CA, USA) fluorescence
was used to quantify relative amplicon amount. Separate
controls included a no template-control and no reverse
transcriptase-control, and standard curves were con-
structed for all primers used. Cycle time (Ct) values for all
samples were normalized to RPL-19, the housekeeping
gene encoding the 60 S ribosmal protein L19. Specifically,
relative amplicon quantification was performed using the
formula: 1þ Erefð ÞCt refð Þ= 1þ Etargetð ÞCt targetð Þñ 100%,
with ref: RPL19; target: CCL2; E: primer pair efficiency;
and Ct: threshold cycle.
For all cell culture studies and in vivo LPS studies, rela-
tive CCL2 gene expression values (after normalization to
RPL19) were expressed as percentage of control. For EAE
studies, relative CCL2 gene expression values were desig-
nated as percentage of RPL-19 expression, as control
CCL2 level (time-point 0) was undetectable. The primer
sequences used in this study were as following: for mouse
CCL2, 5′- GGC TCA GCC AGATGC AGT TAA-3′ (for-
ward) and 5′- CCA GCC TAC TCA TTG GGA TCA −3′
(reverse); for RPL-19, 5′- CGC TGC GGG AAA AAG
AAG-3′ (forward) and 5′- CTG ATC TGC TGA CGG
GAG TTG −3′ (reverse).
CCL2 protein determination
The level of CCL2 was measured with mouse JE/CCL2
commercial enzyme-linked immunoassay kit (BioSource
International Inc., Camarillo, CA) according to the man-
ufacturer’s instructions.
Statistical analysis
Statistical significance of differences between mean
values of bindarit-treated cultures and control cultures
was analyzed using a paired two-tailed t-test, while com-
parisons of bindarit treatment on LPS-treated mice were
performed using a two-tailed t-test for independent
samples. For analysis of bindarit effects on clinical
EAE, a chi-squared (χ2) test was used for comparisons
of disease incidence; a Mann–Whitney U-test was
used for comparisons of disease index; and a two-
tailed t-test for independent samples was used for
comparison of disease onset. A P-value< 0.05 was
considered significant in all cases.
Results
Bindarit differentially suppresses CCL2 expression by
cultured CNS cells
The effects of bindarit on cultured glial and BMEC were
investigated first (Figures 1, 2, 3). Figure 1 shows that
cultured microglia demonstrated both a dose and time
dependency of bindarit effect on CCL2 mRNA level.
Suppression of basal CCL2 mRNA was seen beginning
with the lowest dose of 50 μM for 4 hr, amounting to
nearly 75% reduction. Increasing the dose to 300 and
500 μM resulted in still further diminution of CCL2
mRNA to approximately 10% and 5%, respectively, of
control level. Treatment with bindarit at 300 μM for as
little as 2 hr resulted in near 60% reduction in CCL2
mRNA level, and treatment for longer times at this
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concentration resulted in suppression of CCL2 mRNA
to ≥ 90% of control level.
BMEC demonstrated a similar qualitative response
in basal CCL2 mRNA to increasing bindarit concen-
tration, but suppression was not as severe as seen
with microglia (Figure 2). Significant reduction was
not observed until 100 μM, and the maximal suppres-
sion achieved was about 20% that of control. The
time course of bindarit action on BMEC also differed.
Maximal suppression by 300 μM bindarit was
achieved at the earliest time-point of 2 hr, reaching a
level of approximately 20% of that of the control.
Longer time-points, however, appeared to result in a
lesser effect. It is important to reemphasize that, in
the normal CNS, CCL2 expression is barely detect-
able. This would suggest that both cultured microglia
and BMEC, possibly removed from a normally sup-
pressive microenvironment, are in a somewhat acti-
vated state.
This situation appears different for astrocytes. In
this case, bindarit’s effects on constitutive CCL2 gene
expression could not be accurately assessed, as level
of this chemokine’s mRNA in murine culture of these
cells is very low. Astrocyte cultures were thus stimu-
lated with LPS for different lengths of time to greatly
induce CCL2 mRNA, and the effect of bindarit on
this CCL2 induction was assayed (Figure 3A). Stimu-
lation with 100 ng/ml LPS for both 4 hr and 20 hr
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Figure 1 Bindarit effects on CCL2 mRNA in cultured microglia.
Microglia, prepared from C57BL/6 mouse brain, were incubated with
bindarit at the indicated concentrations for 4 hr (A), or exposed to
300 μM bindarit for the indicated times (B). Control cultures
received only vehicle. Relative CCL2 RNA levels were determined by
qRT-PCR, and effects of bindarit treatment reported as % change
compared to control cultures. *P< 0.05; #P< 0.01 (compared to
control at 0 concentration or 0 time of bindarit).
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Figure 2 Bindarit effects on CCL2 mRNA in cultured BMEC. Brain
microvascular endothelial cells (BMEC), prepared from C57BL/6
mouse brain, were incubated with bindarit at the indicated
concentrations for 4 hr (A), or exposed to 300 μM bindarit for the
indicated times (B). Control cultures received only vehicle. Relative
CCL2 RNA levels were determined by qRT-PCR, and effects of
bindarit treatment reported as % change compared to control
cultures. *P< 0.05; #P< 0.01 (compared to control at 0 concentration
or 0 time of bindarit).
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produced similar elevations in CCL2 gene expression,
and bindarit treatment at 300 μM similarly suppressed, by
40 to 60%, the induction of CCL2 mRNA at both time-
points.
In light of bindarit’s success at mitigating induction
of CCL2 in astrocytes, we next assayed whether it
was similarly effective in preventing induction in LPS-
stimulated microglia. Figure 3B shows that this was in
fact the case, bindarit completely suppressing the in-
duction and reducing CCL2 mRNA level to 15% of
the control (basal) value.
Bindarit blocks LPS-induced CCL2 expression in brain and
spinal cord
It was next investigated whether bindarit could suppress
LPS-induced CCL2 expression in the CNS in vivo
(Figure 4). In the normal, resting state, CNS CCL2
mRNA level is barely detectable in C57BL/6 mice
[50], but is elevated 50- to 100-fold shortly after per-
ipheral LPS injection [51]. Pretreatment with bindarit
was nevertheless able to effectively block this induc-
tion both in the brain and spinal cord, by 92% and
86%, respectively. In addition to abrogating LPS-
induction of CCL2 mRNA in the CNS, bindarit was
also effective at reducing CCL2 protein level in both
brain and spinal cord, though not to the same extent
as mRNA.
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Figure 3 Bindarit effects on LPS-stimulated CCL2 mRNA in
cultured astrocytes and microglia. Separate cultures of astrocytes
(A) and microglia (B), prepared from C57BL/6 mouse brain, were
pre-treated with 300 μM bindarit for 1 hr, then incubated
with ± 100 ng/ml lipopolysaccharide (LPS) in the continued presence
of bindarit. Astrocytes cultures were exposed to LPS for the
indicated times to stimulate CCL2 expression. Microglial cultures
were only exposed to LPS for 4 hr, as these highly express CCL2
even under basal conditions. Control cultures received only vehicle.
Relative CCL2 RNA levels were determined by qRT-PCR, and effects
of bindarit treatment reported as % change compared to control
cultures. Brackets designate comparison between the two respective
groups. *P< 0.05; #P< 0.01.
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Figure 4 Bindarit’s effects on CCL2 mRNA and protein in brain
and spinal cord following LPS. Mice received i.p. injection of
200 mg/kg bindarit (or vehicle) once a day for 4 days, followed by i.
p. injection of 5 mg/kg lipopolysaccharide (LPS) at 30 minutes after
the last bindarit treatment. At 4 hr after LPS injection, brain and
spinal cord were prepared for CCL2 mRNA (A) and protein (B)
determinations. LPS + bindarit-treated brain or spinal cord samples
were compared to corresponding samples treated with LPS + vehicle
(control). *P< 0.05; #P< 0.01.
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Bindarit therapeutically modifies clinical EAE
The ability of bindarit to modify clinical EAE was exam-
ined next. Figure 5 shows that, with a bindarit schedule
of daily injections for the first three days, and beginning
at day −1, then injections every other day till day 20,
bindarit yielded several therapeutic effects. By the criter-
ion that disease is manifest when a clinical score of at
least 1 is demonstrated for at least two consecutive days
[49], bindarit delayed onset of EAE. Specifically, control
mice developed acute disease beginning at day 8, while
bindarit-treated mice did not show evidence of clinical
disease until days 14 to 15. A second therapeutic effect
observed was reduced disease progression and severity.
Control mice showed rapid progression of EAE, pro-
ceeding towards a maximum mean clinical score of
approximately 2.1 to 2.2 by day 9. Bindarit-treated
mice evidenced slower progression, and only reached
a maximum mean clinical score of 1.5. A third therapeutic
effect was apparent reversal of disease course. After ex-
periencing rapid onset, control mice showed a plateau in
disease score typical of this monophasic MOG-induced
EAE [52,53]. However, in marked distinction, bindarit-
treated mice demonstrated a consistent downward trend
in disease score following their delayed and attenuated
peak in clinical presentation. A summary of the effects of
bindarit treatment on clinical EAE is presented in Table 1.
We next sought to examine how bindarit modifies
CCL2 expression in the brain during EAE. First, the
temporal expression of CCL2 was determined only in
MOG-immunized mice not receiving any bindarit, to
gauge the window of opportunity during which bindarit
might act. As seen in Figure 6, CCL2 RNA is barely
detectable at the time of immunization. Its expression
then accelerates beginning around day 9, is significantly
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Figure 5 Bindarit effects on clinical experimental autoimmune encephalomyelitis (EAE). Mice were subject to EAE by active immunization
with MOG peptide, beginning on day 0, as detailed in Methods. Bindarit (or vehicle) was injected i.p. at 200 mg/kg according to the schedule
indicated, beginning at day −1 (one day before MOG immunization). Mean clinical score (A) and % incidence of EAE (B) were determined. EAE
was diagnosed when animals demonstrated a clinical score≥ 1 for two consecutive days.
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elevated by day 14, rapidly declines at day 17, and
reaches near basal level by day 21. Because bindarit has
been shown to most effectively suppress stimulated, ra-
ther than basal, CCL2 expression [33,54], bindarit effects
on CCL2 were analyzed selectively during this peak
interval. Additionally, brain tissue was resolved into
microvascular and parenchymal fractions to further
identify targeted cell types. This resolution was deemed
important, as both microvessels (BMEC) and parenchy-
mal neural cells (astrocytes and microglia) have been
reported as sources of CCL2 during EAE [55-58], though
microvessels only contribute< 1% to brain volume [59].
It was thus reasoned that parenchymal effects could
overshadow possible bindarit-induced changes in micro-
vascular CCL2 expression if only whole-brain levels were
evaluated. Figure 7 reveals that bindarit significantly
reduced peak CCL2 expression during EAE in both
microvascular and parenchymal fractions, in agreement
with what was found in our culture studies. Also, bin-
darit did not affect CCL2 expression outside the peak
window, reinforcing that its action appears restricted to
activated cells within and outside the CNS [33,54].
Discussion
Given the success of the CCL2 synthesis inhibitor bindarit
in ameliorating several animal disease models and human
clinical conditions associated with peripheral inflamma-
tory disease, initial studies were conducted to examine its
effects on elements critical to neuroinflammatory disease.
Focusing on the three main cell types responsible for
CCL2 expression during neuroinflammation, experiments
revealed bindarit significantly suppressed CCL2 in cul-
tured BMEC, microglia and astrocytes. Bindarit was
further shown to be effective in vivo in two neuroinflam-
matory paradigms: 1) it blocked LPS induction of CCL2 in
both brain and spinal cord; and 2) it therapeutically modi-
fied the course of EAE while suppressing CCL2 ex-
pression in both brain microvascular and parenchymal
compartments.
As to the effects on the seminal sources of CCL2, it
was critical to determine whether each was susceptible
to bindarit, as the specific cellular pool(s) responsible for
CCL2’s pathogenic actions during neuroninflammatory
disease remain unclear [51]. While all three cell types
responded with significant reduction in CCL2 mRNA,
microglia were the most sensitive - experiencing> 90%
diminution in this chemokine’s expression. This high
sensitivity to bindarit holds particular significance, as
microglia are widely considered the primary immune ef-
fector cells in the CNS [60-63], and their expression of
CCL2 has been linked to monocyte recruitment into the
CNS [64,65]. As CCL2 can also direct recruitment and
proliferation of microglia [66-68], as well as activation of
these cells [68], microglial expression of CCL2 can poten-
tially support a self-sustaining cycle of neuroinflammation.
Bindarit action, however, might effectively abrogate such a
scenario.
That bindarit also suppressed CCL2 mRNA in BMEC
is noteworthy. As these cells form the first line of
defense in the BBB [69], their expression of CCL2 might
strongly influence incipient steps of neuroinflammation
[70]. Indeed, elevated CCL2 expression by BMEC has
been reported in MS [71] and EAE [55,56], as well as in
autoimmune inflammation of the peripheral nervous
system [3]. Furthermore, intravenously administered anti-
CCL2 antibody blocked heightened leukocyte adhesion to
pial venular endothelium in vivo in mice suffering acute
Table 1 Summary of bindarit effects on clinical experimental autoimmune encephalomyelitis (EAE) parameters
Group Sick/total, number Mean day of onseta Mean max clinical score Mean disease indexb
MTC 14/14 11.42 ± 1.76 2.43 ±0.47 163.7 ± 20.53
BND 8/14 16.85 ± 2.17 1.52 ± 0.88 99.3 ± 10.21
P-value - <0.005 <0.001 <0.01
Mean presented ± SD.
aDay of onset established when clinical score ≥ for two consecutive days.
bDisease index calculated at day 21.
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EAE [72], as well as prevented recurring clinical episodes
in a chronic relapsing EAE model [73], possibly by antag-
onizing CCL2 at the luminal endothelial surface. Support-
ing this possibility, CCL2 harbors in its C-terminal α-helix
a binding site for GAGs typically found on the luminal
endothelial surface [74], and has been shown to bind
to the luminal surface of cultured endothelial cells
and then trigger firm adhesion followed by transmi-
gration of mononuclear leukocytes [75,76]. Binding of
CCL2 released from BMEC in culture has most re-
cently been shown to switch from the luminal to the
abluminal surface following cytokine-induced activa-
tion [77], possibly reflecting the changing roles of this
chemokine pool from first promoting leukocyte adhe-
sion to later directing extravasation into the paren-
chyma. Thus, by targeting the BMEC reservoir of
CCL2 during disease, bindarit might be able to blunt
neuroinflammation at different stages.
Bindarit action on CCL2 expression by cultured astro-
cytes had to be studied in the context of LPS stimula-
tion, as these cells exhibit barely detectable CCL2
mRNA in culture or in situ in the naïve state [50,51].
Yet despite significant induction, astrocyte CCL2 mRNA
was reduced by half or more following bindarit expos-
ure. As astrocytes constitute the most abundant glial cell
population in the CNS [78], suppression of their CCL2
production by bindarit in vivo might well exert profound
influence on pathologic events.
That bindarit could indeed act in vivo to effectively
suppress neuroinflammation was evident in both the
LPS and EAE paradigms. Injection of bindarit dramatic-
ally reduced LPS-stimulated expression of CCL2 in both
brain and spinal cord, dropping mRNA levels to near
10% of vehicle-injected control values, while cutting pro-
tein levels approximately by half. In this case, the effi-
cacy of bindarit in suppressing brain CCL2 may have
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Figure 7 Effects of bindarit on CCL2 expression in central nervous system (CNS) fractions during experimental autoimmune
encephalomyelitis (EAE). Mice were immunized with MOG peptide to induce EAE, and were injected with bindarit (or MTC vehicle) as in
Figure 5. At the indicated days post-immunization, mice were sacrificed and CCL2 mRNA levels determined in microvascular (A) and parenchymal
(B) fractions. Bindarit treated groups were compared to vehicle treated groups. *P< 0.01.
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been aided by the fact that LPS can severely disrupt the
BBB [79,80], and thereby possibly facilitate bindarit entry
into the CNS parenchyma. As CCL2 can also disrupt tight
junctions leading to elevated BBB permeability [10-12],
CCL2 generated early after LPS injection may have con-
tributed to its subsequent suppression by further enabling
bindarit CNS access.
The effects of bindarit on clinical EAE suggest that bin-
darit exerted both preventative and therapeutic actions.
Preventative action is indicated by the considerable delay
in disease onset in the bindarit-treated group, as well as
the reduced incidence and severity of disease displayed by
these mice. Possible therapeutic action is conveyed by the
steady decline in disease severity following diminished
peak clinical score. Such decline was in marked contrast
to the typical plateau in clinical score exhibited by EAE
mice given vehicle. These results are qualitatively similar
to those recently reported by Laborde et al. [81] who,
employing a regimen of twice daily oral dosage of a novel
heteroaroylphenylurea antagonist of CCL2 function, also
described delayed disease onset and resolution of EAE
symptoms. In the case of bindarit, however, clinical symp-
toms seemed to steadily remit following attenuated peak
disease, and a reduced incidence was also noted. Both
studies nevertheless highlight the prospect that selective
targeting of CCL2 activity might prevent EAE, as well as
reverse its course.
The effect of bindarit on clinical EAE was accompan-
ied by significant reduction of CCL2 mRNA in both
brain microvessel and parenchymal fractions, consistent
with bindarit’s mechanism of action being inhibition of
CCL2 transcription [33]. Reinforcing this point, global
knockout of the CCL2 gene has been shown to similarly
delay EAE onset, and reduce both disease incidence and
severity, effects that have been attributed to absence of
CCL2 expression within the CNS compartment [81,82].
This, along with demonstration that CCL2-deficient
mice also exhibit reduced neuroinflammatory responses
to peripheral LPS injection [83,84], underscores CCL2’s
non-redundant role in neuroinflammatory disease and
accentuates its value as a therapeutic target. Results with
bindarit and EAE may further suggest that both micro-
vascular and parenchymal sources of CCL2 contribute
to pathogenesis. If this is so, it could further imply bin-
darit would not have to penetrate the BBB in order to
reach at least one of its targets, BMEC. In contrast to
the acute situation with LPS, which acts directly on the
endothelium, it is reasoned that the BBB was more in-
tact in EAE mice receiving bindarit, as mean disease
score only reached approximately 1.5. Thus, a likely
scenario is that bindarit also sufficiently crossed the
BBB to suppress the astrocyte and/or microglial re-
sponse as well. This lends promise that bindarit can
access the CNS parenchyma during the early stages of
neuroinflammatory disease, when BBB breakdown is
not yet manifested.
Conclusions
In summary, the CCL2 synthesis inhibitor bindarit,
previously shown to be highly effective in myriad ex-
perimental disease models as well as human condi-
tions having inflammatory involvement [34-40], was
observed to significantly reduce steady state and LPS-
induced CCL2 expression in cultured microglia,
BMEC and astrocytes, as well as LPS-stimulated
CCL2 mRNA and protein levels in CNS tissue in situ.
Bindarit was further effective in delaying, preventing
and attenuating clinical EAE, and evidenced signs of
possibly reversing disease course while also suppres-
sing elevation of CCL2 in brain microvascular and
parenchymal compartments. Collectively, these data
are consistent with the widely proposed critical role
for CCL2 in neuroinflammation [18-20], and suggest
bindarit, by targeting cells of the NVU [41], might
have therapeutic success in the treatment of MS and/or
other human neuroinflammatory diseases.
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Immuno-laser  capture  microdissection  (immuno-LCM)  enables  highly  selective  retrieval  of  designated
cell  populations  from  their  in  situ  locations  in complex  tissue  like  the  brain.  However,  the  amount  of
tissue  acquired  by immuno-LCM  is  extremely  limited,  and  the  RNA  purification,  amplification  and  label-
ing  steps  necessary  for expression  analysis  by  hybridization  microarray  are  tedious  and  time  consuming.
This report  therefore  describes  a protocol  in  which  these  RNA  steps  are  eliminated  altogether,  yet  allows
for  global  gene  profiling.  Specifically,  immuno-LCM  tissue  was  solubilized  and  the extract  directly  sub-
jected  to reverse  transcription  to generate  cDNA.  Pre-amplification  of  cDNA  was  performed  next,  and
then relative  expression  of 96  different  immune-related  genes  simultaneously  determined  by  quan-
titative  real-time  PCR  using  a microfluidic  card  TaqMan® Low  Density  Array  (TLDA).  This  protocol  was
highly  reproducible  and  extremely  sensitive,  demonstrating  high  correlation  of raw  Ct values  among  both
technical  and  biological  replicate  samples  when  using  only  1/32  of total  pre-amplified  cDNA  obtained
from  as  little  as  500  LCM  ‘shots.’  As this  abridged  protocol  takes  only  approximately  7 h from  LCM tis-
sue acquisition  to  analysis  by TLDA,  it can  prove  a very  effective  tool  for both  screening  and  validation
purposes  when  investigating  gene  regulation  in  health  and  disease  of the nervous  system  and  other
tissues.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
The endothelium shows considerable phenotypic and molecular
diversity along the CNS vascular tree (Ge et al., 2005). Segmen-
tal heterogeneity exists between the endothelium of parenchymal
microvessels (e.g., arterioles, capillaries and venules) and sur-
face macrovessels (e.g., arteries and veins), and even between the
endothelium of the respective microvascular tributaries. There is
also regional heterogeneity between the endothelium of similar type
vessel segments within different CNS regions.
Endothelial heterogeneity poses challenges to studying CNS
vascular gene expression. Whole brain and/or spinal cord
homogenates suffer from pooling different vascular segments from
different CNS regions, providing at best a mosaic of endothelial
subtypes. This can lead to significant misinterpretation of vascu-
lar function. A means to enrich for specific endothelial populations,
coupled to a platform to quantitatively analyze gene expression
efficiently, is needed to accurately assess the CNS endothelium in
health and disease.
∗ Corresponding author. Tel.: +1 860 679 3698.
E-mail address: pachter@nso1.uchc.edu (J.S. Pachter).
Laser capture microdissection (LCM) enables selective isolation
of cells from microscopic samples of tissue (Espina et al., 2007)
– and presents opportunity to exploit CNS endothelial hetero-
geneity in depth. This laboratory showed that, when guided by
combined immunohistochemistry/immunofluorescence and cou-
pled to SYBR® Green-based, quantitative real-time PCR (qrt-PCR),
immuno-LCM allowed analysis of endothelial gene expression in
separate populations of CNS arterioles, capillaries and venules
(Macdonald et al., 2010).
Coupling gene expression to LCM has nonetheless been encum-
bered by the rigors of isolating intact RNA from mere fractions of
cells and, thus, largely limited to analyzing only a few genes at a
time. Moreover, isolating RNA on such a small scale from multi-
ple samples can become unmanageable in time and cost. A method
that would avoid time-consuming and inefficient RNA isolation,
yet allow for more extensive gene profiling, would thus be advan-
tageous.
Here we describe a novel protocol, whereby brain microvascular
endothelial cell (BMEC) tissue retrieved by LCM is lysed and directly
reverse-transcribed, then subject to pre-amplification of cDNA, and
analyzed by TaqMan® Low Density Array (TLDA) for simultaneous
assessment of 96 different genes. Significantly, the high sensitivity
of this approach enables analysis of a modest amount of LCM tissue
0165-0270/$ – see front matter ©  2012 Elsevier B.V. All rights reserved.
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that can be quickly acquired, allowing in situ gene profiling on this
global scale to be completed in approximately 7.0 h from beginning
to end.
2. Materials and methods
Specific aspects of immuno-LCM, including examples of
immunostained tissue, discussion of tissue preservation and
confirmation of endothelial purity, have been elaborated in pre-
vious reports from this laboratory (Kinnecom and Pachter, 2005;
Macdonald et al., 2008), and not reiterated here. Where appropri-
ate, approximate times are indicated below next to individual steps
in the immuno-LCM/TLDA protocol, to allow comparison to other
procedures used for global gene profiling.
2.1. Animals
Female C57 BL/6 mice, age 8–10 weeks and obtained from
Charles River Laboratories, Inc. (Wilmington, MA), were used to
minimize microvascular heterogeneity due to genetic variability,
sex, and age (Macdonald et al., 2008). Animals were euthanized
by CO2 inhalation, following Animal Care and Use Guidelines of the
University of Connecticut Health Center (Animal Welfare Assurance
# A3471-01).
2.2. Induction of experimental autoimmune encephalomyelitis
(EAE)
EAE was induced in mice by active immunization with MOG35–55
peptide (MEVGWYRSPFSRVVHLYRNGK), of murine origin (W.M.
Keck Biotechnology Resource Center, Yale University), as described
(Juedes et al., 2000). Mice were observed daily and scored on a scale
of 0–4 with gradations of 0.5 for intermediate scores: 0, no clinical
signs; 1, loss of tail tone; 2, wobbly gait; 3, hind limb paralysis; and
4 hind and fore limb paralysis. LCM tissue was acquired at day 16
post-immunization (score ∼2.0).
2.3. Tissue preparation and sectioning
Following euthanasia, the brain was removed, snap-frozen in
dry ice-cooled 2-methylbutane (Acros; Geel, Belgium) and pro-
cessed for cryosectioning (Macdonald et al., 2008). Coronal sections
(7 !m thick) of cerebellum were cut between Bregma −6.56 mm
and −7.32 mm,  adhered to glass slides, and stored at −80 ◦C until
immuno-LCM.
2.4. Fixation and immunostaining of sections for identification of
microvessels [30 min]
To obtain sufficient material for comparing two  samples by
LCM/qrt-PCR analysis, two slides, each containing two  consecutive
brain sections, were fixed, stained, and dehydrated simultaneously.
Two sections provided sufficient material for each sample. Pairing
samples this way enabled both samples to experience the same
environmental conditions for the same time (Macdonald et al.,
2008). Double immunostaining of BMEC and astrocyte populations,
by combined immunohistochemistry and immunofluorescence,
respectively, was carried out as detailed (Macdonald et al., 2008).
2.5. Dehydration [8.0 min]
After immunostaining, sections were dehydrated in the fol-
lowing solutions, made by diluting 100% EtOH (Pharmco-AAPER;
Brookfield, CT) with DEPC treated water: 75% EtOH for 10 s, 95%
EtOH for 30 s, 100% EtOH for 60 s, 100% EtOH for 90 s, xylene (Fisher
Scientific; Pittsburgh, PA) for 2 min  and a final xylene for 3 min.
2.6. LCM [20–30 min]
The Arcturus PixCell IIe microscope (Life Technologies; Bedford,
MA)  was  used to retrieve BMEC according to the LCM conditions
described (Kinnecom and Pachter, 2005; Macdonald et al., 2008).
In brief, the LCM parameters utilized were as follows: 7.5 !m spot
size; 72 mW power; and 0.950 ms  pulse duration. BMEC were cap-
tured exclusively from capillaries (∼ 5–9 !m diameter) within the
designated cerebellar boundaries. As LCM can only be performed
on one slide at a time, one of the two  simultaneously stained slides
was left at room temperature until action on the first slide was
completed. Tissue samples were captured onto HS® caps (Life Tech-
nologies Corp.) by a designated number of ‘shots’ (i.e., laser pulses),
with one cap used per sample. An equal number of LCM shots was
necessary to standardize the amount of input RNA, and was pre-
viously shown to provide a highly reproducible amount of tissue
equivalent (Macdonald et al., 2008).
Because LCM acquires material from tissue sections, only “frac-
tions” of cells are obtained with each LCM shot. However, the
following sample calculation may  be used to estimate the num-
ber of endothelial cells captured in an LCM session: Assuming
the typical endothelial cell is 10–15 !m deep × 25–50 !m long
(Simionescu and Simnionescu, 1977), then in 7 !m-thick sections
each capillary endothelial profile cut in longitudinal section would
represent 0.47–0.7 cells in thickness. Using a 7.5 !m diameter laser
spot size, the number of capillary endothelial cells cut length-
wise would be 0.15–0.3. Hence, the number of endothelial cells
captured/shot = 0.07–0.21 cells; 500 shots would thus represent
35–105 cells, and 1000 shots represent 70–210 cells.
2.7. Tissue extraction [15 min]
Once LCM was completed, tissue was solubilized in Cell Lysate
Buffer® (Signosis; Sunnyvale, CA) for direct reverse transcription.
Cell Lysate Buffer®, pre-heated to 75 ◦C, was  added and the result-
ing lysate heated at 75 ◦C for an additional 15 min. Samples of both
extracts were immediately frozen at −80 ◦C.
2.8. DNase treatment and cDNA synthesis [2 h]
Cell Lysate Buffer® extracts were treated with Turbo DNase
(Ambion; Austin, TX) according to the manufacturer’s instructions.
Specifically, Turbo DNase buffer and DNase were added and sam-
ples incubated at 37 ◦C for 30 min. Next, DNAse inactivation reagent
was added for 2 min  at room temperature. Samples were then
reverse transcribed using the SuperScript III (Invitrogen) standard
protocol with random hexamers (Roche; Indianapolis, IN), and
employing an extension temperature of 42 ◦C – optimal for ran-
dom hexamers – for 60 min. cDNA was stored at −20 ◦C until used
for analysis.
2.9. cDNA pre-amplification [1 h 40 min]
Pre-amplification was carried out using TaqMan® PreAmp Mas-
ter Mix  and a custom PreAmp Pool containing all the primers for
detection by TaqMan® Gene Expression Assays. Relative amplifica-
tion was  validated using single gene (single-plex) probes for CCL2,
VCAM1 and GAPDH prior to analysis by TaqMan® Low Density
Array (TLDA) Microfluidic Cards. Both 10 and 14 cycles of pre-
amplification were evaluated initially, with an initial hold at 95 ◦C
for 10 min, followed by 10/14 cycles at 95 ◦C for 15 s and 60 ◦C for
4 min. For TLDA analysis, 14 cycles of pre-amplification were used.
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2.10. qrt-PCR [2 h]
Relative cDNA levels were quantified by qrt-PCR using an ABI
PRISM 7500 Sequence Detection System Version 2.3, and custom
TaqMan® MGB  probes. For single-plex assays, separate controls
included no template or no reverse transcriptase, and standard
curves were constructed for all primers used. Custom TaqMan®
primers/probes were used for both single-plex qrt-PCR and the
Mouse Immune Panel TLDA (Life Technologies Corp.). TLDA analy-
sis was conducted as per the manufacturer’s protocol, with 100 !l
sample volumes containing a 1/32 or 1/4 dilution of pre-amplified
cDNA added to each port of the microfluidic card.
2.11. Statistical analysis
Data from single-plex reactions were analyzed in SDS 2.3 and
Microsoft Excel 2007, while that from TLDA plates were imported
to the SDS 2.3 companion software RQ Manager and exported
to Microsoft Excel 2007 for calculations. Linear regression anal-
ysis was conducted and a Pearson product-moment correlation
(Pearson r) determined using GraphPad Prism 5.0. Pearson r was
calculated from paired Ct values reflecting expression of each of the
96 genes represented in the Immune Panel TLDA. A Spearman-Rho
rank order correlation (Spearman r) was calculated to determine
if these 96 gene expression values were comparable in rank order
between samples.
3. Results
Because of the extremely low level of RNA from LCM sam-
ples, the first step was to determine if cDNA generated directly
from LCM tissue extracted in Cell Lysate Buffer® – without RNA
purification – could be amplified using a commercially available
pre-amplification kit prior to quantification by qrt-PCR. A sampling
of three genes represented on the Mouse Immune-TLDA (GAPDH,
VCAM-1 and CCL2) was individually analyzed in single-plex format.
These genes were selected as they exhibit high (GAPDH), moderate
(VCAM-1), and relatively low expression (CCL2) by BMEC during
acute EAE, the animal model for the neuroinflammatory disease
multiple sclerosis (MS) (Furlan et al., 2009) – and thus provide a
wide spectrum by which to judge efficacy of the pre-amplification.
Fig. 1 demonstrates a 14-cycle pre-amplification significantly low-
ered Ct values for all three genes. Both GAPDH and VCAM-1 had
their Ct values similarly lowered by 12 cycles, while Ct value of CCL2
decreased by 10.2 cycles, thus indicating the relative abundance of
amplicons was generally preserved through pre-amplification. The
apparent lesser amplification of CCL2 signal may  have resulted from
expression of this gene being lower than that which was reliably
detectable in the non-amplified sample.
It was next determined if pre-amplified BMEC cDNA, generated
from Cell Lysate Buffer extracts® without RNA isolation, could be
coupled to the Immune Panel TLDA for simultaneous analysis of 96
genes related to inflammation/autoimmunity. This specific TLDA
was selected as it contains a cadre of genes thought to be involved
in MS/EAE.
Two different dilutions of the pre-amplified cDNA were assayed
to cover a broad range of gene expression and test the limits of
sensitivity. Fig. 2(a) and (b) depicts linear regression analyses of
raw Ct values for the genes represented in the TLDA, contrasting
values obtained from 1/4 and 1/32 dilutions of pre-amplified cDNA
samples generated from 500 or 1000 LCM shots. Notably, raw Ct
values – as apposed to values normalized to a reference gene –
reflect the absolute values of input RNA for qrt-PCR and, thus, reveal
an accurate picture of the reproducibility of the immuno-LCM/TLDA
approach (Chen et al., 2009).
Fig. 1. Pre-amplification of cDNA from Cell Lysate Buffer® proportionally enhances
LCM/qrt-PCR of BMEC. At day 16 following MOG35–55 peptide immunization to
induce EAE (disease score ∼2.0), mouse cerebellar tissue was processed for immuno-
LCM, and BMEC captured by 1000 LCM shots then extracted with Cell Lysate Buffer® .
BMEC extract then underwent reverse transcription reaction without prior RNA
isolation, and equal aliquots of the resulting cDNA were either not pre-amplified
or  subject to 14 cycles of pre-amplification prior to single-plex qrt-PCR detection
with TaqMan® probes/primers for the genes GAPDH, VCAM1 and CCL2. Each qrt-
PCR reaction was run in duplicate (technical replicates), and the mean Ct values for
each gene are depicted. Pre-amplification of 14 cycles with extract from 1000 shots
of  LCM-derived BMEC yielded the following mean !Ct [cDNA – pre-AMP] values:
GAPDH (12.087), VCAM1 (12.34), and CCL2 (10.21). Inherent lower expression of
CCL2 may  explain the lesser-detected amplification of this gene.
Raw Ct values considered “undetermined” by the software, or at
a level ≥40 cycles, were excluded from analysis. In the case of 1000
LCM shots, 14 genes were so excluded, while only 6 genes were
omitted from the 500 LCM shot sample. Both 1000 and 500 LCM
shot samples yielded Pearson r values of >0.95, signifying extremely
high linear correlation between technical replicates. These techni-
cal replicates originated from the same tissue sections and resultant
cDNA pools, their only difference being they represented either
1/4 or 1/32 dilutions of pre-amplified cDNA applied to the TLDA.
The high Pearson r thus highlights that diluting cDNA samples over
an eightfold range did not distort the relationship between ampli-
con measurements of the different genes. Such technical replicates
showed a high Spearman r value as well, denoting that raw Ct scores
for each gene maintained their rank position relative to all other
genes in the TLDA when 1/4 and 1/32 dilutions of pre-amplified
cDNA were compared.
Immuno-LCM/TLDA further demonstrated both a high Pearson
r (0.95) and Spearman r (0.93) among raw Ct values obtained from
“biological” replicates (Fig. 2(c)). To obtain biological replicates, 500
LCM shots were performed on separate brain sections of the same
animal, and a 1/32 dilution of pre-amplified cDNA derived from
these respective sections was  used in each case. As such, these
biological replicates were subject to potential technical variability
as well. Brain tissue from different animals was  intentionally not
compared here, as the immunization protocol itself could produce
varying disease states in individual mice, and the objective was  to
isolate any variability due solely to analysis of random BMEC pop-
ulations. Despite undergoing a multitude of separate acquisition
and processing steps, however, biologic replicates also demon-
strated high fidelity. Specifically, linear regression yielded a line
with a slope of 1.03 ± 0.038 (SD) and Y and X intercepts of near
zero – reflecting that raw scores of any specific gene were virtu-
ally identical in the biological replicates. These results collectively
demonstrate – for the first time – high efficiency and reproducibil-
ity of linking immuno-LCM to TLDA format without need of tedious
RNA isolation and amplification steps.
4. Discussion
Coupling LCM to genomic profiling platforms has greatly
expanded the capacity to probe gene expression within the most
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Fig. 2. Expression profiling of BMEC by immuno-LCM/TLDA with no RNA purification shows high reproducibility. Immuno-LCM of BMEC was carried out on separate EAE
cerebellar sections, and captured tissue extracted with Cell Lysate Buffer® then processed through reverse transcription and cDNA pre-amplification, as in Fig. 1. To gauge
sensitivity and exclusively highlight technical reproducibility, different dilutions (1/4 or 1/32) of pre-amplified cDNA derived from 500 (a) or 1000 (b) LCM shots were analyzed
by  qrt-PCR using the Immune Panel TLDA, and linear regression performed on the two  corresponding raw Ct values obtained for each gene at the respective dilutions. To
highlight overall reproducibility, while accounting for all potential variation due to both biological and technical components, the results of 500 LCM shots from two different
tissue  sections were compared (c), and linear regression performed on the two corresponding raw Ct values obtained for each gene from the respective sections.
discrete CNS domains in situ. Linking LCM to hybridization-based
microarrays, in particular, has enabled transcriptional profiling of
tens of thousands of genes from select cell groups in CNS tis-
sue samples (Rossner et al., 2006). Nevertheless, this particular
combinatorial approach is labor intensive, expensive, and presents
difficulties with quantification and statistical evaluation.
Much of this labor stems from RNA isolation and downstream
amplification steps needed to generate sufficient labeled comple-
mentary RNA (cRNA) for detection (usually >1 !g). These steps can
become unmanageable when dealing with multiple samples. Thus,
proceeding directly from solubilization of LCM tissue to reverse
transcription and then cDNA pre-amplification, would save consid-
erable time and effort when comparing a number of variables (e.g.,
stages of disease progression or different drug dosages). Concerns
have also been raised regarding bias in the RNA amplification pro-
cess (Li et al., 2005). Furthermore, while the wide breadth of genes
that can be analyzed with hybridization-based microarrays may
be advantageous in certain applications (e.g., whole-cell transcrip-
tome analysis), it may  not be warranted in others. A limited analysis
may  be more desirable when investigating a specific biological pro-
cess or tissue property. As qrt-PCR is often used to confirm results
of hybridization arrays – which frequently illuminate no more than
a few hundred significantly variable genes – coupling LCM to a qrt-
PCR-based array format without RNA purification would also prove
an efficient validation or screening tool.
Given these considerations, this report described a simplified
and expeditious approach whereby immuno-LCM of BMEC was  fol-
lowed by tissue solubilization and direct reverse transcription (in
the absence of RNA purification), pre-amplification of the resulting
cDNA, and then simultaneous qrt-PCR analysis of 96 immune-
related genes by TLDA. Because RNA was not isolated in this study,
equal number of LCM shots served as basis for sample comparisons.
Previous work from this laboratory showed utilizing equal num-
bers of LCM shots was an effective means to standardize RNA input
(Macdonald et al., 2008), this approach yielding no statistically
significant variance in relative gene expression values between
technical or biological replicates as detected by single-plex qrt-PCR.
The number of shots in the present study was capped at 1000 to
minimize the time between immunostaining and processing of RNA
for analysis, as restricting this period to <30 min has been shown to
be critical for reliable qrt-PCR detection (Macdonald et al., 2008).
Notably, 500 LCM shots was  able to be performed in <20 min, and
yielded a higher number of detectable genes than did 1000 LCM
shots (90 genes vs. 82 genes, respectively) – perhaps reflecting loss
of RNA with increased LCM time. Both 500 and 1000 LCM shots
nevertheless showed high reproducibility in technical and biolog-
ical replicates among 96 different genes assayed simultaneously
by TLDA – even in the absence of RNA purification. These results
support the findings of Keays et al. (2005),  who  coupled LCM to
single-plex qrt-PCR without purifying RNA. But, to the best of our
knowledge, this is the first report to describe linkage of LCM to
microarray while bypassing RNA purification and employing cDNA
pre-amplification.
While there have been more than 100 published reports of
LCM/microarray analysis, the array format used has near exclu-
sively been genomic DNA chip hybridization – necessitating RNA
purification and amplification. Most recently, Balogh et al. (2007)
described coupling LCM of hemotoxylin/eosin-stained tissue to
the Immune Panel TLDA used in this study. However, they uti-
lized a four-step RNA amplification process: first purifying RNA,
then amplifying it based on dT-T7 and switch T7 primers followed
by in vitro transcription, and finally purifying the synthetic RNA
population. The present study averted these steps entirely. It is
further significant that high reproducibility of immuno-LCM/TLDA
was demonstrated with raw Ct scores – not gene expression values
normalized to a housekeeping gene.
The validity of the immuno-LCM/TLDA approach was under-
scored by the distribution of raw Ct scores obtained – from the
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low 20s to upper 30s – reflecting the variable expression patterns
of genes during evolving EAE. Moreover, preliminary comparison
between naïve and EAE mice revealed several significant differ-
ences. Among these were elevated expression of STAT6 and CCR4
(data not shown), both of which have been shown to be up-
regulated in EAE (Zaheer et al., 2007; Forde et al., 2011).
In summary, the immuno-LCM/TLDA approach described offers
a relatively quick, reliable and inexpensive means to globally pro-
file gene expression patterns of select cell groups in situ.  Given
the significant cellular heterogeneity within the nervous system,
immuno-LCM/TLDA holds high promise for elaborating gene regu-
latory mechanisms in the neurobiology of health and disease, and
could provide a highly efficient clinical diagnostic tool for neu-
ropathologists (McShea et al., 2006).
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Abstract
Background: There is increasing awareness that, aside from producing cerebrospinal fluid, the choroid plexus (CP)
might be a key regulator of immune activity in the central nervous system (CNS) during neuroinflammation.
Specifically, the CP has recently been posited to control entry of sentinel T cells into the uninflamed CNS during
the early stages of neuroinflammatory diseases, like multiple sclerosis (MS) and its animal model experimental
autoimmune encephalomyelitis (EAE). As the CP is compartmentalized into a stromal core containing fenestrated
capillaries devoid of typical blood–brain barrier properties, surrounded by a tight junction-expressing choroidal
epithelium, each of these compartments might mount unique responses that instigate the neuroinflammatory
process.
Methods: To discern responses of the respective CP stromal capillary and choroidal epithelial tissues during
evolving neuroinflammation, we investigated morphology and in situ expression of 93 immune-related genes
during early stages of EAE induced by immunization with myelin oligodendrocyte glycoprotein peptide (MOG35-55).
Specifically, 3-D immunofluorescent imaging was employed to gauge morphological changes, and laser capture
microdissection was coupled to an Immune Panel TaqMan Low Density Array to detail alterations in gene
expression patterns at these separate CP sites on days 9 and 15 post-immunization (p.i.). To resolve CP effects due
to autoimmunity against MOG peptide, from those due to complete Freund’s adjuvant (CFA) and pertussis toxin
(PTX) included in the immunization, analysis was performed on MOG-CFA/PTX-treated, CFA/PTX-treated, and naïve
cohorts.
Results: The CP became swollen and displayed significant molecular changes in response to MOG-CFA/PTX
immunization. Both stromal capillary and choroidal epithelial tissues mounted vigorous, yet different, changes in
expression of numerous genes over the time course analyzed - including those encoding adhesion molecules,
cytokines, chemokines, statins, interleukins, T cell activation markers, costimulatory molecules, cyclooxygenase, pro-
inflammatory transcription factors and pro-apoptotic markers. Moreover, CFA/PTX-treatment, alone, resulted in
extensive, though less robust, alterations in both CP compartments.
(Continued on next page)
* Correspondence: Pachter@nso1.uchc.edu
Blood–brain Barrier Laboratory, Department of Cell Biology, University of
Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030, USA
FLUIDS AND BARRIERS
OF THE CNS
© 2012 Murugesan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Murugesan et al. Fluids and Barriers of the CNS 2012, 9:15
http://www.fluidsbarrierscns.com/content/9/1/15
(Continued from previous page)
Conclusions: MOG-CFA/PTX immunization significantly affects CP morphology and stimulates distinct expression
patterns of immune-related genes in CP stromal capillary and epithelial tissues during evolving EAE. CFA/PTX
treatment, alone, causes widespread gene alterations that could prime the CP to unlock the CNS to T cell
infiltration during neuroinflammatory disease.
Keywords: Laser capture microdissection (LCM), Choroid plexus, EAE, Pertussis toxin, Neuroinflammation
Introduction
Though the choroid plexus (CP) is commonly recognized
as the production site of cerebrospinal fluid (CSF) [1-3], it
has relatively recently gained attention as a critical player
in central nervous system (CNS) inflammation [4-6]. Spe-
cifically, the CP has been suggested as the site of entry
into the uninflamed CNS of pioneer T cells searching for
their cognate antigens during immunosurveillance and in
the early stages of neuroinflammatory diseases such as
multiple sclerosis (MS) and its animal model experimental
autoimmune encephalomyelitis (EAE) [7,8]. Current the-
ory holds that, after crossing the CP into the CSF, pioneer
T cells travel to the subarachnoid space (SAS), where
antigen-presenting cells reactivate them. In turn, reactiva-
tion is thought to set off a burst of cytokines and other
mediators that inflames meningeal and parenchymal
venules to initiate disease [9-11].
The anatomy of the CP appears well suited to orchestrat-
ing the initial steps of CNS inflammation. It projects from
the roofs of all four ventricles into the CSF, and is com-
posed of two distinct tissue layers: a highly vascularized
stroma encapsulated by a “tight” layer of epithelial cells
[12]. Unlike the parenchymal capillaries forming the re-
strictive blood–brain barrier (BBB), CP stromal capillaries
are fenestrated and contain pentilaminar junctions whose
outer leaflets are not fused [13] – properties that render the
CP capillary population highly permeable to macromole-
cules [14]. This juxtaposition of “leaky” capillaries and tight
epithelium constitutes the blood-cerebrospinal fluid barrier
(BSCFB) [15,16], an arrangement construed as enabling
blood-born leukocytes to extravasate into an uninflamed
brain during the incipient stages of MS and EAE [17,18].
Supporting this process, expression of chemokine CCL20
by choroidal epithelial cells is thought to chemotactically
draw T cells – bearing the cognate receptor CCR6 – from
the CP stroma, across the epithelium and into the CSF [8].
In situ hybridization and immuno-electron microscopy
of the CP has further revealed expression of adhesion
molecules, VCAM-1 and ICAM-1, by choroidal epithelial
cells of the healthy CP, and additionally of MAdCAM-1
by these same cells during EAE [19,20]. Also, transcrip-
tome analysis of the whole adult CP has highlighted ex-
pression of immune mediators in both healthy mice [21]
and those subject to peripheral inflammation [22], reinfor-
cing the view this organ is a critical conduit linking
immune/inflammatory activities between the periphery
and CNS. But the extremely close apposition of the differ-
ent CP layers has posed a significant challenge to studying
the depth of their respective contributions to inflamma-
tory processes. In fact, no immune function has yet been
ascribed to the CP capillary endothelium, leaving com-
pletely unresolved the factors that drive T cell emigration
into the stroma. And gene regulatory events surrounding
transmigration of T cells across the choroidal epithelium
further remain unsettled.
To elaborate the sequence of events in the CP that set
the stage for CNS inflammation during EAE induced by
active immunization with MOG35-55 peptide, we used
laser capture microdissection (LCM) coupled to qrt-
PCR-based microarray [23] to establish the time course
of expression of a panorama of immune mediators in
the separate stromal (including capillaries) and choroid
epithelial layers. Morphological changes in the CP asso-
ciated with MOG immunization were also examined by
quantitative 3-D image analysis following confocal mi-
croscopy. Results reveal substantial changes in CP gene
expression and morphology occurred in response to
vspecific aspects of the MOG immunization process.
These results could hold relevance for how combina-
tions of environmental factors trigger neuroinflamma-
tory disease.
Materials and methods
Animals
Female C57BL/6 mice, age 8–10 weeks and obtained
from Charles River Laboratories, Inc. (Wilmington,
MA), were used to minimize microvascular heterogen-
eity due to genetic variability, sex, and age [24]. Animals
were euthanized by CO2 inhalation, following Animal
Care and Use Guidelines of the University of Connecti-
cut Health Center (Animal Welfare Assurance # A3471-
01). A total of n = 3 animals/group were used for each
treatment and time-point assessed.
Induction of experimental autoimmune encephalomyelitis
(EAE)
EAE was induced in mice by active immunization with
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK),
of murine origin (W. M. Keck Biotechnology Resource
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Center, Yale University), as described [25]; following
Animal Care and Use Guidelines of the University of
Connecticut Health Center (Animal Welfare Assurance
# A3471-01). Briefly, on day 0, one group of female mice
7–9 weeks of age was injected subcutaneously with
300 μg of MOG peptide in complete Freund’s adjuvant
(CFA, DIFCO) into the right and left flank, 100 μl per
site. These mice were also injected i.p. with 500 ng per-
tussis toxin (PTX, List Laboratories, Campbell CA) in
PBS on days 0 and 2 following the first immunization
(referred to as the MOG-CFA/PTX group). The second
group of age-matched mice received CFA alone and
PTX (500 ng) injections on day 0 and a second injection
of 500 ng PTX alone on day 2 (referred to as the CFA/
PTX group). The third group of naïve age-matched fe-
male mice was left untreated. Animals were monitored
and scored daily for clinical disease severity according to
the following scale: 0 = normal; 1 = tail limpness; 2 = limp
tail and weakness of hind legs; 3 = limp tail and complete
paralysis hind legs; 4 = limp tail, complete hind leg and
partial front leg paralysis; and 5 = death. LCM tissue was
acquired at day 9 (score 0) and day 15 (score ~ 2.0) post-
immunizations.
Tissue preparation for Immuno-LCM
Brains were snap-frozen in dry ice-cooled 2-methylbu-
tane (Acros; Geel, Belgium), and stored at −80°C. Frozen
brain was embedded in cryomatrix compound (Thermo
Fisher Scientific, Waltham, MA) prior to sectioning.
Coronal sections (7 μm) were cut on a Microm HM
505 M cryostat (Mikron Instruments; Oakland, NJ) and
affixed to uncoated, pre-cleaned glass slides (Fisher Sci-
entific, Pittsburgh, PA) and stored in a slide box at −
80°C. Tissue was processed for LCM within a week of
sectioning.
Immunostaining for Immuno-LCM
Immunostaining was performed as detailed [24,26,27],
with minor modifications. Briefly, sections were fixed in
75% ethanol, on ice, for 3 min prior to staining. The CP
stromal capillaries were stained using alkaline phosphat-
ase substrate NBT (nitro-blue tetrazolium chloride)/
BCIP (5-bromo-4-chloro-3'-indolyphosphate p-toluidine
salt), (Vector Labs, Burlingame, CA) for 3–5 minutes in
100 Mm Tris–HCl (pH 9.5) to detect endogenous alka-
line phosphatase activity in the endothelial cells. In this
case, endothelial cells were intentionally not immunos-
tained by anti-CD31/ABC alkaline phosphatase [24,27],
as it resulted in extensive deposition of chromogenic
precipitate, which made the stromal capillaries difficult
to resolve from the choroidal epithelial layer. The chor-
oidal epithelial cells were immunostained with monoclo-
nal pan-cytokeratin-FITC antibody (Sigma) for 10
minutes (diluted 1:10 in 1X PBS+ 0.5% Tween-20).
RNAsinW RNAse inhibitor (Promega, Madison, WI) was
added to all staining reagents. Immediately after immu-
nostaining, sections were dehydrated through graded al-
cohol and xylenes as described [24].
Laser capture microdissection (LCM)
A PixCell IIe laser capture microscope (ABI, Foster
City, CA) was used to separately procure CP stromal ca-
pillary and CP choroidal epithelial tissues, as previously
described for brain parenchymal vessels [24,27,28]. We
refer specifically to CP stromal capillary tissue, instead
of pure capillary endothelium, as it was not possible to
completely resolve vascular from matrix elements (in-
cluding extravasating leukocytes) within the dense CP
stroma. Likewise, the choroidal epithelial tissue may
contain some epiplexus cells, and so is not described as
pure epithelium. Only choroid plexus material from
within the fourth ventricle and lateral recess of the
fourth ventricle was retrieved.
Tissue extraction
LCM-retrieved tissue was solubilized in Cell Lysate
BufferW (Signosis; Sunnyvale, CA) for direct reverse
transcription. Cell Lysate BufferW, pre-heated to 75°C,
was added and the resulting lysate heated at 75°C for an
additional 15 min. Samples were immediately frozen at
−80°C.
DNase treatment and cDNA synthesis
Cell Lysate BufferW extracts were treated with Turbo
DNase (Ambion; Austin, TX) according to the manufac-
turer’s instructions. Specifically, Turbo DNase buffer and
DNase were added and samples incubated at 37°C for
30 min. Next, DNAse inactivation reagent was added for
2 min at room temperature. Samples were then reverse
transcribed using the SuperScript III (Invitrogen) stand-
ard protocol with random hexamers (Roche; Indianapo-
lis, IN), and employing an extension temperature of
42°C – optimal for random hexamers – for 60 min.
Resulting cDNA was stored at −20°C until used for
analysis.
cDNA Pre-Amplification
Pre-amplification was carried for array analysis out using
TaqManW PreAmp Master Mix and a PreAmp Pool con-
taining all the primers for detection by the Mouse Im-
mune Panel TaqManW Low density Array (TLDA; Life
Technologies Corp., Foster City, CA) [23]. This panel
conatins 93 immune-related genes plus three housekeep-
ing control genes (see Additional file 1: Mouse Immune
Panel TLDA). Pre-amplification was carried out with an
initial hold at 95°C for 10 min, followed by 14 cycles at
95°C for 15 sec and 60°C for 4 min.
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qrt-PCR
Relative cDNA levels were quantified by qrt-PCR using
an ABI PRISM 7500 Sequence Detection System Version
2.3, and reported compared to housekeeping gene
GAPDH. Relative quantitation to GAPDH was per-
formed using the standard 2–δCt method of Pfaffl [29],
where δCt =Ct target threshold cycle – Ct reference
(GAPDH) threshold cycle. Expression of genes relative
to GAPDH was then represented as percent expression
of GAPDH. To assure consistency in relating gene ex-
pression patterns to a housekeeping gene, GAPDH and
two other housekeeping genes, β-actin and 18 S riboso-
mal RNA, were evaluated for constant expression across
treatments. Additionally, gene expression values for a
handful of randomly selected immune-related genes
were also determined relative to β-actin and 18 S riboso-
mal RNA (see Additional file 2: Housekeeping control
genes). Custom TaqManW primers/probes were used for
the Mouse Immune Panel TLDA. TLDA analysis was
conducted as per the manufacturer’s protocol, with
100 μl sample volumes containing a 1/32 dilution of
pre-amplified cDNA added to each port of the microflui-
dic card [23]. For qrt-PCR analysis of CD31 and Cyto-
keratin 8, ‘singleplex’ assays were used as neither of these
genes are represented in the mouse Immune Panel
TLDA.
Immunostaining for confocal microscopy
Frozen cryosections (60 μm) were fixed with 4% parafor-
maldehyde, permeabilized with 1% Triton X-100 (in
PBS) and incubated with PowerblockW for 10 min. Puri-
fied rat anti-mouse CD31 antibody (BD Pharmingen;
1:150 dilution in 10% NBS in 1X PBS + 0.5% TW-20)
was used to stain the CP capillary network followed by
incubation with goat anti-rat Alexa-555 secondary anti-
body (1:200). Pan-cytokeratin-FITC 1: 150 dilution,
(Sigma) was used to stain the CP epithelium. Next,
Alexa-647 anti-mouse CD45 antibody (1:160 dilution)
was used to stain leukocytes.
Confocal microscopy
Images were acquired on a Zeiss LSM 510 Meta laser scan-
ning confocal microscope, and optical slices (at 2-μm inter-
vals) obtained using a 40x objective. Acquired z-stacks were
background-subtracted, and 3-D isosurface rendering per-
formed using Bitplane IMARIS suite version 7.1 x 64 soft-
ware (Bitplane Inc. Saint Paul, MN). Each z-stack was
thresholded and the “filament tracker” module used to gen-
erate a 3-D traced outline of immunostained vessels in
order to determine the diameter range of the CD31-
immunostained capillary network within the choroid plexus
across different treatments.
Statistical analysis
Relative gene expression values are given as mean±
SEM. Student’s two-tailed test (Microsoft Excel 2003,
Redmond, WA) was employed to assess statistical sig-
nificance in gene expression values between MOG-CFA/
PTX and CFA/PTX samples from the CP capillary
stroma and CP epithelium groups, separately for the two
different time points assessed. Results were considered
significant at a p ≤ 0.05. Additionally, two-way ANOVA
followed by post-hoc Bonferroni analysis was performed
using GraphPad Prism 5 (GraphPad, La Jolla, CA) to de-
termine interactive effects between immunization treat-
ment and time of analysis post-immunization, and
assessed for each CP compartment.
Results
Anatomy of the CP is altered in response to MOG-
immunization
First, the anatomy of the CP was investigated using con-
focal microscopy followed by 3-D isosurface rendering.
The close apposition of stromal capillary and choroidal
epithelial layers in the CP is depicted in Figure 1. The 3-
D analysis highlights the tortuosity of the capillary
plexus. At day 15 post immunization (p.i.) with PTX and
MOG35-55 peptide in CFA to induce EAE (MOG-CFA/
PTX group), or with PTX and CFA alone (CFA/PTX
group), which does not produce disease in this para-
digm, the capillary plexus can be seen to locally ‘swell’ in
certain regions (Figure 1). Specifically, the range in
diameter of capillaries in the MOG-CFA/PTX and CFA/
PTX groups was 1.24 to 11.39 μm and 1.86 to 10.84 μm
respectively, as compared to that found in naïve (1.24 to
6.22 μm) mice. In contrast to that seen within CP capil-
laries, the morphology of the choroidal epithelial layer
remained relatively constant following immunization.
LCM enables resolution of CP stromal capillaries from the
choroidal epithelium
Studies were next carried out to confirm the ability of
LCM to resolve the stromal capillary and choroidal epi-
thelial layers. Figure 2A shows an example of the highly
selective retrieval of both tissues from naïve and EAE
brain specimens. Microscopic analysis indicates no ap-
pearance of fluorescently-stained choroidal epithelial tis-
sue in the LCM-captured capillaries and, conversely, no
alkaline phosphatase-stained capillary tissue in the
retrieved epithelial samples. Figure 2B further highlights
the purity in qrt-PCR detection of LCM tissue from the
respective CP compartments. Using equivalent amounts
of input LCM tissue (1000 laser ‘shots’) from both CP
compartments, the endothelial marker CD31 was signifi-
cantly enriched in the CP capillary tissue, while the epi-
thelial marker cytokeratin 8 was observed in CP
epithelial tissue alone. The extremely low level of CD31
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mRNA detected in CP epithelial tissue may reflect the
few monocytes and/or dendritic cells circulating through
this area in the steady-state mouse brain [29,30]. There
is thus high confidence that LCM effectively separates
CP stromal capillary from choroidal epithelial layers with
high purity.
Expression of immune-related genes by stromal CP
capillary tissue following immunization
The next series of experiments coupled LCM to TLDA
qrt-PCR arrays to further characterize expression
patterns of a panorama of 93 immune-related genes in
the separate CP compartments at different stages of the
neuroinflammatory response to immunization. Expres-
sion of these genes relative to housekeeping gene
GAPDH (GAPDH was unaffected across treatments;
Additional file 2: Housekeeping control genes), was deter-
mined in three groups of mice: MOG-CFA/PTX, CFA/
PTX and naïve at two time points: day 9 and 15 p.i.
Contrasting these three treatment groups enabled effects
of the adjuvants CFA and PTX to be distinguished from
the autoimmune response to MOG. Furthermore,
Figure 1 Morphological analysis of CP compartments following immunization. CP epithelium was stained with polyclonal antibody to pan-
cytokeratin (FITC, green), and CP stromal capillaries were immunostained with monoclonal anti-CD31 antibody (red). A CD45 antibody was used
to stain for any leukocytes present within the CP (blue). Confocal microscopy z-stack images of thick (60 μm) frozen sections of the CP were
acquired, and three dimensional rendering was performed using Imaris image analysis software. Shown are rendered images of the CP from all
three treatment conditions (MOG-CFA/PTX day 15 p.i., CFA-PTX day 15 p.i. and Naïve), revealing swelling of the stromal capillaries (arrows)
following both immunization protocols. The left side shows leukocyte and capillary staining, emphasizing the distended capillary diameters. The
right side is a composite of leukocyte, capillary, and epithelial staining. Mean capillary diameter ranges for each group were determined using the
Filament tracer module in Imaris. The choroidal epithelium appears unaltered by immunization. ‘p’ indicates brain parenchymal region. Scale:
20 μm.
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examining effects at day 9 p.i. (prior to any evidence of
clinical disease) and day 15 p.i. (after disease onset),
highlighted the progression of gene changes that may be
linked with developing pathology.
At day 9 p.i. (EAE clinical score 0), numerous gene
changes were already evident in the CP stromal capillary
tissue, despite the lack of onset of any clinical disease
signs. Specifically, both MOG-CFA/PTX- and CFA/
PTX-immunized mice showed up-regulated expression
in 49 of the genes in the panel compared to naïve ani-
mals, (Table 1), with there being no statistically signifi-
cant differences between the two immunized groups.
Some prominent inflammatory genes that were equiva-
lently elevated at this time point included: CCL2, CCL5,
CXCL10, Sele (E-selectin), Selp (P-selectin), IL1b, Stat1
and Fasl all of which were modulated more than 10 fold
higher than naïve levels. It would thus appear that, at
this early stage before clinical EAE symptoms are
present, the gene responses in the CP stromal capillary
tissue following MOG immunization may stem largely
from adjuvants CFA and/or PTX.
By day 15 p.i. (EAE clinical score 1.5-2.0), however,
the MOG-CFA/PTX-immunized group surpassed the
CFA/PTX group in up-regulation of several genes, high-
lighting what might specifically be the autoimmune re-
sponse of the CP vascular stroma. These genes included
B2m, C3, CCL19, CCL5, CD4, Gzmb, Ptgs2, Ptprc
(CD45), Smad3, Stat4, and CD40l – which were select-
ively augmented in the CP stromal capillary tissue of the
MOG-CFA/PTX group (Figure 3). The fold changes in
these genes following immunization (Figure 3, bottom)
indicate their super-stimulation by MOG-CFA/PTX
Figure 2 Immuno-LCM allows retrieval of tissue from specific CP compartments. A) Evidence of histological purity. Immunofluorescence
was performed using FITC-conjugated pan-cytokeratin antibody to highlight the CP epithelium (green), while immunohistochemistry using
alkaline phosphatase detection with NBT/BCIP as substrate was carried-out to label the endothelium of CP stromal capillaries (dark brown). LCM
was performed on a Pixcell IIe LCM unit. Images both BEFORE and AFTER LCM, as well as LCM retrieved tissue deposited on the cap, are shown
to highlight selective retrieval of CP stromal capillary (top row) and CP choroidal epithelial tissues (bottom row). B) Evidence of purity by qrt-PCR.
Levels of CD31, an endothelial marker, and Cytokeratin-8, an epithelial marker, were probed to determine the purity of the CP capillary and CP
epithelial tissues, respectively, retrieved by LCM.
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treatment. The lymphoid chemokine CCL19, expressed
by venules in brain and spinal cord in mice afflicted with
EAE [31], was elevated nearly 80-fold in the MOG-CFA/
PTX immunized mice at this time-point. And CCL5, an-
other chemokine shown to play an important role in
EAE [32], was elevated 146-fold higher than naïve levels.
Expression of Ptgs2 (COX2), suppression of which has
been associated with resistance to EAE [33,34], was near
similarly elevated – having increased 96-fold higher than
that in naïve cohorts. Slightly less elevated was Stat4, a
transcription factor whose absence has been shown to
inhibit EAE [35], which was increased > 40-fold in the
MOG immunized group. It is further noteworthy that
expression of Ptprc (CD45), the common leukocyte mar-
ker, stimulated 219-fold higher, possibly reflecting
increased leukocyte extravasation across the stromal ca-
pillaries at this later time-point. Consistent with this in-
terpretation is that message for CD40l (CD154), a
protein primarily expressed on activated T cells [36], was
detected within the CP stromal capillary tissue only fol-
lowing MOG-CFA/PTX immunization.
Notably, the CFA/PTX group indicated some dampen-
ing of immune regulation by this time, as certain genes
e.g., Smad3 and Gzmb, dropped back to levels matching
those of naïve mice, after initially displaying an elevation
at day 9. Genes that trended towards elevated expression
following MOG-CFA/PTX treatment (but with p values
slightly > 0.05) are displayed in Additional file 3: Genes
that trended towards elevated expression in MOG-CFA/
PTX- immunized CP stromal capillary tissue compared
to CFA-PTX-immunized mice, at day 15 p.i, while those
that were similarly up-regulated in CP stromal capillary
tissue of MOG-CFA/PTX- and CFA/PTX-immunized
mice compared to naïve mice at day 15 are listed in
Additional file 4: Genes similarly up-regulated in CP
stromal capillary tissue from both MOG-CFA/PTX- and
CFA-PTX-immunized mice at day 15 p.i. Genes that
were undetected in the CP capillary tissue in all treated
and naïve mice at both time-points were the following:
CCR4, CD19, CD3e, CSF3, Ctla4, Cyp1a2, Cyp7a1, H2-
Ea, IL12b, IL13, IL3, IL4, IL5, IL6, IL9, and Lta.
Expression of immune-related genes by CP choroidal
epithelium following immunization
Immunization also produced a change in expression of
numerous immune-related genes within the CP chor-
oidal epithelium. Moreover, these changes differed from
those observed in the capillary stroma, emphasizing the
differential immune sensitivities of the two tissues.
At day 9 p.i., the CP choroidal epithelium of only
MOG-CFA/PTX-immunized mice displayed increased ex-
pression of any immune-related genes compared to that
of naïve cohorts. Specifically, the following eight immune-
related genes were up-regulated: B2m, CCL19, CCL2,
CCR2, CD8a, CXCL10, Sele, and Selp (Figure 4A). B2m
(beta 2 microglobulin), a biomarker for certain peripheral
inflammatory conditions [37] was increased 2.2-fold in
MOG-treated versus naïve mice. The chemokine CCL2
has been demonstrated to play a critical, non-redundant
role in directing mononuclear leukocyte extravasation into
the CNS during EAE [32,38,39], and was stimulated> 24-
fold higher in the CP choroidal epithelial tissue of MOG-
CFA/PTX-treated mice compared to that in naïve cohorts.
CXCL10 and CCL19 were 28-and 14-fold higher than
naïve values, respectively. Sele (E-selectin) and Selp
(P-selectin), CCL19 and CD8a further showed pronounced
Table 1 Genes similarly up-regulated in CP stromal
capillary tissue from both MOG-CFA/PTX- and CFA-PTX-
immunized mice at day 9 p.i
Genes modulated similarly in stromal CP capillary of MOG-CFA/
PTX mice at day 9 p.i
Gene name Gene name
B2m{ ll15*
Bcl2l1 ll18*
C3**{ ll1b**
Ccl19{ ll7
Ccl2** Lrp2
Ccl5**{ Nfkb1*
Ccr2** Nfkb2
Cd34** Ptgs*{
Cd80 Sele**
Cd86* Selp**
Cd8a Amad3{
Col4a5 Socs2
Csf1* Stat1**
Cxcl10** Stat3
Cxcr3* Stat4{
Ece1 Stat6
Edn1 Tbx21
Fas Tfrc*
Fn1 Tgfb1
Gzmb{ Cd40
Hmox1 Fasl**
Hprt1 Vcam1
lcos Vegfa
lfng**
genes with *≥ 5 and **≥ 10 fold increase in expression in comparison to Naïve
animals.
Relative mRNA expression values of 93 immune-related genes were
determined by immuno-LCM/TLDA in CP stromal capillary tissue from
immunized and naïve mice at day 9 p.i. At this early time-point, all 49
immunization-induced genes were similarly stimulated in both MOG-CFA/PTX-
and CFA-PTX-immunized mice compared to naïve animals, and only these are
listed. { denotes genes that show specific upregulation later on with disease
progression on day 15.
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stimulation specifically following MOG immunization,
being undetectable in the epithelium of both CFA/PTX and
naïve cohorts. In what appears to reflect the differential
sensitivities of the two CP tissues, CFA/PTX immunization
clearly ‘activated’ the stromal CP capillary tissue on day 9
p.i. at both the anatomical and molecular levels (Figure 1
and Table 1), but produced no detectable changes in the
CP epithelium at this time.
By day 15 p.i., genes B2m and CXCL10 displayed fur-
ther increases in expression in the CP choroidal epithe-
lium of MOG-CFA/PTX mice compared to that seen in
this cohort at day 9 (Figure 4B), showing > 19-fold and >
800-fold higher levels, respectively, compared to naïve
mice. Expression levels of yet additional genes in MOG-
treated mice also became elevated by this time; these
included Bax, Bcl2l1, C3, CD68, Gusb, H2-Eb1 and Ski
(Figure 4B). Moreover, genes CCL19, CCL2, CCR2,
CD8a, Sele and Selp, which had previously shown up-
regulation only in the MOG-CFA/PTX group at day 9,
became similarly induced in the CFA/PTX group at this
later time-point. Genes that trended towards elevated
expression following MOG-CFA/PTX treatment for
both time points (but with p values slightly >0.05) are
displayed in Additional file 5 and Additional file 6: Genes
that trended towards elevated expression in MOG-CFA/
PTX immunized CP epithelium tissue compared to CFA-
PTX-immunized mice, at day 9/15p.i., while those that
were similarly up-regulated in CP choroidal epithelial
tissue of MOG-CFA/PTX- and CFA/PTX-immunized
mice compared to naïve mice for both time points are
listed in Additional file 7 and Additional file 8: Genes
similarly up-regulated in CP epithelium from both
MOG-CFA/PTX- and CFA-PTX-immunized mice at day
9/15 p.i. Those few genes that were in the CP epithelial
tissue in both immunized groups and naïve mice
included IL3, IL4, IL5, IL6, Lta.
Interaction between immunization treatment and time
In order to gain further appreciation of the extent to
which time impacted the effect of specific type
immunization on the expression patterns of immune-
related genes, two-way ANOVA was performed to
Figure 3 Genes super-induced in CP stromal capillary tissue from MOG-CFA/PTX-immunized mice at day 15 p.i. Relative mRNA expression
values were determined by immuno-LCM/TLDA in CP stromal capillary tissue from MOG-CFA/PTX-immunized, CFA-PTX-immunized, and naïve mice at
day 15 p.i. Those genes that were more stimulated; i.e., ‘super-induced’, in MOG-CFA/PTX- versus CFA-PTX-immunized mice at day 15 p.i. (compared to
naïve mice) are graphed. The bar graphs depict those specific genes showing statistically significant differences in relative expression values (p values
indicated by asterisks) between MOG-CFA/PTX and CFA/PTX experimental groups. RNA values are presented as mean percent expression relative to
GAPDH (± SEM) in log scale. * and ** represent comparisons made between MOG-CFA/PTX and CFA-PTX- treatment groups, * p< 0.05, ** p < 0.005,
Student’s t-test, n = 3 animals/group. Fold changes in gene expression normalized to naïve animals are tabulated below the graph. Fold changes of
those genes that were up-regulated after immunizations but undetectable in naïve are denoted as ‘∞’.
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deduce interactive effects between immunization treat-
ment (e.g., MOG-CFA/PTX, CFA/PTX or naïve) and
time post-immunization. For example, the expression of
CCL19 in CP stromal capillary tissue following MOG-
CFA/PTX immunization was time-dependent (p < 0.05
for positive interaction). Two-way ANOVA was done on
all genes that displayed statistically significant modula-
tion after immunization in at least one of the CP
Figure 4 (See legend on next page.)
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compartments (as shown in Figures 3 and 4A, B) in ei-
ther of the time-points analyzed (twenty-three genes in
total). Interactive effects differed depending on the CP
compartment, further highlighting the unique responses
of the two CP tissues analyzed. Specifically, two-way
ANOVA of CP stromal capillary tissue revealed the fol-
lowing twelve genes displayed positive interaction be-
tween immunization treatment and time post-
immunization: B2m, C3, CCL19, CCL5, CD4, Gzmb,
Ptgs2, Ptprc, Stat4, CCR2, CD68, Gusb (Figure 5). CP
choroidal epithelial tissue, on the other hand, demon-
strated positive interaction for another collective of
genes: B2m, Bax, C3, CXCL10 (Figure 5).
Figure 6 qualitatively summarizes the differential
responses of the CP capillary and CP choroidal epithelial
tissues, respectively, to MOG-CFA/PTX immunization
versus CFA/PTX immunization, contrasting adjuvant
versus autoimmune effects on immune-related gene
regulation over the two time-points analyzed.
Discussion
Due to increasing awareness of the CP as fundamental
to the development of CNS inflammation [4-6],
immuno-LCM coupled to qrt-PCR array was used to
separately acquire CP stromal capillary and choroidal
epithelial tissues and assess their respective patterns of
expression in situ of a wide panorama of immune-
related genes. Gene patterns were evaluated during pre-
clinical and early clinical stages of EAE to appreciate the
switches in gene expression that accompany evolving
disease.
It is clear that the CP responds vigorously to MOG
immunization at both the anatomical and molecular
levels. Interestingly, immunization with CFA and PTX
alone produced striking effects. Swelling of the capillary
plexus occurred to nearly the same extent with injection
of just these agents, as with PTX and MOG in CFA.
PTX is an ancillary adjuvant commonly employed to
elicit EAE, as well as several other experimental auto-
immune diseases [40-44]. And while its mechanism of
action in this regard has generally been attributed to in-
creasing vascular permeability [45-47] – most notably
that of the BBB [48-51] – additional hypotheses have
been put forth [52-55]. However, to the best of our
knowledge, this is the first report to turn attention to
the CP as a possible target of PTX. It is of further inter-
est to point out that the distension of CP capillaries
noted here study bears similarity to that seen following
systemic neutralization of VEGF and TGFβ [56]. In the
latter case, CP capillary swelling was accompanied by
loss of fenestrae from endothelial cells and appearance
of multiple caveolae, transport vesicles that transcytose a
variety of cargo [57] – including chemokines [58] – and
are often associated with heightened vascular permeabil-
ity and inflammation [59,60]. Engelhardt et al. [4] had
also described ultrastructural changes of the CP during
EAE (along with CFA and PTX as adjuvants), but noted
these were mostly restricted to the CP choroidal epithe-
lium. Moreover, as comparison in this latter study was
just between healthy mice and those afflicted with EAE,
it is unclear whether the observed epithelial response
was autoimmune in nature and/or due to adjuvant
action.
Our results suggest that injection of PTX and/or CFA,
alone, might trigger an immune response in the CP ca-
pillaries that helps “set the stage” for CNS inflammation
[61]. The CP capillaries might be uniquely responsive in
this regard, as CFA/PTX treatment evoked an early re-
sponse (day 9 p.i.) in the CP stromal capillary tissue,
while the choroidal epithelium experienced neither overt
morphological nor gene expression changes at this time.
If, as speculated during MS/EAE, Th17 cells first transit
through the CP, and then travel in the CSF to reach their
cognate antigens in the SAS, then the CP capillaries
must somehow initially be rendered capable of support-
ing T cell extravasation. In the EAE paradigm used here,
PTX and/or CFA might provide the stimulus to evoke
such capability. In this regard, we noted > 10-fold in-
crease in chemokines CCL2, CCL5 and CXCL10 in the
CP stromal capillaries of both MOG-CFA/PTX- and
CFA/PTX-treated mice at day 9 p.i. Constitutive CCL2
expression within the CP stromal tissue has been
reported using in situ hybridization analysis, and shown
to be induced following peripheral tissue inflammation
[62]. The ability of CFA/PTX treatment to stimulate ex-
pression of these chemokines could potentially reflect
the actions of one or both of these adjuvants to ‘prime’
the neuroinflammatory process by activating the
(See figure on previous page.)
Figure 4 Genes super-induced in CP choroidal epithelial tissue from MOG-CFA/PTX-immunized mice at days 9 and 15 p.i. Relative
mRNA expression values of 93 immune-related genes were determined by immuno-LCM/TLDA in CP choroidal epithelial tissue from MOG-CFA/
PTX-immunized, CFA-PTX-immunized, and naïve mice at two time-points. Those genes that were more stimulated in MOG-CFA/PTX- versus CFA-
PTX-immunized mice at day 9 (Figure 4A) and day 15 p.i (Figure 4B) (compared to naïve mice) are graphed. The bar graphs depict those specific
genes showing statistically significant differences in relative expression values (p values indicated by asterisks) between MOG-CFA/PTX and CFA/
PTX experimental groups. RNA values are presented as mean percent expression relative to GAPDH (± SEM) in log scale. * and ** represent
comparisons made between MOG-CFA/PTX and CFA-PTX- treatment groups, * p < 0.05, ** p < 0.005, Student’s t-test, n = 3 animals/group. Fold
changes in gene expression normalized to naïve animals are tabulated below the corresponding graphs. Fold changes of those genes that were
up-regulated after immunizations but undetectable in naïve are denoted as ‘∞’.
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endothelium to elicit initial auto reactive T cell extrava-
sation from the circulation into the stromal compart-
ment. This hypothesis is consistent with the recent
observation that administration of PTX to transgenic
mice over-expressing CCL2 in the CNS causes disrup-
tion of the BBB and promotes leukocyte migration into
the brain parenchyma [63].
Notwithstanding the effects of CFA/PTX treatment on
CP capillary morphology and gene expression, immu-
nization with MOG-CFA/PTX further induced the expres-
sion of additional genes – some or all of which might
specifically reflect the autoimmune response and associated
development of EAE. While perhaps necessary for disease
to develop, the CP conditions set in place by PTX and CFA
are insufficient for inducing EAE in wild-type C57BL/6
mice. For disease to occur, supernumerary induction of
some genes, and de novo induction of others must take
place. The findings by Goverman et al. and Brabb et al.
[61,64], that injection of PTX alone can “trigger” EAE in
TCR-transgenic mice specific for myelin basic protein, by
fostering T cell access to the CNS, comports with our
results and the view that PTX enables mice to reach the
disease threshold. And helping pull this trigger may be add-
itional effects of PTX on T cell behavior. Our observation
of increased mRNA for genes CD8a, CD80, CD86, Gzmb
(granzyme) and Ptprc (CD45) in the CP capillary stromal
tissue of both MOG-CFA/PTX and CFA/PTX cohorts may
reflect capture of PTX-activated CD8 T cells in transit
across the CP and into the CSF. This interpretation is con-
sistent with the recent finding by Murphey et al. [65], that
PTX stimulation of cultured spleen cells results in CD 8 T
cell activation via CD80/86 co-stimulation.
As to signals responsible for the extravasation of T cells
from the circulation into the CP stroma during MOG-
induced EAE, a combination of chemokines may fill this
role, as these immune mediators do in guiding
Figure 5 Interaction between immunization treatment and time of analysis post-immunization on expression of immune-related genes
within CP stromal capillary and choroidal epithelial compartments. Interactive effects of treatment (MOG-CFA/PTX, CFA-PTX and naïve) and
time post-immunization were determined by two-way ANOVA on the 23 immune-related genes that were super-induced following MOG-CFA/
PTX immunization in either of the two CP compartments (those genes graphed in Figures 3, 4A and B). Of these 23 genes, 13 genes in the CP
stromal capillary and 4 genes in the CP epithelial tissue exhibited significant positive interaction between treatment and time post-immunization,
and are denoted with their corresponding p values. The remaining genes that showed no significant interaction are labeled by (x). Time-
dependent changes in expression of CCL19 in stromal capillary tissue and CXCL10 in choroidal epithelial tissue are graphed as representative
examples * p< 0.05, ** p< 0.005.
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parenchymal leukocyte infiltration. In particular, CCL5
level was increased significantly in CP stromal capillary
tissue at day 15 p.i., which coincides with high CCL5 pro-
tein level reported in whole brain extract of EAE mice at a
similar time-point, and argued to mediate leukocyte ad-
herence to the CNS microvasculature [32]. And CCL19 –
a CCR7 ligand known to play a crucial role in EAE devel-
opment through IL-23 producing Th17 cells [66] – was
likewise up-regulated dramatically in the CP stromal capil-
laries of MOG immunized mice at day 15 p.i.
With specific regard to those mechanism(s) further
driving T cell migration from the CP stroma into the
CSF, recent evidence points toward expression of an-
other chemokine - CCL20 - by the CP choroidal epithe-
lium as directing CCR6+ T cells across this layer and
into ventricular fluid during MS/EAE [8]. However, as
this chemokine:cognate receptor pair was not repre-
sented on the commercial TLDA card used in these
experiments, confirmation of this pathway was not per-
formed. Aside from CCL20 providing a driving force for
T cell migration into CP epithelium, CCL2 might also
serve in this capacity, as Chodobska et al. [67] noted the
latter chemokine was rapidly stimulated in this tissue
in vivo and then released into the CSF, following trau-
matic brain injury. Indeed, the significant increase in
CCL2 we observed in the MOG-CFA/PTX CP choroidal
epithelium at day 9 p.i. might just reflect such a role for
this chemokine in EAE. The cognate receptor for CCL2,
CCR2 was also seen to be elevated in the choroidal epi-
thelium at this early time-point. Presently, it is unclear if
the high levels of CCR2 mRNA indicate activation of the
epithelium, which, in the periphery, has been shown to
express CCR2 [68,69], or the accumulation of infiltrating
CCR2+ T cells.
In what might suggest multi-level control of leukocyte
extravasation into the CSF, still other chemokines were also
significantly up-regulated by the CP during EAE – namely
CXCL10 and CCL19. As CXCL10 has been reported to be
up-regulated in the sub-ventricular zone (SVZ) during
EAE, and postulated to stimulate migration of activated T
cells into the SVZ [70], its spike in expression by CP chor-
oidal epithelial tissue at day 9 p.i. and more robust elevation
by day 15 p.i., might imply this chemokine is obligate for T
cell entry into the ventricles. In analogous manner, CCL19
was also elevated at this site at day 9 p.i. In fact, the timing
of the CP epithelial spikes in this chemokine during early
stages of EAE noted here, coincides well with that reported
by Reboldi et al. [8] for initial T cell entry into the unin-
flamed CNS through the CP. Recently, Marques et al.
[22,71] used hybridization-based microarray to assess the
global transcriptome of the whole CP following chronic
peripheral LPS stimulation. When compared to our study,
there were some common and unique findings. Among the
common findings, complement protein C3, and chemo-
kines CCL2 and CCL5 were elevated following either acute
or chronic peripheral LPS stimulation, as well as during
MOG-induced EAE (complement C3 in both CP capillary
tissue and epithelium; CCL2 in CP epithelium; and CCL5
in CP capillary tissue). And Selectin (Sele and Selp) expres-
sion was also elevated both following acute peripheral LPS
stimulation [22], and in the CP epithelium after MOG-
induced EAE. These common gene modulations may thus
reflect more generic CP inflammatory response genes.
As for unique findings, these too involved chemokines.
Marques et al. [71] reported stimulation of CCL7 and
CXCL1 in the CP following chronic LPS stimulation, while
we detected stimulation of CCL19 and CXCL10 in the CP
epithelium and CCL19 in the CP endothelium during
Figure 6 Schematic summary of the induction of immune-related genes in the choroid plexus compartments following MOG-CFA/PTX
versus CFA-PTX immunization. Depicted are qualitative ‘heat maps’ of overall modulation in immune-related gene expression patterns over
time, within the separate CP stromal capillary (left) and CP choroidal epithelial (right) tissues after the two type immunization regimens. While
CFA/PTX immunization alone induces expression of immune-related genes in both tissues, MOG-CFA/PTX immunization causes supernumerary
stimulation above this level. The differences in gene expression between the immunization regimens highlight what might reflect gene changes
specifically due to MOG-associated autoimmunity. The effects due solely to CFA/PTX immunization might reveal priming of the immune response
that is necessary for the development of EAE.
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MOG-induced EAE. A priori, up-regulation of these latter
two chemokine genes may more distinguish an EAE signa-
ture for the respective CP tissue compartments.
Of further note was our observation of a MOG-sensitive
increase in expression of B2m at day 15 p.i. in CP stromal
capillary tissue, and at both time-points in the choroidal
epithelial tissue. Aside from perhaps reinforcing a more
ubiquitous role for B2m in inflammation [37], this result
complements previous reports of increased B2m mRNA
and protein levels in both neuronal and non neuronal cell
types during EAE [72,73], a response thought to be due to
induction of synaptic plasticity by infiltrating autoreactive
immune cells. The sharp induction of complement C3,
also noted in both CP compartments of MOG-CFA/PTX
mice at the later time point (day 15 p.i), further supports
previous studies highlighting C3 deficiency inhibits devel-
opment of EAE [74].
As to the specific approach used here, i.e., LCM coupled
to TLDA, it offered extraordinary opportunity to probe, in
extensive detail, the focused immune response within the
distinct CP compartments. Earlier reports, using immuno-
histochemistry and in situ hybridization, had shown that
the respective CP stromal capillary endothelial cells and
the CP choroidal epithelial cells displayed different expres-
sion patterns of a small nucleus of adhesion molecules
during EAE [4,20]. Specifically, VCAM-1 and ICAM-1
were found to be expressed constitutively by CP choroidal
epithelial cells of healthy SJL/N mice, and then further
induced following active immunization with spinal cord
homogenate. MAdCAM-1 was only seen in these cells
after induction of EAE. However, none of these adhesion
molecules, nor E- or P-selectin, was detected in CP stro-
mal capillary endothelial cells [75].
We too noted constitutive VCAM-1 expression in the
CP choroidal epithelial tissue of healthy naïve mice. Like-
wise, VCAM-1 trended toward elevation within this CP
compartment of MOG-CFA/PTX cohorts at both days 9
and 15 p.i., though it showed no up-regulation in CFA-
PTX-immunized mice at either time-point. In further
agreement with previous observations [75], our analysis
demonstrated induction of E-selectin and P-selectin in the
CP choroidal epithelial tissue from MOG-CFA/PTX-
immunized mice at day 9. Our results nevertheless dis-
played some stark differences with earlier reports. Specif-
ically, we also noted a trend of increased VCAM-1
expression by day 15 in CP stromal capillary tissue with
MOG immunization, paralleling what has been described
in MS brain tissue [6]. And both E- and P-selectin mRNA
were also observed to be induced in CP stromal capillary
tissue of both MOG-CFA/PTX- and CFA/PTX-immu-
nized mice compared to that of naïve mice at day 9 p.i. E-
selectin increased expression in the two immunized
groups by >100-fold, while P-selectin was stimulated >10-
fold.
A priori, differences in results between these EAE
studies could result from several factors, among them
being 1) the EAE model employed (e.g., immunization of
SJL/6 mice with spinal cord homogenate versus
immunization of C57BL/6 mice with MOG35-55 peptide),
the time of analysis post-immunization (e.g, before or
after disease onset), and 3) the sensitivity of the analytic
techniques (e.g., in situ hybridization versus qrt-PCR).
As neither MAdCAM-1 nor ICAM-1 were represented
on the TLDA card used in these experiments, confirm-
ation of expression or lack thereof was not possible for
these genes.
Most recently, Liddelow et al. [76] employed LCM to
collect mouse lateral ventricular CP tissue CP for tran-
scriptome analysis of transporter gene expression during
normal development. Here, we extended this application,
utilizing LCM to resolve – for the first time – the CP ca-
pillary stromal tissue from the CP choroidal tissue, and
then separately analyzing each for their unique immune
responses to MOG immunization.
Conclusions
Induction of EAE in C57BL/6 mice by active immu-
nization with MOG35-55 peptide results in the respective
CP stromal capillary and choroidal epithelial compart-
ments each mounting vigorous, yet distinct, immune
responses, underscoring the active role of the CP in in-
stigating CNS inflammatory disease. Furthermore, our
results make clear that a significant component of the
total CP response is due to effects elicited by adjuvants
PTX and/or CFA used in the immunization protocol –
which might serve to prime the CP to support auto-
immune activity necessary for developing MS/EAE.
These results are summarized schematically in Figure 6.
Additional files
Additional file 1: Mouse Immune Panel TLDA. The card map for the
96 genes (93 immune-related genes and 3 control genes) on the
commercially available mouse Immune panel TLDA is shown, with gene
names and corresponding accession numbers.
Additional file 2: Housekeeping control genes. Ct (Threshold cycle)
values for the three housekeeping genes – GAPDH, β-Actin and 18 S
represented on the mouse Immune-panel TLDA are shown. The
housekeeping genes were almost unchanged across treatments (shown
in A and B) with < 1 cycle difference between samples. C, Six genes were
normalized to each of the three housekeeping gene and expression
patterns plotted, indicating identical patterns of expression across
housekeeping control gene used.
Additional file 3: Genes that trended towards elevated expression
in MOG-CFA/PTX- immunized CP stromal capillary tissue compared
to CFA-PTX-immunized mice, at day 15 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/
TLDA in CP stromal capillary tissue from immunized and naïve mice at
day 15 p.i. A total of 14 genes trended towards greater induction in the
MOG-CFA/PTX group compared to the CFA-PTX group; these genes are
listed with their corresponding p values. Analysis was by Student’s two-
tailed t-test.
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Additional file 4: Genes similarly up-regulated in CP stromal
capillary tissue from both MOG-CFA/PTX- and CFA-PTX-immunized
mice at day 15 p.i. Relative mRNA expression values of 93 immune-
related genes were determined by immuno-LCM/TLDA in CP stromal
capillary tissue from immunized and naïve mice at day 15 p.i. At this later
time-point, 25 immunization-induced genes were similarly stimulated in
both MOG-CFA/PTX- and CFA-PTX-immunized mice compared to naïve
animals, and only these are listed.
Additional file 5: Genes that trended towards elevated expression
in MOG-CFA/PTX immunized CP epithelium tissue compared to
CFA-PTX-immunized mice, at day 9 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/
TLDA in CP epithelium from immunized and naïve mice at day 9 p.i. A
total of 15 genes trended towards greater induction in the MOG-CFA/
PTX group compared to the CFA-PTX group; these genes are listed with
their corresponding p values. Analysis was by Student’s two-tailed t-test.
Additional file 6: Genes that trended towards elevated expression
in MOG-CFA/PTX immunized CP epithelium tissue compared to
CFA-PTX-immunized mice, at day 15 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/
TLDA in CP epithelium from immunized and naïve mice at day 15 p.i. A
total of 19 genes trended towards greater induction in the MOG-CFA/
PTX group compared to the CFA-PTX group; these genes are listed with
their corresponding p values. Analysis was by Student’s two-tailed t-test.
Additional file 7: Genes similarly up-regulated in CP epithelium
from both MOG-CFA/PTX- and CFA-PTX-immunized mice at day 9
p.i. Relative mRNA expression values of 93 immune-related genes were
determined by immuno-LCM/TLDA in CP epithelium from immunized
and naïve mice at day 9 p.i. At this early time-point, 10 immunization-
induced genes were similarly stimulated in both MOG-CFA/PTX- and
CFA-PTX-immunized mice compared to naïve animals, and only these are
listed.
Additional file 8: Genes similarly up-regulated in CP epithelium
from both MOG-CFA/PTX- and CFA-PTX-immunized mice at day 15
p.i. Relative mRNA expression values of 93 immune-related genes were
determined by immuno-LCM/TLDA in CP epithelium from immunized
and naïve mice at day 15 p.i. At this later time-point, 8 immunization-
induced genes were similarly stimulated in both MOG-CFA/PTX- and
CFA-PTX-immunized mice compared to naïve animals, and only these are
listed.
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